Sitemap Report for astrazeneca.com
Generated on: 2025-09-16T19:26:55.548Z
Total No. of URL's in the Sitemap: 2409

URLs from Sitemap:
- https://www.astrazeneca.com/
- https://www.astrazeneca.com/publication.html
- https://www.astrazeneca.com/r-d.html
- https://www.astrazeneca.com/r-d/our-approach.html
- https://www.astrazeneca.com/r-d/our-approach/stem-at-astrazeneca.html
- https://www.astrazeneca.com/r-d/next-generation-therapeutics.html
- https://www.astrazeneca.com/r-d/next-generation-therapeutics/small-molecule.html
- https://www.astrazeneca.com/r-d/next-generation-therapeutics/protacs.html
- https://www.astrazeneca.com/r-d/next-generation-therapeutics/in-vivo-expressed-biologics.html
- https://www.astrazeneca.com/r-d/next-generation-therapeutics/sodium-zirconium-cyclosilicate.html
- https://www.astrazeneca.com/r-d/next-generation-therapeutics/monoclonal-antibodies.html
- https://www.astrazeneca.com/r-d/next-generation-therapeutics/antibody-drug-conjugate.html
- https://www.astrazeneca.com/r-d/next-generation-therapeutics/bispecific-antibody.html
- https://www.astrazeneca.com/r-d/next-generation-therapeutics/fragment-antibody.html
- https://www.astrazeneca.com/r-d/next-generation-therapeutics/therapeutic-proteins.html
- https://www.astrazeneca.com/r-d/next-generation-therapeutics/bicyclic-peptides.html
- https://www.astrazeneca.com/r-d/next-generation-therapeutics/anticalin-proteins.html
- https://www.astrazeneca.com/r-d/next-generation-therapeutics/T-cell-engager.html
- https://www.astrazeneca.com/r-d/next-generation-therapeutics/nucleotide-based-therapeutics.html
- https://www.astrazeneca.com/r-d/next-generation-therapeutics/gene-therapy.html
- https://www.astrazeneca.com/r-d/next-generation-therapeutics/cell-therapies.html
- https://www.astrazeneca.com/r-d/next-generation-therapeutics/multispecifics.html
- https://www.astrazeneca.com/r-d/next-generation-therapeutics/radioconjugates.html
- https://www.astrazeneca.com/r-d/transformative-science.html
- https://www.astrazeneca.com/r-d/our-strategic-r-d-centres.html
- https://www.astrazeneca.com/r-d/data-science-and-ai.html
- https://www.astrazeneca.com/r-d/digital-health-revolutionising-healthcare-for-patients.html
- https://www.astrazeneca.com/r-d/precision-medicine.html
- https://www.astrazeneca.com/r-d/glossary.html
- https://www.astrazeneca.com/r-d/clinical-innovation.html
- https://www.astrazeneca.com/r-d/our-technologies.html
- https://www.astrazeneca.com/r-d/our-technologies/acoustic-tube-sample-management.html
- https://www.astrazeneca.com/r-d/our-technologies/advanced-molecular-imaging.html
- https://www.astrazeneca.com/r-d/our-technologies/cryo-em.html
- https://www.astrazeneca.com/r-d/our-technologies/functional-genomics.html
- https://www.astrazeneca.com/r-d/our-technologies/multi-omics.html
- https://www.astrazeneca.com/r-d/our-technologies/ilab.html
- https://www.astrazeneca.com/r-d/our-technologies/machine-learning-drug-discovery.html
- https://www.astrazeneca.com/r-d/our-technologies/genomics.html
- https://www.astrazeneca.com/our-therapy-areas.html
- https://www.astrazeneca.com/our-therapy-areas/oncology.html
- https://www.astrazeneca.com/our-therapy-areas/oncology/clinical-strategy.html
- https://www.astrazeneca.com/our-therapy-areas/oncology/medicines-portfolio-and-pipeline.html
- https://www.astrazeneca.com/our-therapy-areas/oncology/patient-experience.html
- https://www.astrazeneca.com/our-therapy-areas/oncology/our-people-and-culture.html
- https://www.astrazeneca.com/our-therapy-areas/oncology/haematology.html
- https://www.astrazeneca.com/our-therapy-areas/oncology/immuno-oncology.html
- https://www.astrazeneca.com/our-therapy-areas/oncology/dna-damage-response.html
- https://www.astrazeneca.com/our-therapy-areas/oncology/Liver-cancer.html
- https://www.astrazeneca.com/our-therapy-areas/oncology/prostate-cancer.html
- https://www.astrazeneca.com/our-therapy-areas/oncology/breast-cancer.html
- https://www.astrazeneca.com/our-therapy-areas/oncology/leading-the-revolution-in-pancreatic-cancer.html
- https://www.astrazeneca.com/our-therapy-areas/oncology/ovarian-cancer.html
- https://www.astrazeneca.com/our-therapy-areas/oncology/at-the-forefront-of-lung-cancer-treatment.html
- https://www.astrazeneca.com/our-therapy-areas/biopharmaceuticals.html
- https://www.astrazeneca.com/our-therapy-areas/respiratory-and-immunology.html
- https://www.astrazeneca.com/our-therapy-areas/respiratory-and-immunology/epithelial-science.html
- https://www.astrazeneca.com/our-therapy-areas/respiratory-and-immunology/lupus.html
- https://www.astrazeneca.com/our-therapy-areas/vaccines-and-immune-therapies.html
- https://www.astrazeneca.com/our-therapy-areas/vaccines-and-immune-therapies/respiratory-syncytial-virus.html
- https://www.astrazeneca.com/our-therapy-areas/vaccines-and-immune-therapies/covid-19.html
- https://www.astrazeneca.com/our-therapy-areas/vaccines-and-immune-therapies/hMPV.html
- https://www.astrazeneca.com/our-therapy-areas/rare-disease.html
- https://www.astrazeneca.com/our-therapy-areas/pipeline.html
- https://www.astrazeneca.com/our-therapy-areas/medicines.html
- https://www.astrazeneca.com/our-therapy-areas/eosinophilic-inflammation.html
- https://www.astrazeneca.com/our-therapy-areas/cardiovascular-renal-and-metabolism.html
- https://www.astrazeneca.com/our-therapy-areas/cardiovascular-renal-and-metabolism/cardiovascular-disease.html
- https://www.astrazeneca.com/our-therapy-areas/cardiovascular-renal-and-metabolism/renal.html
- https://www.astrazeneca.com/our-therapy-areas/cardiovascular-renal-and-metabolism/metabolism.html
- https://www.astrazeneca.com/our-therapy-areas/cardiovascular-renal-and-metabolism/heart-failure.html
- https://www.astrazeneca.com/government-contract-t-cs.html
- https://www.astrazeneca.com/az-suppliers.html
- https://www.astrazeneca.com/az-suppliers/supplier-contact-information.html
- https://www.astrazeneca.com/az-suppliers/az-coupa-supplier.html
- https://www.astrazeneca.com/az-suppliers/az-coupa-supplier/faq.html
- https://www.astrazeneca.com/az-suppliers/az-coupa-supplier/faq/CSP.html
- https://www.astrazeneca.com/az-suppliers/az-coupa-supplier/faq/coupa-supplier-portal.html
- https://www.astrazeneca.com/az-suppliers/az-coupa-supplier/faq/cXML-invoices.html
- https://www.astrazeneca.com/az-suppliers/az-coupa-supplier/faq/SAN.html
- https://www.astrazeneca.com/az-suppliers/az-coupa-supplier/faq/CSP-linked.html
- https://www.astrazeneca.com/az-suppliers/az-coupa-supplier/faq/Supplier-Actionable-Notification.html
- https://www.astrazeneca.com/az-suppliers/az-coupa-supplier/latest-update.html
- https://www.astrazeneca.com/az-suppliers/az-coupa-supplier/japanese-suppliers.html
- https://www.astrazeneca.com/az-suppliers/az-coupa-supplier/german-suppliers.html
- https://www.astrazeneca.com/az-suppliers/az-coupa-supplier/spanish-suppliers.html
- https://www.astrazeneca.com/az-suppliers/az-coupa-supplier/french-suppliers.html
- https://www.astrazeneca.com/az-suppliers/az-coupa-supplier/mexican-suppliers.html
- https://www.astrazeneca.com/az-suppliers/az-coupa-supplier/brazil-suppliers.html
- https://www.astrazeneca.com/az-suppliers/az-coupa-supplier/sweden-suppliers.html
- https://www.astrazeneca.com/az-suppliers/az-coupa-supplier/CSP.html
- https://www.astrazeneca.com/az-suppliers/az-coupa-supplier/selected-suppliers-page.html
- https://www.astrazeneca.com/patient-reported-outcomes.html
- https://www.astrazeneca.com/patient-reported-outcomes/gastrointestinal.html
- https://www.astrazeneca.com/patient-reported-outcomes/cardiovascular.html
- https://www.astrazeneca.com/patient-reported-outcomes/respiratory.html
- https://www.astrazeneca.com/patient-reported-outcomes/order-instrument.html
- https://www.astrazeneca.com/patient-reported-outcomes/faqs.html
- https://www.astrazeneca.com/patient-reported-outcomes/contact-us.html
- https://www.astrazeneca.com/patient-reported-outcomes/confirmation.html
- https://www.astrazeneca.com/astrazeneca-exchange.html
- https://www.astrazeneca.com/media-centre.html
- https://www.astrazeneca.com/media-centre/press-releases.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/datopotamab-deruxtecan-granted-priority-review-in-the-us-for-patients-with-previously-treated-advanced-egfr-mutated-non-small-cell-lung-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/full-year-and-q4-2024-results.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/calquence-combination-approved-in-us-for-1l-mcl.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/dato-dxd-approved-in-us-for-hr-p-breast-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-plans-c820-million-us570m-investment-in-canada-to-advance-growing-global-hub-and-clinical-delivery.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/enhertu-approved-in-us-for-breast-cancer-post-et.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/imfinzi-recommended-for-eu-approval-for-ls-sclc.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/imfinzi-perioperative-regimen-improved-event-free-survival-and-overall-survival-of-niagara-phase-iii-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/camizestrant-improved-pfs-in-1l-hr-breast-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/enhertu-recommended-approval-eu-chmp-patients-low-ultralow-metastatic-breast-cancer-following-least-one-endocrine-therapy.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/imfinzi-recommended-for-eu-approval-for-aegean.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/positive-results-from-the-tezspire-phase-iii-waypoint-trial-highlight-rapid-and-sustained-effect-in-chronic-rhinosinusitis-with-nasal-polyps.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/imfinzi-improved-efs-in-early-stage-gastric-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/eneboparatide-phase-iii-trial-met-primary-endpoint.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-enters-license-agreement-with-alteogen-for-subcutaneous-formulations-of-multiple-oncology-assets.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/imfinzi-approved-in-eu-for-limited-stage-sclc.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-to-acquire-esobiotec.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-invests-2-and-half-bn-in-beijing-r-and-d-and-manufacturing.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/new-study-results-reinforce-tagrisso-as-the-backbone-therapy-for-egfr-mutated-lung-cancer-across-stages-and-settings.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/alexion-data-presented-at-the-2025-aan-annual-meeting-highlight-advancements-in-improving-care-for-rare-neurological-diseases.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/q1-2025-results.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/calquence-recommended-for-eu-approval-in-1l-mcl.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/azd0780-a-novel-oral-pcsk9-inhibitor-demonstrated-significant-ldl-cholesterol-ldl-c-reduction-in-pursuit-phase-iib-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/imfinzi-approved-in-the-us-for-bladder-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/imfinzi-approved-in-eu-for-aegean.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/enhertu-approved-in-eu-in-post-et-breast-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-showcases-innovation-in-infectious-disease-protection-at-escmid-global-2025.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/enhertu-combination-improved-pfs-in-1l-her-positive-mbc.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/fixed-duration-calquence-recommended-in-eu-for-cll.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/update-on-capitello-280-phase-iii-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/breztri-met-primary-endpoints-in-ph3-asthma-trials.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/calquence-combination-approved-in-eu-for-1l-mcl.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/enhertu-improved-pcr-in-early-stage-breast-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/imfinzi-improved-dfs-in-early-bladder-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/trixeo-aerosphere-approved-in-the-uk-as-first-inhaled-respiratory-medicine-using-next-generation-propellant-with-near-zero-global-warming-potential.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-to-showcase-latest-research-on-comprehensive-portfolio-and-pipeline-aimed-at-transforming-respiratory-diseases-at-ats-2025.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/statistically-significant-clinically-meaningful-batura-phase-iii-trial-provide-evidence-airsupra-standard-care-as-needed-rescue-treatment-asthma.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/acquisition-of-esobiotec-completed.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/astrazenecas-record-seventh-year-of-plenary-data-at-asco-furthers-ambition-to-redefine-breast-cancer-care-and-transform-outcomes-in-gastric-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/imfinzi-recommended-in-eu-for-bladder-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/camizestrant-reduced-the-risk-of-disease-progression-or-death-by-56-in-patients-with-advanced-hr-positive-breast-cancer-with-an-emergent-esr1-tumour-mutation-in-serena-6-phase-iii-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/imfinzi-regimen-reduced-risk-of-progression-recurrence-or-death-by-29-in-early-stage-gastric-cancer-vs-chemotherapy-alone-in-matterhorn-phase-iii-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/enhertu-plus-pertuzumab-reduced-the-risk-of-disease-progression-or-death-vs-thp-as-1st-line-therapy-in-patients-with-her2-positive-metastatic-breast-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/fixed-duration-calquence-approved-in-eu-for-1l-cll.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-enters-into-collaboration-with-cspc.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/alexion-data-presented-at-ean-2025-highlights-its-leadership-and-commitment-to-improving-patient-outcomes-in-rare-neurological-diseases.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/datroway-approved-in-us-for-egfrm-lung-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/imfinzi-approved-in-the-eu-for-bladder-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/baxdrostat-met-primary-and-all-secondary-endpts-in-baxhtn-phiii-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/update-on-anselamimab-in-al-amyloidosis.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/h1-and-q2-2025.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/tagrisso-plus-chemotherapy-demonstrated-statistically-significant-and-clinically-meaningful-improvement-in-overall-survival-in-egfr-mutated-advanced-lung-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-plans-to-invest-50bn-dollars-in-the-us.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/gefurulimab-nanobody-met-phase-iii-endpoints.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/trixeo-aerosphere-receives-positive-eu-chmp-opinion-first-inhaled-medicine-using-next-generation-propellant-with-near-zero-global-warming-potential.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/imfinzi-granted-priority-review-and-breakthrough-therapy-designation-us-patients-with-resectable-early-stage-gastric-gastroesophageal-junction-cancers.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/baxdrostat-demonstrated-statistically-significant-clinically-meaningful-reduction-sbp-patients-hard-control-hypertension-baxhtn-phase-iii-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2025/tagrisso-plus-chemotherapy-demonstrated-a-median-overall-survival-of-nearly-four-years.html
- https://www.astrazeneca.com/media-centre/press-releases/2024.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/beyfortus-approved-in-china-for-the-prevention-of-rsv-disease-in-infants-bkp.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/full-year-and-q4-2023-results.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/voydeya-danicopan-granted-first-ever-regulatory-approval-in-japan-for-adults-with-pnh-to-be-used-in-combination-with-c5-inhibitor-therapy.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/imfinzi-with-tace-and-bevacizumab-in-patients-with-hepatocellular-carcinoma-eligible-for-embolisation.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/enhertu-granted-priority-review-in-the-us-for-patients-with-metastatic-her2-positive-solid-tumours.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/positive-results-japan-phase-iii-trial-acoramidis-transthyretin-mediated-amyloid-cardiomyopathy-attr-cm-consistency-global-attribute-cm-phase-iii.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/tagrisso-improved-pfs-in-stage-iii-lung-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/fda-accepts-dato-dxd-bla-for-nonsquamous-nsclc.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/tagrisso-plus-chemo-approved-in-us-for-lung-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-completes-acquisition-of-icosavax.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/acquisition-of-gracell-completed.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/voydeya-recommended-for-eu-approval.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/ema-validates-dato-dxd-maas-for-nsq-nsclc-and-bc.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-to-acquire-amolyt.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/lynparza-and-imfinzi-demonstrated-strong-clinical-benefit-and-more-than-doubled-median-duration-of-response-vs-chemotherapy.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-to-acquire-fusion.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/tagrisso-the-addition-chemotherapy-showed-favourable-trend-overall-survival-egfr-mutated-advanced-lung-cancer-further-follow-flaura2-phase-iii-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/ultomiris-approved-in-the-us-for-nmosd.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/beyfortus-approved-in-japan-for-the-prevention-of-rsv-disease-in-infants.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/truqap-plus-faslodex-approved-in-japan-for-patients-with-advanced-hr-positive-breast-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/fda-accepts-dato-dxd-bla-for-breast-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/voydeya-approved-in-us.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/imfinzi-improved-os-and-pfs-in-limited-stage-sclc.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/alexion-data-at-aan-2024-demonstrate-how-ultomiris-and-soliris-can-transform-outcomes-for-rare-neurological-diseases.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/enhertu-approved-in-the-us-as-first-tumour-agnostic-her2-directed-therapy-for-previously-treated-patients-with-metastatic-her2-positive-solid-tumours.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/q1-2024-results.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/new-modelling-reveals-the-escalating-toll-of-chronic-kidney-disease-on-patients-planet-and-economies.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-increases-2024-dividend-by-7.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/imfinzi-plus-chemotherapy-doubled-overall-survival-rate-at-three-years-for-patients-with-advanced-biliary-tract-cancer-in-topaz-1-phase-iii-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-advances-the-science-of-infectious-disease-protection-at-eccmid-2024.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/voydeya-approved-in-the-eu-as-add-on-treatment-to-ravulizumab-or-eculizumab-for-adults-with-rare-disease-pnh-who-have-residual-haemolytic-anaemia.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/truqap-recommended-for-eu-breast-cancer-approval.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/enhertu-improved-pfs-in-her2-low-and-ultralow.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/az-unveils-latest-research-across-key-respiratory-and-immune-mediated-diseases-at-ats-2024-showcasing-strength-of-its-broad-pipeline-and-portfolio.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/calquence-combination-improved-pfs-in-1l-mcl.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-completes-cellectis-equity-investment.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/supernova-trial-met-covid-19-prevention-endpoint.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-to-manufacture-adcs-in-singapore.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-to-deliver-80bn-revenue-by-2030.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-furthers-ambition-to-transform-outcomes-in-early-lung-cancer-and-redefine-metastatic-breast-cancer-treatment-at-asco-2024.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/dato-dxd-improved-os-in-nonsquamous-lung-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/early-chronic-kidney-disease-intervention-could-save-four-european-health-systems-up-to-15-billion-euro-over-10-years.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/Enhertu-demonstrated-median-progression-free-survival-thirteen-months.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/imfinzi-is-first-and-only-immunotherapy-to-show-survival-benefit-in-limited-stage-small-cell-lung-cancer-in-global-phase-iii-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/tagrisso-reduced-the-risk-of-disease-progression-or-death-by-84-percent-in-patients-with-unresectable-stage-iii-egfr-mutated-lung-cancer-vs-placebo.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/tagrisso-plus-chemo-recommended-for-approval-in-eu.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/acquisition-of-fusion-completed.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/tagrisso-granted-priority-review-in-the-us-for-patients-with-unresectable-stage-iii-egfr-mutated-lung-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/farxiga-approved-in-the-us-for-the-treatment-of-paediatric-type-2-diabetes.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/calquence-plus-chemoimmunotherapy-reduced-the-risk-of-disease-progression-or-death-by-27-percent.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/imfinzi-approved-in-the-us-for-endometrial-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/update-on-capitello-290-phase-iii-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/truqap-plus-faslodex-approved-in-the-eu-for-patients-with-advanced-er-positive-breast-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/tagrisso-addition-chemotherapy-approved-japan-new-first-line-treatment-patients-egfr-mutated-advanced-lung-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/update-on-imfinzi-adjuvant-br31-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/imfinzi-improved-efs-and-os-in-bladder-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/sipavibart-ema-regulatory-submission-accepted-under-accelerated-assessment-for-covid-19-prevention.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/tagrisso-with-the-addition-of-chemotherapy-approved-in-china-as-1st-line-treatment-for-patients-with-egfr-mutated-advanced-lung-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/lynparza-and-imfinzi-positive-chmp-in-endometrial.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/tagrisso-with-the-addition-of-chemotherapy-approved-in-the-eu-as-new-1st-line-treatment-for-patients-with-egfr-mutated-advanced-lung-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/h1-and-q2-2024-results.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/acquisition-of-amolyt-pharma-completed.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/odac-reviewed-imfinzi-in-resectable-lung-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/calquence-fixed-duration-combo-improved-1l-cll-pfs.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/enhertu-approved-in-china-for-patients-with-previously-treated-her2-positive-advanced-or-metastatic-gastric-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/lynparza-and-imfinzi-combination-approved-in-the-eu-for-patients-with-mismatch-repair-proficient-advanced-or-recurrent-endometrial-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/imfinzi-granted-priority-review-and-breakthrough-therapy-designation-for-patients-with-limited-stage-small-cell-lung-cancer-in-the-us.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/imfinzi-approved-in-us-for-resectable-lung-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/fasenra-approved-in-china-for-the-treatment-of-severe-eosinophilic-asthma.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-advances-ambition-to-improve-standards-of-care-in-multiple-cancer-types-at-wclc-and-esmo-2024.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/novel-computational-pathology-based-trop2-biomarker-for-dato-dxd-was-predictive-of-clinical-outcomes-in-patients-with-nsclc-in-tropion-lung01-phase-iii-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-announces-the-completion-of-the-clinical-programme-to-support-the-transition-of-breztri-to-next-generation-propellant-with-near-zero-global-warming-potential.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/dato-dxd-showed-median-overall-survival-of-146-months-in-patients-with-advanced-nsclc-in-tropion-lung01-phase-iii-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/enhertu-showed-substantial-clinical-activity-in-patients-with-her2-positive-metastatic-breast-cancer-and-brain-metastases.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/imfinzi-perioperative-regimen-reduced-risk-recurrence-by-32-risk-death-by-25-vs-neoadjuvant-chemotherapy-alone-in-mibc-niagara-phase-iii-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/imfinzi-plus-imjudo-demonstrated-unprecedented-overall-survival-alc-with-one-in-five-patients-surviving-five-years-himalaya-phase-iii-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/fasenra-approved-in-the-us-for-eosinophilic-granulomatosis-with-polyangiitis.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/flumist-approved-for-self-administration-in-the-us.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/fasenra-recommended-for-eu-approval-in-egpa.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/datopotamab-deruxtecan-final-overall-survival-results-reported-in-patients-with-metastatic-hr-positive-her2-low-or-negative-breast-cancer-in-tropion-breast01-phase-iii-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/tagrisso-us-approval-in-unresectable-lung-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/enhertu-granted-priority-review-us-for-patients-her2-low-or-her2-ultralow-metastatic-breast-cancer-who-have-received-at-least-1-line-endocrine-therapy.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/calquence-granted-priority-review-in-the-us-for-patients-with-untreated-mantle-cell-lymphoma.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/airsupra-positive-results-phase-iii-batura-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-licenses-lipid-lowering-lpa-asset.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/alexion-astrazeneca-rare-disease-data-at-the-2024-aanem-annual-meeting-and-mgfa-scientific-session-further-demonstrate-advancement-in-gmg-care.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/enhertu-approved-in-china-as-first-her2-directe-therapy-for-patients-with-her2-mutant-metastatic-non-small-cell-lung-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-advances-science-of-infectious-disease-protection-at-idweek-2024.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/wainzua-recommended-for-approval-in-the-eu.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/fasenra-approved-in-the-eu-for-eosinophilic-granulomatosis-with-polyangiitis.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-china-president-currently-under-investigation.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/9m-and-q3-2024-results.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/azn-share-price-movement.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-showcases-strength-of-haematology-portfolio-and-pipeline-at-ash-2024.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/tezspire-nasal-polyps-trial-met-primary-endpoints.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/dato-dxd-new-bla-submitted-nsq-bla-withdrawn.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/komet-phase-iii-trial-met-primary-endpoint.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-invests-3bn-500mn-in-us.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/tagrisso-recommended-for-eu-approval-laura.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/truqap-improved-rpfs-in-advanced-prostate-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-appoints-iskra-reic-as-executive-vice-president-international.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/imfinzi-approved-in-us-for-limited-stage-sclc.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/imfinzi-granted-priority-review-in-the-us-for-patients-with-muscle-invasive-bladder-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/fixed-duration-calquence-plus-venetoclax-demonstrated-superior-pfs-vs-standard-care-previously-untreated-cll-with-77-of-patients-progression-free-3-years-amplify-phase-iii-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/datopotamab-deruxtecan-granted-breakthrough-therapy-designation-us-patients-previously-treated-advanced-egfr-mutated-non-small-cell-lung-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/lynparza-demonstrated-clinically-meaningful-prolonged-survival-benefit-in-early-breast-cancer-in-olympia-phase-iii-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/tagrisso-approved-in-eu-based-on-laura-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2024/dato-dxd-nsq-nsclc-application-withdrawn-in-eu.html
- https://www.astrazeneca.com/media-centre/press-releases/2023.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/nirsevimab-us-regulatory-submission-accepted-for-the-prevention-of-rsv-lower-respiratory-tract-disease-in-infants-and-children.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-acquire-cincor-for-cardiorenal-asset.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/airsupra-pt027-approved-in-the-us-for-asthma.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/tezspire-approved-for-self-administration-in-the-eu-in-a-new-pre-filled-pen.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/acquisition-of-neogene-therapeutics-completed.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/enhertu-approved-in-the-eu-as-the-first-her2-directed-therapy-for-patients-with-her2-low-metastatic-breast-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/update-on-evusheld-us-eua.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/tezspire-approved-for-self-administration-in-the-us-with-a-new-pre-filled-pen.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/full-year-and-q4-2022-results.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/forxiga-approved-in-the-eu-for-the-treatment-of-symptomatic-chronic-heart-failure.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/overall-survival-analysis-of-the-lynparza-propel-phase-iii-trial-in-metastatic-castration-resistant-prostate-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/resvinet-2023-data-reinforce-astrazenecas-commitment-to-help-prevent-respiratory-syncytial-virus-in-infants.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/imfinzi-plus-imjudo-approved-in-the-eu-for-patients-with-advanced-liver-and-non-small-cell-lung-cancers.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/calquence-tablet-formulation-approved-in-the-eu-for-patients-with-chronic-lymphocytic-leukaemia.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-enters-license-agreement-with-kym-biosciences-for-cmg901-a-claudin-182-antibody-drug-conjugate.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/enhertu-approved-in-china-for-patients-with-her2-positive-metastatic-breast-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-acquires-cincor-for-cardiorenal-asset.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/update-on-us-regulatory-review-of-lynparza-in-combination-with-abiraterone-for-mcrpc.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/enhertu-destiny-pantumor02-shows-positive-results.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/imfinzi-improved-efs-in-resectable-lung-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/tagrisso-demonstrated-strong-overall-survival-benefit-in-the-adaura-phase-iii-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-launches-call-for-entries-to-the-2023-global-rd-postdoctoral-challenge.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/calquence-granted-first-regulatory-approval-in-china-for-adults-with-previously-treated-mantle-cell-lymphoma.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/eplontersen-demonstrated-sustained-benefit-in-phase-iii-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-completes-agreement-with-kym-for-cmg901.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/ultomiris-recommended-for-nmosd-eu-approval.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/lynparza-imfinzi-met-endpoint-in-ovarian-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/update-to-arrangements-with-sobi-and-sanofi.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-advances-its-pipeline-and-highlights-progress-in-immuno-oncology-adcs-cell-therapy-and-epigenetics-at-aacr.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/eccmid-data-reinforces-astrazenecas-commitment-to-transform-protection-for-the-most-vulnerable-by-advancing-science-in-vaccines-and-immune-therapies.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/imfinzi-based-treatment-before-and-after-surgery-reduced-the-risk-of-disease-recurrence-progression-events-or-death-in-resectable-non-small-cell-lung-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/q1-2023-results.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/neuro-ttransform-phase-iii-results-presented-at-aan-showed-eplontersen-demonstrated-consistent-and-sustained-improvement.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/odac-vote-on-lynparza-combo-in-prostate-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/koselugo-approved-in-china-for-paediatric-patients-with-neurofibromatosis-type-1-and-plexiform-neurofibromas.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/farxiga-extended-in-the-us-for-heart-failure.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/ultomiris-approved-in-the-eu-for-adults-with-neuromyelitis-optica-spectrum-disorder-nmosd.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-showcases-scientific-advances-across-rare-and-malignant-haematological-conditions-at-eha-2023.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/tagrisso-plus-chemo-improved-pfs-in-lung-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-will-highlight-momentum-of-practice-changing-cancer-medicines-across-its-robust-pipeline-at-asco-2023.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/imfinzi-lynparza-prolonged-pfs-in-endometrial-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/ultomiris-approved-in-japan-for-the-prevention-of-relapses-in-patients-with-nmosd.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/lynparza-approved-in-us-for-brcam-prostate-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/update-on-brazikumab-development-programme.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/lynparza-and-imfinzi-combination-reduced-risk-of-disease-progression-or-death-vs-chemotherapy-and-bevacizumab-in-patients-with-advanced-ovarian-cancer-without-tumour-brca-mutations-in-the-duo-o-phase-iii-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/imfinzi-plus-chemotherapy-significantly-improved-pathologic-complete-response-in-gastric-and-gastroesophageal-junction-cancers-in-matterhorn-phase-iii-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/tagrisso-achieved-unprecedented-survival-in-early-stage-egfr-mutated-lung-cancer-with-88-of-patients-alive-at-five-years-in-adaura-phase-iii-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/andexxa-phase-iv-trial-stopped-early-after-achieving-pre-specified-criteria-on-haemostatic-efficacy-versus-usual-care.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/enhertu-demonstrated-clinically-meaningful-and-durable-responses-in-patients-across-multiple-her2-expressing.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/datopotamab-deruxtecan-combinations-showed-encouraging-tumour-responses-in-patients.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/danicopan-as-add-on-to-ultomiris-or-soliris-improved-haemoglobin-levels-and-maintained-disease-control-in-patients.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/nirsevimab-recommended-for-infant-rsv-protection.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-agreement-with-quell-therapeutics.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/capivasertib-in-combination-with-faslodex-granted-priority-review-in-the-us.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/soliris-approved-in-china-for-the-treatment-of-adults-with-refractory-generalised-myasthenia-gravis.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/soliris-recommended-for-approval-in-the-eu-by-chmp-for-children-and-adolescents.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/xigduo-xr-approved-in-china-for-adults-with-type-2-diabetes.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-announces-400-million-investment-in-reforestation-and-biodiversity-in-support-of-climate-action-and-human-health.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/imfinzi-plus-imjudo-demonstrated-sustained-overall-survival-benefit-in-the-himalaya-phase-iii-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/datopotamab-deruxtecan-met-dual-primary-endpoint-of-progression-free-survival-in-patients-with-advanced-non-small-cell-lung-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/enhertu-approved-in-china-as-the-first-her2-directed-therapy-for-patients-with-her2-low-metastatic-breast-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/beyfortus-approved-in-the-us-for-the-prevention-of-rsv-lower-respiratory-tract-disease-in-infants.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/h1-and-q2-2023-results.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/soliris-approved-in-the-eu-for-children-and-adolescents-with-refractory-generalised-myasthenia-gravis-gmg.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/enhertu-demonstrated-clinically-meaningful-progression-free-survival-and-overall-survival-in-destiny-pantumor02-phase-ii-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-appoints-sharon-barr-as-executive-vice-president-biopharmaceuticals-rd.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/alexion-enters-gene-therapy-agreement-with-pfizer.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/wclc-advance-ambition-astrazeneca-medicine-for-more-than-half-of-all-patients-treated-for-lung-cancer-2030.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-demonstrates-scientific-leadership-with-compelling-new-data-at-esc-congress-2023-on-the-interconnections-across-chronic-diseases.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/forxiga-approved-china-reduce-risk-cardiovascular-death-hospitalisation-patients-with-symptomatic-chronic-heart-failure.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/soliris-approved-japan-paediatric-patients-generalised-myasthenia-gravis-gmg.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/lynparza-plus-abiraterone-approved-japan-treatment-brca-mutated-metastatic-castration-resistant-prostate-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-data-ers-2023-demonstrate-leadership-transforming-care-across-broad-respiratory-portfolio-inhaled-biologic-medicines.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/calquence-approved-china-chronic-lymphocytic-leukaemia.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/update-on-us-review-of-ultomiris-for-nmosd.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/datopotamab-deruxtecan-plus-imfinzi-showed-promising-clinical-activity-in-the-first-line-advanced-non-small-cell-lung-cancer-setting.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/tagrisso-plus-chemotherapy-extended-median-progression-free-survival-by-nearly-9-months-in-egfr-mutated-advanced-lung-cancer-in-flaura2-phase-iii-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/enhertu-demonstrated-strong-and-durable-tumour-responses-in-previously-treated-her2-mutant-advanced-lung-cancer-in-the-destiny-lung02-phase-ii-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/fasenra-phase-iii-egpa-trial-met-primary-endpoint.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/enhertu-recommended-for-approval-in-the-eu-by-chmp-for-patients-with-her2-mutant-advanced-non-small-cell-lung-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/alexion-completes-purchase-licence-agreement-early-stage-rare-disease-gene-therapy-portfolio-pfizer.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/dato-dxd-improved-pfs-in-breast-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/forxiga-met-primary-endpoint-in-t2now-phase-iii-trial-one-of-the-largest-paediatric-type-2-diabetes-studies-performed-to-date.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-settles-nexium-and-prilosec-product-liability-litigations.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-research-reveals-unique-associations-between-rare-changes-in-genes-and-plasma-proteins-that-could-improve-drug-discovery.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/alexion-data-at-9th-joint-ectrims-actrims-meeting-msmilan2023-showcase-impact-of-c5-inhibition-in-nmosd.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-advances-scientific-leadership-across-multiple-cancers-with-first-data-from-four-pivotal-phase-iii-trials-at-esmo.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-reinforces-commitment-to-protecting-the-most-vulnerable-from-serious-infectious-diseases-at-idweek-2023.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-awards-funding-to-eight-innovative-research-projects.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/tagrisso-plus-chemotherapy-granted-priority-review-us-patients-egfr-mutated-advanced-lung-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/soliris-approved-china-treatment-adults-neuromyelitis-optica-spectrum-disorder-nmosd.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/imfinzi-plus-chemotherapy-doubled-pathologic-complete-response-rate-resectable-early-stage-gastric-gastroesophageal-junction-cancers-vs-chemotherapy.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/tagrisso-plus-chemotherapy-reduced-risk-disease-progression-brain-42-percent-patients-egfr-mutated-advanced-lung-cancer-brain-metastases-baseline.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/imfinzi-plus-lynparza-reduced-risk-disease-progression-death-45-percent-vs-chemotherapy-advanced-recurrent-endometrial-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/dato-dxd-plus-imfinzi-robust-durable-tumour-responses-1st-line-treatment-patients-metastatic-triple-negative-breast-cancer-begonia-phase-ibii-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/enhertu-approved-in-the-eu-as-the-first-her2-directed-therapy-for-patients-with-her2-mutant-advanced-non-small-cell-lung-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/datopotamab-deruxtecan-significantly-extended-progression-free-survival-vs-chemotherapy-in-tropion-breast01-phase-iii-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/datopotamab-deruxtecan-improved-progression-free-survival-vs-chemotherapy-in-tropion-lung01-phase-iii-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/enhertu-demonstrated-clinically-meaningful-survival-across-multiple-her2-expressing-advanced-solid-tumours-in-destiny-pantumor02-phase-ii-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/us-food-drug-administration-accepts-review-astrazeneca-supplemental-biologics-license-application-self-administration-flumist-quadrivalent.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/9m-and-q3-2023-results.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-cell-and-gene-therapy-deal-w-cellectis.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/zora-real-world-evidence-demonstrates-that-lokelma-substantially-increases-cardiorenal-patients-chances-of-maintaining-lifesaving-raasi-therapy.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/zibotentan-dapagliflozin-combination-demonstrated-significant-albuminuria-reduction-in-patients-with-chronic-kidney-disease-and-proteinuria-in-zenith-ckd-phase-IIb-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/agreement-with-eccogene-for-clinical-stage-glp-1ra.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/imfinzi-combination-improves-pfs-in-liver-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/imfinzi-plus-chemotherapy-approved-in-china-as-first-immunotherapy-regimen-for-patients-with-locally-advanced-or-metastatic-biliary-tract-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/update-on-pacific-2-phase-iii-trial-for-imfinzi.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/truqap-approved-in-us-for-hr-plus-breast-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-launches-evinova-health-tech-business-to-accelerate-innovation-across-the-life-sciences-sector.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-advances-scientific-leadership-in-haematology-at-ash-2023.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/update-on-crystalize-evidence-trials.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/long-term-alpha-phase-iii-trial-data-danicopan-ultomiris-soliris-improvement-patients-pnh-experiencing-clinically-significant-extravascular-haemolysis.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-to-acquire-icosavax-including-potential-first-in-class-rsv-and-hmpv-combination-vaccine-with-positive-phase-ii-data.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/wainua-eplontersen-granted-first-ever-regulatory-approval-us-treatment-of-adults-with-polyneuropathy-hereditary-transthyretin-mediated-amyloidosis.html
- https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-to-acquire-gracell-furthering-cell-therapy-ambition-across-oncology-and-autoimmune-diseases.html
- https://www.astrazeneca.com/media-centre/press-releases/2022.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/full-year-2021-and-q4-results.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/transfer-of-global-rights-for-eklira-and-duaklir-to-covis-pharma-completed.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-and-neurimmune-sign-deal-for-ni006.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/new-vaxzevria-data-further-support-its-use-as-third-dose-booster.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-and-scorpion-therapeutics-enter-agreement-to-discover-develop-and-commercialise-novel-cancer-treatments-against-undruggable-targets.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-aims-to-redefine-liver-biliary-tract-and-prostate-cancer-treatment-with-practice-changing-imfinzi-and-lynparza-data-at-asco-gi-and-gu.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-granted-priority-review-for-breast-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-plus-chemotherapy-reduced-risk-of-death-by-20-in-1st-line-advanced-biliary-tract-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-plus-tremelimumab-unprecedented-survival-1st-line-unresectable-liver-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/lynparza-combo-delays-progression-risk-in-prostate-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/saphnelo-approved-in-eu-for-sle.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/nirsevimab-ema-regulatory-submission-accepted-under-accelerated-assessment-for-rsv-protection-in-all-infants.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-improves-pfs-and-os-in-her2-low-bc.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-progresses-ambition-zero-carbon-programme-with-honeywell-partnership-to-develop-next-generation-respiratory-inhalers.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-and-neurimmune-close-deal-for-ni006.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/nirsevimab-significantly-protected-infants-against-rsv-disease-in-phase-iii-melody-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/lynparza-approved-in-the-us-as-adjuvant-treatment-for-patients-with-germline-brca-mutated-her2-negative-high-risk-early-breast-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/update-on-us-review-of-fasenra-in-nasal-polyps.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/lynparza-reduced-risk-of-death-by-32-percent-in-the-adjuvant-treatment-of-patients-with-germline-brca-mutated-high-risk-early-breast-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-launches-global-rd-postdoctoral-challenge-to-accelerate-scientific-discovery-and-diversity.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-reaches-settlement-agreement-resolving-patent-litigation-related-to-ultomiris.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/astrazenecas-antibody-combination-evusheld-authorised-for-use-in-great-britain-for-pre-exposure-prophylaxis-prevention-of-covid-19.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/update-on-calla-phase-iii-trial-for-imfinzi.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/evusheld-long-acting-antibody-combination-recommended-for-approval-in-the-eu-for-the-pre-exposure-prophylaxis-prevention-of-covid-19.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-aims-to-transform-the-oncology-treatment-landscape-with-diverse-early-pipeline-and-novel-combinations-at-aacr.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/evusheld-approved-in-the-eu-for-covid-19.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/ondexxya-approved-in-japan-for-fxai-reversal.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/ultomiris-demonstrated-sustained-improvements-functional-activities-quality-life-adults-generalised-myasthenia-gravis-60-weeks.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/human-ventricular-progenitor-cells-promote-formation-new-heart-tissue-following-heart-attack.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/ultomiris-approved-in-the-us-for-adults-with-generalised-myasthenia-gravis.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-aims-transform-cancer-care-practice-changing-data-asco-2022.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/farxiga-hfpef-phase-iii-trial-met-primary-endpoint.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-combo-granted-priority-review-for-btc.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/ultomiris-nmosd-ph-iii-trial-met-primary-endpoint.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/azd8233-reduced-low-density-lipoprotein-cholesterol-levels-73-patients-high-risk-hypercholesterolemia-etesian-phase-iib-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-granted-priority-review-for-her2m-nsclc.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/vaxzevria-approved-eu-third-dose-booster-covid-19.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-approved-in-us-for-2l-her2-positive-breast-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-signs-licence-agreement-with-rq-biotechnology-for-monoclonal-antibodies-against-covid-19.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/evusheld-significantly-protected-against-symptomatic-covid-19-for-at-least-six-months-in-provent-phase-iii-trial-in-high-risk-populations1.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-announces-plans-for-new-strategic-rd-centre-and-alexion-headquarters-in-cambridge-massachusetts.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/q1-2022-results.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-granted-btd-her2-low-breast-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/tremelimumab-us-priority-review-imfinzi-combo.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/pt027-significantly-reduced-the-risk-of-a-severe-exacerbation-compared-to-albuterol-in-patients-with-asthma.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/astrazenecas-pascal-soriot-awarded-british-knighthood-services-uk-life-sciences-leadership-global-response-covid-pandemic.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/calquence-plus-obinutuzumab-demonstrated-sustained-survival-benefit-in-1st-line-chronic-lymphocytic-leukaemia.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-efficacy-results-in-her2-low-breast-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/evusheld-significantly-prevented-covid-19-disease-progression-or-death-in-tackle-phase-iii-treatment-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-demonstrates-pipeline-and-portfolio-strength-across-malignant-and-rare-haematological-diseases-at-eha-2022.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/eplontersen-phase-iii-trial-met-co-primary-endpoints.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/alxn1840-shows-rapid-and-sustained-improvement-in-copper-mobilisation-from-tissues.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/lynparza-recommended-in-eu-for-early-breast-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-recommended-for-breast-cancer-eu-approval.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/new-chronic-kidney-disease-ckd-study-indicates-that-ckd-is-present-in-one-out-of-ten-adults.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-improved-pcr-in-resectable-lung-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-to-acquire-teneotwo-and-t-cell-engager.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-approved-in-eu-for-her2-positive-mbc.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-granted-priority-review-for-her2-low-mbc.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/ultomiris-recommended-for-approval-in-the-eu-by-chmp.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/tezspire-recommended-for-approval-in-the-eu-by-chmp.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/h1-2022-results.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/michel-demare-to-succeed-leif-johansson-as-non-executive-chair-of-the-board.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/lynparza-approved-in-eu-for-early-breast-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/calquence-tablet-formulation-approved-in-the-us-across-current-indications.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-approved-in-the-us-for-her2-low-mbc.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/tagrisso-plus-savolitinib-demonstrated-49-objective-response-rate-in-lung-cancer-patients-in-savannah-phase-ii-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/datopotamab-deruxtecan-based-combinations-show-promising-clinical-activity-in-patients.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/acquisition-of-teneotwo-for-its-clinical-stage-t-cell-engager-completed.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-approved-in-us-for-her2-mutant-nsclc.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-improved-pfs-in-mbc-in-destiny-breast02.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/lynparza-granted-fda-priority-review-for-propel.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-aims-to-transform-cancer-outcomes-with-new-data-across-industry-leading-portfolio-at-esmo-2022.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/lynparza-approved-in-japan-for-early-breast-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/tagrisso-approved-in-japan-for-early-lung-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/ultomiris-approved-in-japan-for-the-treatment-of-adults-with-generalised-myasthenia-gravis.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/farxiga-deliver-phase-III-trial-reduced-cv-death.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/farxiga-lowers-risk-cv-death-heart-failure.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/evusheld-approved-for-covid-19-in-japan.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/forxiga-approved-in-china-for-ckd.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-approved-in-us-for-biliary-tract-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/lynparza-in-combination-with-bevacizumab-demonstrates-clinically-meaningful-survival-benefit-in-advanced-ovarian-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/tagrisso-demonstrated-5-year-median-disease-free-survival-in-the-adjuvant-treatment-of-patients-with-egfr-mutated-lung-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-and-tremelimumab-with-chemotherapy-demonstrated-sustained-survival-benefit-in-metastatic-non-small-cell-lung-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-continues-to-demonstrate-clinically-meaningful-tumour-response-in-patients-with-her2-mutant-metastatic-non-small-cell-lung-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-plus-chemotherapy-further-improved-overall-survival-benefit-in-advanced-biliary-tract-cancer-in-the-topaz-1-phase-iii-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/nirsevimab-recommended-for-approval-in-eu-by-chmp.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/evusheld-positive-chmp-opinion-in-eu.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/danicopan-phase-iii-trial-met-primary-endpoint.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/evusheld-approved-in-eu-for-covid-19-treatment.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/tezspire-approved-in-the-eu-for-the-treatment-of-severe-asthma.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/lynparza-approved-in-china-for-ovarian-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/ultomiris-approved-in-eu-for-gmg.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/tezspire-approved-in-japan-for-severe-asthma.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/koselugo-approved-in-japan-for-paediatric-patients-with-plexiform-neurofibromas.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/alexion-aims-to-advance-nmosd-treatment-landscape-with-exceptional-ultomiris-efficacy-data-at-ectrims-2022.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/idweek-data-reinforces-astrazenecas-commitment-to-advance-science-in-vaccines-and-immune-therapies.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-and-imjudo-approved-in-advanced-liver-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/update-on-messina-phase-iii-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/capivasertib-phase-iii-trial-met-primary-endpoints.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/camizestrant-significantly-improved-progression-free-survival.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/ultomiris-showed-zero-relapses-in-adults-with-neuromyelitis-optica-spectrum-disorder-nmosd-with-median-treatment-duration-of-73-weeks.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-advances-scientific-leadership-in-cardiovascular-and-renal-diseases-with-over-60-abstracts.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-funds-rd-postdoctoral-challenge-finalists.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/vaxzevria-receives-full-marketing-authorisation-in-the-eu-for-the-prevention-of-covid-19.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/beyfortus-approved-in-the-eu-for-the-prevention-of-rsv-lower-respiratory-tract-disease-in-infants.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/az-data-at-asn-kidney-week-reinforces-urgent-need-for-early-screening-of-ckd-and-benefits-of-earlier-treatment-for-patients-and-healthcare-systems.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/farxiga-improved-symptom-burden-in-deliver-phase-iii-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/year-to-date-and-q3-2022-results.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/fda-advisory-committee-recommends-pt027-in-asthma.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-and-imjudo-approved-in-us-for-lung-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-expands-global-footprint-in-rare-disease-with-availability-of-first-alexion-rare-disease-therapy-for-patients-in-china.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/lynparza-in-combination-with-abiraterone-recommended-for-approval-in-the-eu-by-chmp-as-1st-line-treatment-for-patients-with-metastatic-castration-resistant-prostate-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-plus-chemotherapy-recommended-for-approval-in-the-eu-by-chmp-as-first-immunotherapy-regimen-for-advanced-biliary-tract-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-recommended-for-approval-in-the-eu-by-chmp-for-patients-with-previously-treated-her2-positive-advanced-gastric-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-ranked-in-top-three-in-the-access-to-medicine-index.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-aims-to-redefine-breast-cancer-care-with-new-data-across-the-treatment-spectrum-at-sabcs-2022.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-to-acquire-neogene-therapeutics-accelerating-ambition-in-oncology-cell-therapy.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-announces-sale-of-west-chester-site.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-showcases-strength-of-haematology-portfolio-and-pipeline-across-multiple-hard-to-treat-conditions-at-ash-2022.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-achieved-statistically-significant-overall-survival.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/capivasertib-pfs-in-hr-positive-breast-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/camizestrant-significantly-delayed-disease-progression-in-advanced-er-positive-breast-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/datopotamab-deruxtecan-showed-encouraging-and-durable-efficacy-in-patients-with-metastatic-breast-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/datopotamab-deruxtecan-showed-promising-responses-as-monotherapy-and-in-combination-with-imfinzi-in-patients.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/update-on-us-review-of-lynparza-propel-snda.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/forxiga-chmp-opinion-for-symptomatic-chronic-hf.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/update-on-imfinzi-pearl-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-imjudo-recommended-for-approvals-in-eu.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-approved-in-eu-for-gastric-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-recommended-for-eu-approval-in-her2-low-bc.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-approved-in-eu-for-biliary-tract-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/lynparza-approved-in-eu-for-prostate-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/calquence-japan-approval-for-treatment-naive-cll.html
- https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-imjudo-approved-in-japan-for-3-cancers.html
- https://www.astrazeneca.com/media-centre/press-releases/2021.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/us-clearance-of-proposed-acquisition-of-alexion.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/atacand-divestment-in-over-70-countries-completed.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/farxiga-granted-us-priority-review-for-ckd.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/serum-institute-of-india-obtains-emergency-use-authorisation-in-india-for-astrazenecas-covid-19-vaccine.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-to-showcase-transformative-data-across-diverse-pipeline-at-world-conference-on-lung-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/imfinzi-new-dosing-approved-in-eu.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/enhertu-approved-in-the-us-for-gastric-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/enhertu-approved-in-the-eu-for-breast-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/calquence-approved-in-japan-for-cll.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/calquence-met-primary-endpoint-against-ibrutinib.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/symbicort-approved-in-china-for-mild-asthma.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/datopotamab-deruxtecan-and-enhertu-show-promising-early-clinical-activity-in-patients-with-advanced-non-small-cell-lung-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/tagrisso-extended-disease-free-survival-regardless-of-prior-adjuvant-chemotherapy-in-early-stage-egfr-mutated-lung-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/covid-19-vaccine-astrazeneca-recommended-for-use-in-the-eu.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/covid-19-vaccine-authorised-for-use-in-the-eu.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-agrees-to-divest-viela-shareholding.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/covid-19-vaccine-astrazeneca-confirms-protection-against-severe-disease-hospitalisation-and-death-in-the-primary-analysis-of-phase-iii-trials.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/forxiga-approved-in-china-for-heart-failure.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/update-on-kestrel-phase-iii-trial-for-imfinzi.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/full-year-2020-results.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/divestment-of-crestor-in-europe-completed.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-and-idt-biologika-sign-letter-of-intent-to-increase-covid-19-vaccine-manufacturing-in-europe-and-secure-long-term-supply-capacity.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/olympia-trial-of-lynparza-idmc-recommend-early-analysis.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-covid-19-vaccine-authorised-for-emergency-use-by-the-world-health-organization.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/voluntary-withdrawal-imfinzi-us-bladder-indication.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/tezepelumab-is-the-first-biologic-to-consistently-and-significantly-reduce-exacerbations-in-broad-population-of-severe-asthma-patients.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/further-update-on-us-regulatory-review-of-roxadustat-in-anaemia-of-chronic-kidney-disease.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-advances-mass-global-rollout-of-covid-19-vaccine-through-covax.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/us-court-decision-favours-symbicort-patents.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/update-on-the-safety-of-covid-19-vaccine-astrazeneca.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/divestment-of-viela-shareholding-completed.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/us-supply-agreement-for-additional-azd7442-doses.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/uk-and-eu-regulatory-agencies-confirm-covid-19-vaccine-astrazeneca-is-effective-and-generally-well-tolerated.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/statement-on-the-passing-of-jose-baselga.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-us-vaccine-trial-met-primary-endpoint.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/update-following-statement-by-niaid-on-azd1222-us-phase-iii-trial-data.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/statement-on-covid-19-vaccine-supply-at-anagni-plant-in-italy.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/azd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-accelerates-early-oncology-pipeline-across-key-strategic-scientific-platforms-at-aacr.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/update-on-farxiga-covid-19-dare-19-phase-iii-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/tagrisso-approved-in-china-in-early-lung-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/tagrisso-adjuvant-receives-positive-chmp-opinion.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/selumetinib-recommended-for-eu-approval-in-nf1.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/nirsevimab-phase-iii-trial-met-primary-endpoint.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/q1-2021-results.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/farxiga-approved-in-the-us-for-ckd.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/imfinzi-and-tremelimumab-showed-survival-in-poseidon.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/results-of-annual-general-meeting-held-on-11-may-2021.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/approval-recognises-acquisitions-advancement-of-the-companys-strategic-and-financial-development.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-asco-2021-data-support-ambition-to-revolutionise-cancer-outcomes-by-treating-earlier-and-transforming-the-patient-experience.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-covid-19-vaccine-vaxzevria-authorised-for-emergency-use-in-japan.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/tagrisso-approved-in-eu-in-early-lung-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/anifrolumab-showed-benefit-across-different-measures-of-skin-and-joint-disease-activity-in-patients-with-systemic-lupus-erythematosus.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/lynparza-reduced-the-risk-of-cancer-recurrence-by-42-in-the-adjuvant-treatment-of-patients-with-germline-brca-mutated-high-risk-early-breast-cancer-in-olympia-phase-iii-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/imfinzi-demonstrated-unprecedented-survival-in-unresectable-stage-iii-lung-cancer-with-43-percent-of-patients-surviving-five-years.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-appoints-aradhana-sarin-as-new-chief-financial-officer.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/calquence-head-to-head-results-versus-ibrutinib.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/covid-19-vaccine-astrazeneca-effective-against-delta-indian-variant.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/update-on-azd7442-storm-chaser-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-welcomes-court-ruling-on-supply-of-its-covid-19-vaccine-to-europe.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/koselugo-approved-in-the-eu-for-children-with-neurofibromatosis-type-1-and-plexiform-neurofibromas.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/orpathys-approved-in-china-for-patients-with-lung-cancer-and-met-gene-alterations.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/lynparza-approved-in-china-for-prostate-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/first-covid-19-variant-vaccine-azd2816-phase-ii-iii-trial-participants-vaccinated.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/forxiga-recommended-in-eu-for-patients-with-ckd.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/nirsevimab-phii-iii-trial-confirms-safety-profile.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-appoints-dr-susan-galbraith-as-executive-vice-president-oncology-research-and-development.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/vaxzevria-induced-immunity-for-at-least-1-year-following-a-single-dose-and-strong-immune-responses-following-either-a-late-second-dose-or-a-third-dose.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-alexion-transaction-cleared-in-the-eu.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/tezepelumab-granted-fda-priority-review-for-asthma.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-alexion-transaction-cleared-in-the-uk.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/status-on-us-fda-advisory-committee-for-roxadustat.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/imfinzi-approved-in-china-for-extensive-stage-sclc.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/acquisition-of-alexion-completed.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/vaxzevria-is-highly-effective-after-one-dose-against-severe-disease-or-hospitalisation-caused-by-beta-and-delta-variants-of-concern.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/ultomiris-recommended-in-eu-for-children-with-pnh.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-and-regeneron-to-research-develop-and-commercialise-new-small-molecule-medicines-for-obesity.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/h1-2021-results.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/vaxzevria-showed-no-increased-incidence-of-thrombosis-with-thrombocytopenia-after-second-dose.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/vaxzevria-and-mrna-covid-19-vaccines-showed-similar-and-favourable-safety-profiles-in-a-population-based-cohort-study-of-over-a-million-people.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/saphnelo-approved-in-the-us-for-sle.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/forxiga-approved-in-the-eu-for-ckd.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/enhertu-head-to-head-trial-meets-primary-endpoint.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/update-on-us-review-of-roxadustat.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/update-on-ultomiris-phase-iii-als-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/azd7442-prophylaxis-trial-met-primary-endpoint.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/forxiga-approved-in-japan-for-ckd.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/alxn1840-wilson-phase-iii-met-primary-endpoint.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/imfinzi-combined-with-novel-immunotherapies-improved-clinical-outcomes-for-patients-with-unresectable-stage-iii-non-small-cell-lung-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-lung-and-breast-cancer-data-at-wclc-and-esmo-2021-underscore-ambition-to-revolutionise-outcomes-for-patients.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/ultomiris-approved-in-eu-for-children-with-pnh.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-and-european-commission-reach-settlement-agreement-over-vaccine-supply-ending-litigation.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/international-respiratory-coalition-launches-to-transform-post-pandemic-respiratory-healthcare.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/imfinzi-improves-survival-in-nsclc-in-poseidon.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/pt027-phiii-asthma-trials-met-primary-endpoints.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/imfinzi-plus-chemotherapy-tripled-patient-survival-at-three-years-in-the-caspian-phase-iii-trial-in-extensive-stage-small-cell-lung-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/enhertu-demonstrated-clinically-meaningful-and-durable-response-in-patients-with-her2-positive-advanced-gastric-cancer-in-destiny-gastric02-phase-ii-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/enhertu-demonstrated-robust-and-durable-tumour-response-of-549-in-patients-with-her2-mutant-metastatic-non-small-cell-lung-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/enhertu-reduced-the-risk-of-disease-progression-or-death-by-72-vs-trastuzumab-emtansine-t-dm1-in-patients-with-her2-positive-metastatic-breast-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-360m-irish-manufacturing-investment.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-to-discover-and-develop-self-amplifying-rna-therapeutics-in-new-collaboration-with-vaxequity.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/lynparza-propel-trial-meets-primary-endpoint.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-covid-19-and-rsv-presentations-at-idweek-2021-will-showcase-scientific-progress-in-infectious-diseases.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/saphnelo-approved-in-japan-for-sle.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-to-fully-acquire-caelum-biosciences.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/enhertu-granted-btd-for-breast-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/azd7442-request-for-emergency-use-authorization-for-covid-19-prophylaxis-filed-in-us.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/tezepelumab-granted-orphan-drug-designation-in-the-us-for-eosinophilic-esophagitis.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/azd7442-phiii-trial-positive-in-covid-outpatients.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/imfinzi-and-tremelimumab-improved-os-in-liver-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/imfinzi-improved-survival-in-biliary-tract-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-to-transfer-rights-to-eklira-duaklir.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-advances-ambition-to-redefine-care-for-blood-cancer-at-ash-2021.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/year-to-date-and-q3-2021-results.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/azd8601-epiccure-phase-ii-trial-demonstrated-safety-and-tolerability-in-patients-with-heart-failure.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/two-billion-doses-of-astrazenecas-covid-19-vaccine-supplied-to-countries-across-the-world-less-than-12-months-after-first-approval.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/new-analyses-of-two-azd7442-covid-19-phase-iii-trials-in-high-risk-populations-confirm-robust-efficacy-and-long-term-prevention.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-unveils-the-discovery-centre-disc-in-cambridge.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/lynparza-granted-fda-priority-review-for-olympia.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-reinforces-leadership-in-breast-cancer-at-sabcs-2021-with-new-data-underscoring-ambition-to-redefine-cancer-care.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-ionis-to-collaborate-on-eplontersen.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/evusheld-long-acting-antibody-combination-authorised-for-emergency-use-in-the-us-for-pre-exposure-prophylaxis-prevention-of-covid-19.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/enhertu-additional-analyses-further-reinforce-ground-breaking-efficacy-in-patients-with-her2-positive-metastatic-breast-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/calquence-reduced-the-risk-of-disease-progression-or-death-vs-standard-of-care-combinations-at-three-years-in-the-ascend-phase-iii-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/evusheld-long-acting-antibody-combination-retains-neutralising-activity-against-omicron-variant-in-independent-fda-study.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/tezspire-tezepelumab-approved-in-the-us-for-severe-asthma.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/saphnelo-recommended-for-eu-approval-for-sle.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/ultomiris-accepted-for-fda-priority-review-for-gmg.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/evusheld-long-acting-antibody-combination-retains-neutralising-activity-against-omicron-variant-in-studies-from-oxford-and-washington-universities.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/vaxzevria-significantly-boosted-antibody-levels-against-omicron.html
- https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-and-ionis-close-eplontersen-deal.html
- https://www.astrazeneca.com/media-centre/press-releases/2020.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/farxiga-granted-fast-track-designation-in-the-us-for-heart-failure-following-acute-myocardial-infarction-leveraging-an-innovative-registry-based-trial-design.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/covid-19-vaccine-azd1222-showed-robust-immune-responses-in-all-participants-in-phase-i-ii-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/h1-2020-results.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/breztri-aerosphere-approved-in-the-us-for-copd.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-and-daiichi-sankyo-enter-collaboration-to-develop-and-commercialise-new-antibody-drug-conjugate.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/imfinzi-recommended-for-approval-in-the-eu-by-chmp-for-extensive-stage-small-cell-lung-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/calquence-recommended-for-approval-in-the-eu-by-chmp-for-chronic-lymphocytic-leukaemia.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/farxiga-met-all-primary-and-secondary-endpoints-in-groundbreaking-phase-iii-dapa-ckd-trial-for-the-treatment-of-patients-with-chronic-kidney-disease.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/tagrisso-us-btd-for-egfrm-adjuvant-lung-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/nirsevimab-reduced-respiratory-syncytial-virus-infections-and-hospitalisations-in-preterm-infants-in-phase-iib-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/brilinta-significantly-reduced-the-rate-of-the-composite-of-stroke-and-death-in-patients.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/brilinta-granted-fda-priority-review-for-the-reduction-of-subsequent-stroke-in-patients-who-had-an-acute-ischemic-stroke-or-transient-ischemic-attack.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/lokelma-approved-in-china-for-the-treatment-of-adult-patients-with-hyperkalaemia-06012020.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/farxiga-granted-fda-priority-review-for-patients-with-heart-failure-with-reduced-ejection-fraction-06012020.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/update-on-phase-iii-strength-trial-for-epanova-in-mixed-dyslipidaemia-13012020.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/lynparza-regulatory-submission-granted-priority-review-in-the-us-for-1st-line-maintenance-treatment-with-bevacizumab-in-advanced-ovarian-cancer-13012020.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/lynparza-regulatory-submission-granted-priority-review-in-the-us-for-hrr-mutated-metastatic-castration-resistant-prostate-cancer-20012020.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/imfinzi-and-tremelimumab-granted-orphan-drug-designation-in-the-us-for-liver-cancer-20012020.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-young-health-programme-to-partner-with-unicef-to-prevent-non-communicable-diseases-among-young-people.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/astrazenecas-ambition-zero-carbon-strategy-to-eliminate-emissions-by-2025-and-be-carbon-negative-across-the-entire-value-chain-by-2030-22012020.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-divests-rights-to-established-hypertension-medicines-27012020.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/brilinta-met-primary-endpoint-in-phase-iii-thales-trial-in-stroke-27012020.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-to-recover-the-global-rights-to-brazikumab-medi2070-from-allergan-27012020.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/phase-ii-destiny-gastric01-trial-of-enhertu-versus-chemotherapy-met-primary-endpoint-27012020.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/full-year-and-q4-2019-results.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-divests-global-rights-to-movantik-25022020.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-completes-divestment-agreement-with-atnahs-pharma-for-established-hypertension-medicines.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/update-on-phase-iii-danube-trial-for-imfinzi-and-tremelimumab-in-unresectable-stage-iv-bladder-cancer-06032020.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/update-on-phase-iii-gy004-trial-for-cediranib-added-to-lynparza-in-platinum-sensitive-relapsed-ovarian-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/imfinzi-confirmed-a-sustained-overall-survival-benefit-in-final-analysis-of-the-phase-iii-caspian-trial-in-1st-line-extensive-stage-small-cell-lung-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/lynparza-granted-orphan-drug-designation-in-japan-for-brca-mutated-metastatic-pancreatic-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-to-donate-9-million-face-masks-to-support-healthcare-workers-around-the-world-in-the-fight-against-covid-19.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-to-discover-and-develop-sirna-therapeutics-for-cardiovascular-renal-metabolic-and-respiratory-diseases-in-new-collaboration.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/lokelma-approved-in-japan-for-the-treatment-of-hyperkalaemia.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/farxiga-reduced-the-incidence-of-heart-failure-worsening-or-cardiovascular-death-in-a-sub-analysis-from-landmark-phase-iii-dapa-hf-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/farxiga-phase-iii-dapa-ckd-trial-will-be-stopped-early-after-overwhelming-efficacy-in-patients-with-chronic-kidney-disease.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/imfinzi-approved-in-the-us-for-extensive-stage-small-cell-lung-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/brilinta-reduced-bleeding-vs-dual-therapy-in-high-risk-coronary-patients-in-sub-analyses-from-phase-iv-twilight-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/lokelma-recommended-for-approval-in-eu-for-patients-with-hyperkalaemia-on-stable-haemodialysis.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-divestment-of-movantik-to-redhill-biopharma-completed.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/tagrisso-phase-iii-adaura-trial-will-be-unblinded-early-after-overwhelming-efficacy-in-the-adjuvant-treatment-of-patients-with-egfr-mutated-lung-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/koselugo-selumetinib-approved-in-us-for-paediatric-patients-with-neurofibromatosis-type-1-plexiform-neurofibromas.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-initiates-calavi-clinical-trial-with-calquence-against-covid-19.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-and-saint-lukes-mid-america-heart-institute-initiate-phase-iii-dare-19-trial-with-farxiga-in-covid-19-patients.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/lynparza-shows-overall-survival-in-prostate-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/q1-2020-results.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-and-oxford-university-announce-landmark-agreement-for-covid-19-vaccine.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/farxiga-approved-in-the-us-for-the-treatment-of-heart-failure-in-patients-with-heart-failure-with-reduced-ejection-fraction.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/tlynparza-approved-in-the-us-as-1st-line-maintenance-treatment-with-bevacizumab-for-hrd-positive-advanced-ovarian-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-recovery-of-global-rights-to-brazikumab-medi2070-from-allergan-completed.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/enhertu-granted-breakthrough-therapy-designation-in-the-us-for-her2-positive-metastatic-gastric-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-advances-the-science-of-cancer-medicine-with-practice-changing-data-at-the-asco20-virtual-scientific-program.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/bevespi-aerosphere-approved-in-china-for-patients-with-copd.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/enhertu-granted-breakthrough-therapy-designation-in-the-us-for-her2-mutant-metastatic-non-small-cell-lung-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/lynparza-approved-in-the-us-for-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-advances-response-to-global-covid-19-challenge-as-it-receives-first-commitments-for-oxfords-potential-new-vaccine.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/enhertu-granted-orphan-drug-designation-in-the-us-for-gastric-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-collaborates-with-archerdx-to-use-personalised-cancer-assays-to-detect-minimal-residual-disease-in-lung-cancer-trials.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/tagrisso-demonstrated-unprecedented-disease-free-survival-in-the-adjuvant-treatment-of-stage-ib-iiia-patients-with-egfr-mutated-lung-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/enhertu-achieved-a-tumour-response-rate-of-45p-in-patients-with-her2-positive-metastatic-colorectal-cancer-in-phase-ii-destiny-crc01-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/enhertu-demonstrated-meaningful-clinical-activity-in-patients-with-her2-mutant-non-small-cell-lung-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/enhertu-significantly-improved-tumour-response-rate-and-overall-survival-in-her2-positive-metastatic-gastric-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/imfinzi-showed-a-sustained-overall-survival-benefit-in-1st-line-extensive-stage-small-cell-lung-cancer-in-the-phase-iii-caspian-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/imfinzi-plus-tremelimumab-demonstrated-promising-clinical-activity-and-tolerability-in-patients-with-advanced-liver-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/brilinta-approved-in-the-us-to-reduce-the-risk-of-a-first-heart-attack-or-stroke-in-high-risk-patients-with-coronary-artery-disease.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/lynparza-recommended-for-approval-in-eu-by-chmp-for-brca-mutated-metastatic-pancreatic-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-to-discover-and-develop-novel-therapies-targeting-rna-modifying-proteins-in-oncology-collaboration-with-accent-therapeutics.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-takes-next-steps-towards-broad-and-equitable-access-to-oxford-universitys-covid-19-vaccine.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-presents-new-data-across-continuum-of-care-from-its-broad-renal-portfolio-at-era-edta-2020-virtual-congress.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/calquence-showed-promising-clinical-improvement-in-majority-of-19-hospitalised-covid-19-patients.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-to-showcase-leadership-in-treating-type-2-diabetes-and-cardiorenal-complications-at-ada-2020.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/calquence-showed-long-term-efficacy-and-tolerability-for-patients-with-chronic-lymphocytic-leukaemia-in-two-trials.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-to-supply-europe-with-up-to-400-million-doses-of-oxford-universitys-vaccine-at-no-profit.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/breztri-aerosphere-significantly-reduced-rate-of-moderate-or-severe-copd-exacerbations-in-phase-iii-ethos-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/selumetinib-granted-orphan-drug-designation-in-japan-for-neurofibromatosis-type-1.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/lynparza-approved-in-the-eu-for-brca-mutated-metastatic-pancreatic-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-concludes-agreement-with-the-european-commission-for-the-supply-of-up-to-400-million-doses-of-azd1222-covid-19-vaccine.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/imfinzi-granted-fda-priority-review-for-less-frequent-fixed-dose-use.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/imfinzi-approved-in-japan-for-sclc.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/phase-1-clinical-trial-initiated-for-monoclonal-antibody-combination-for-the-prevention-and-treatment-of-covid-19.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/farxiga-phase-iii-dapa-ckd-trial-paradigm-shifting-data-to-be-presented-at-esc-2020.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/farxiga-demonstrated-reduction-in-the-risk-of-kidney-failure-and-cardiovascular-or-renal-death-in-patients-with-ckd-in-the-phase-iii-dapa-ckd-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/astrazenecas-scientific-and-social-commitment-for-covid-19-vaccine.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/imfinzi-approved-in-EU-for-small-cell-lung-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/development-of-covid-19-vaccine-azd1222-expands-into-us-phase-iii-clinical-trial-across-all-adult-age-groups.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/new-analyses-from-breztri-aerosphere-phase-iii-ethos-trial-to-be-presented-at-the-european-respiratory-society-international-congress-2020.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-aims-to-transform-cancer-treatment-and-advance-clinical-practice-with-data-presented-at-esmo-2020.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/biopharma-leaders-unite-to-stand-with-science.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/statement-on-astrazeneca-oxford-sars-cov-2-vaccine-azd1222-covid-19-vaccine-trials-temporary-pause.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/fasenra-met-both-co-primary-endpoints-of-reduced-nasal-polyp-size-and-blockage-in-the-ostro-phase-iii-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-to-list-us-adr-equity-and-all-us-debt-securities-on-nasdaq.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/tagrisso-reduces-brain-recurrence-in-early-lung.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/imfinzi-demonstrated-unprecedented-survival-in-unresectable-stage-III-nsclc.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/lynparza-reduced-the-risk-of-death-by-31-percent-in-brca-or-atm-mcrpc-in-profound.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/covid-19-vaccine-azd1222-clinical-trials-resumed-in-the-uk.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-acquires-oral-pcsk9-inhibitor-programme-from-dogma-therapeutics.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/lynparza-improved-median-time-patients-lived-without-disease-progression-to-over-four-and-half-years-in-BRCA-mutated-advanced-ovarian-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/lynparza-eu-recommendation-in-prostate-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/lynparza-eu-recommendation-in-ovarian-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/farxiga-granted-breakthrough-therapy-designation-in-us-for-chronic-kidney-disease.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/covid-19-vaccine-azd1222-clinical-trial-resumed-in-japan-follows-restart-of-trials-in-the-uk-brazil-south-africa-and-india.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/covid-19-long-acting-antibody-laab-combination-azd7442-rapidly-advances-into-phase-iii-clinical-trials.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/trixeo-aerosphere-recommended-for-approval-in-the-eu-by-chmp-for-the-maintenance-treatment-of-copd.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/forxiga-recommended-for-approval-in-the-eu-by-chmp-for-heart-failure.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-advances-leadership-in-renal-disease-with-more-than-80-abstracts-at-asn-kidney-week-2020-reimagined.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/tagrisso-adjuvant-lung-cancer-us-priority-review.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/farxiga-dapa-ckd-phase-iii-trial-reduced-worsening-of-kidney-function-risk-of-cardiovascular-or-renal-death-in-patients-with-chronic-kidney-disease.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/fda-authorises-restart-of-the-covid-19-azd1222-vaccine-us-phase-iii-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/year-to-date-and-q3-2020-results.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/enhertu-us-priority-review-in-gastric-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/forxiga-cv-outcomes-benefit-approved-in-china.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/fasenra-eliminated-oral-corticosteroid-use-in-a-majority-of-ocs-dependent-patients-with-asthma-in-ponente-phase-iiib-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/atacand-to-be-divested-to-cheplapharm-in-more-than-70-countries.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/lynparza-approved-in-the-eu-for-prostate-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/lynparza-approved-in-the-eu-for-wider-ovarian-use.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/forxiga-approved-in-the-eu-for-heart-failure.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/calquence-approved-in-the-eu-for-cll.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/brilinta-approved-in-the-us-in-stroke.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/tezepelumab-navigator-phase-iii-trial-met-primary-endpoint.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/update-on-calavi-phase-ii-trials-for-calquence-in-patients-hospitalised-with-respiratory-symptoms-of-covid-19.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-demonstrates-strengths-in-haematology-with-robust-data-at-ash-2020.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/imfinzi-new-dosing-approved-in-the-us.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/azd1222hlr.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/forxiga-approved-in-japan-for-heart-failure.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/crestor-to-be-divested-to-grunenthal-in-europe.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-demonstrates-growing-leadership-in-breast-cancer-at-sabcs.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/calquence-shows-long-term-efficacy-and-tolerability-at-three-years-for-patients-with-relapsed-or-refractory-mantle-cell-lymphoma.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/calquence-data-across-four-trials-reinforces-cardiovascular-safety-profile-in-patients-with-chronic-lymphocytic-leukaemia.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/azd1222-oxford-phase-iii-trials-interim-analysis-results-published-in-the-lancet.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/enhertu-continues-to-demonstrate-durable-responses-with-new-data-from-destiny-breast01-in-her2-positive-metastatic-breast-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-to-acquire-alexion.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/trixeo-aerosphere-approved-in-the-eu-for-copd.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/trastuzumab-deruxtecan-positive-chmp.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/imfinzi-new-dose-receives-positive-eu-chmp-opinion.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/update-on-us-regulatory-review-of-roxadustat-in-anaemia-of-chronic-kidney-disease.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/tagrisso-approved-in-the-us-for-early-lung-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/update-on-source-phase-iii-trial-for-tezepelumab-in-patients-with-severe-oral-corticosteroid-dependent-asthma.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/lynparza-approved-in-japan-for-three-cancers.html
- https://www.astrazeneca.com/media-centre/press-releases/2020/astrazenecas-covid-19-vaccine-authorised-in-uk.html
- https://www.astrazeneca.com/media-centre/press-releases/2019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/update-on-us-regulatory-review-of-pt010-in-copd-01102019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-divests-rights-for-losec-to-cheplapharm-01102019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/fasenra-approved-in-the-us-for-self-administration-in-a-new-pre-filled-auto-injector-the-fasenra-pen-04102019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/trastuzumab-deruxtecan-granted-fda-priority-review-for-treatment-of-patients-with-her2-positive-metastatic-breast-cancer-17102019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/year-to-date-and-q3-2019-results.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/farxiga-approved-in-the-us-to-reduce-the-risk-of-hospitalisation-for-heart-failure-in-patients-with-type-2-diabetes-21102019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-commits-35m-to-help-young-people-tackle-the-threat-of-non-communicable-diseases-22102019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/imfinzi-and-imfinzi-plus-tremelimumab-delayed-disease-progression-in-phase-iii-poseidon-trial-for-1st-line-treatment-of-stage-iv-non-small-cell-lung-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-divests-rights-to-seroquel-and-seroquel-xr-in-europe-and-russia-30102019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-to-present-pivotal-roxadustat-phase-iii-data-at-the-american-society-of-nephrology-kidney-week-2019-30102019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-announces-three-large-scale-initiatives-in-china-to-advance-global-medicine-research-and-development-061120119.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/calquence-data-to-show-improved-progression-free-survival-in-phase-iii-front-line-chronic-lymphocytic-leukaemia-trial-at-ash-2019-annual-meeting.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/roxadustat-significantly-increased-haemoglobin-levels-for-chronic-kidney-disease-patients-with-anaemia-in-phase-iii-olympus-and-rockies-trials.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/roxadustat-phase-iii-programme-pooled-analyses-showed-positive-efficacy-and-no-increased-cv-risk-in-patients-with-anaemia-from-chronic-kidney-disease.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/anifrolumab-demonstrated-superiority-across-multiple-efficacy-endpoints-in-patients-with-systemic-lupus-erythematosus-in-phase-iii-tulip-2-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/us-fda-accepts-regulatory-submission-for-selumetinib-in-neurofibromatosis-type-1-and-grants-priority-review-14112019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/qtrilmet-approved-in-the-eu-for-the-treatment-of-type-2-diabetes-15112019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/calquence-approved-in-the-us-for-adult-patients-with-chronic-lymphocytic-leukaemia-21112019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/harvard-business-review-names-pascal-soriot-among-best-performing-top-100-ceos-in-the-world-2019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/imfinzi-granted-fda-priority-review-for-the-treatment-of-patients-with-extensive-stage-small-cell-lung-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-divests-rights-to-seroquel-and-seroquel-xr-in-the-us-and-canada-03122019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-approved-in-china-as-a-1st-line-maintenance-therapy-in-brca-mutated-advanced-ovarian-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/calquence-significantly-prolonged-the-time-patients-lived-without-disease-progression-or-death-in-previously-untreated-chronic-lymphocytic-leukaemia.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/trastuzumab-deruxtecan-achieved-a-tumour-response-rate-of-60-in-pivotal-phase-ii-her2-positive-metastatic-breast-cancer-trial-11122019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/imfinzi-approved-in-china-for-the-treatment-of-unresectable-stage-iii-non-small-cell-lung-cancer-based-on-the-phase-iii-pacific-trial-12122019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/agreement-with-cheplapharm-for-rights-to-seroquel-and-seroquel-xr-in-europe-and-russia-completed-16122019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-recommended-by-fda-advisory-committee-for-1st-line-maintenance-treatment-of-germline-brca-mutated-metastatic-pancreatic-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-divests-rights-to-arimidex-and-casodex-in-europe-and-certain-additional-countries-20122019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/enhertu-trastuzumab-deruxtecan-approved-in-the-us-for-her2-positive-unresectable-or-metastatic-breast-cancer-following-2-or-more-prior-anti-her2-based-regimens.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/astrazenecas-triple-combination-therapy-approved-in-china-for-patients-with-copd-23122019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/astrazenecas-mene-pangalos-awarded-knighthood-in-the-new-year-2020-honours-list-28122019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-approved-in-the-us-as-a-1st-line-maintenance-treatment-of-germline-brca-mutated-metastatic-pancreatic-cancer-30122019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-receives-positive-eu-chmp-opinion-for-use-in-germline-brca-mutated-her2-negative-advanced-breast-cancer-01032019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-announces-organisational-changes.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/linzess-linaclotide-approved-in-china-for-the-treatment-of-irritable-bowel-syndrome-with-constipation-18012019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/forxiga-receives-positive-eu-chmp-opinion-for-the-treatment-of-adults-with-type-1-diabetes.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/ema-grants-prime-eligibility-for-potential-next-generation-rsv-medicine-medi8897-05022019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/us-fda-grants-breakthrough-therapy-designation-for-potential-next-generation-rsv-medicine-medi8897.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/us-fda-grants-fasenra-orphan-drug-designation-for-hypereosinophilic-syndrome.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-significantly-delayed-disease-progression-as-1st-line-maintenance-treatment-in-germline-brca-mutated-metastatic-pancreatic-cancer-26022019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-to-present-new-cardiovascular-data-on-farxiga-in-type-2-diabetes-at-acc-2019-11032019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/us-fda-grants-saracatinib-orphan-drug-designation-for-idiopathic-pulmonary-fibrosis-18032019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/brilintas-phase-iii-themis-trial-met-primary-endpoint-in-patients-with-established-coronary-artery-disease-and-type-2-diabetes-25022019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/full-year-2018-results-14022019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/first-sub-analyses-from-the-declare-timi-58-trial-further-support-the-cardiovascular-effects-of-farxiga-in-type-2-diabetes-18032019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/forxiga-approved-in-japan-for-type-1-diabetes-27032019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/forxiga-approved-in-europe-for-type-1-diabetes22032019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/astraZeneca-showcases-next-generation-oncology-pipeline-addressing-unmet-patient-needs-at-aacr-annual-meeting.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/proposed-placing-of-new-ordinary-shares.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-and-daiichi-sankyo-enter-collaboration-for-novel-her-2-targeting-antibody-drug-conjugate.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/positive-results-from-fasenra-phase-ii-trial-in-hypereosinophilic-syndrome-published-in-new-england-journal-of-medicine-04042019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-approved-in-eu-for-the-treatment-of-germline-brca-mutated-her2-negative-advanced-breast-cancer-10042019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/selumetinib-granted-us-breakthrough-therapy-designation-in-neurofibromatosis-type-1-01042019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-receives-positive-eu-chmp-opinion-for-1st-line-maintenance-treatment-of-brca-mutated-advanced-ovarian-cancer-26042019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-starts-artificial-intelligence-collaboration-to-accelerate-drug-discovery-30042019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/qternmet-xr-approved-in-the-us-for-the-treatment-of-type-2-diabetes-03052019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/calquence-phase-iii-ascend-trial-met-primary-endpoint-at-interim-analysis-in-relapsed-or-refractory-chronic-lymphocytic-leukaemia-and-will-stop-early-07052019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/trastuzumab-deruxtecan-demonstrated-clinically-meaningful-response-in-patients-with-refractory-her2-positive-metastatic-breast-cancer-a-population-with-high-unmet-need-08052019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/pooled-analyses-of-the-roxadustat-global-phase-3-programme-confirmed-cardiovascular-safety.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/new-data-on-symbicort-as-a-potential-anti-inflammatory-reliever-in-mild-asthma-to-be-presented-at-ats-2019-16052019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-continues-to-redefine-cancer-treatment-at-the-2019-asco-annual-meeting-16052019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/new-data-show-symbicort-reduces-attacks-in-mild-asthma-when-used-as-an-anti-inflammatory-reliever-20052019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-nearly-doubled-the-time-patients-lived-without-disease-progression-from-germline-brca-mutated-metastatic-pancreatic-cancer02062019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/Q1-2019-results.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-nearly-doubled-the-time-patients-lived-without-disease-progression-from-germline-brca-mutated-metastatic-pancreatic-cancer02062019-2.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-achieved-a-72-objective-response-rate-in-patients-with-relapsed-germline-brca-mutated-advanced-ovarian-cancer-03062019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/calquence-phase-iii-elevate-tn-trial-met-primary-endpoint-at-interim-analysis-in-previously-untreated-chronic-lymphocytic-leukaemia06062019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/lokelma-demonstrated-efficacy-in-treating-hyperkalaemia-in-patients-with-end-stage-renal-disease-on-haemodialysis14062019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/imfinzi-is-the-only-immunotherapy-to-demonstrate-overall-survival-at-three-years-in-unresectable-stage-iii-non-small-cell-lung-cancer02062019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/calquence-significantly-prolonged-the-time-patients-lived-without-disease-progression-in-relapsed-or-refractory-chronic-lymphocytic-leukaemia15062019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-approved-in-the-eu-for-1st-line-maintenance-treatment-of-brca-mutated-advanced-ovarian-cancer-18062019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/bevespi-aerosphere-approved-by-the-japanese-ministry-of-health-labour-and-welfare-for-patients-with-chronic-obstructive-pulmonary-disease-19062019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/breztri-aerosphere-pt010-approved-in-japan-for-patients-with-chronic-obstructive-pulmonary-disease-19062019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-approved-in-japan-for-1st-line-maintenance-therapy-in-brca-mutated-advanced-ovarian-cancer-19062019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/imfinzi-improves-overall-survival-at-interim-analysis-in-the-phase-iii-caspian-trial-in-1st-line-extensive-stage-small-cell-lung-cancer-27062019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/fasenra-receives-positive-eu-chmp-opinion-for-self-administration-and-the-new-fasenra-pen-a-pre-filled-single-use-auto-injector-01072019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/forxiga-receives-positive-eu-chmp-opinion-for-declare-timi-58-cardiovascular-outcomes-data-01072019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/imfinzi-granted-us-orphan-drug-designation-for-small-cell-lung-cancer12072019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/update-on-us-regulatory-decision-for-farxiga-in-type-1-diabetes-15072019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/H1-2019-results.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/forxiga-label-updated-in-the-eu-in-type-2-diabetes.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-phase-iii-profound-trial-in-hrr-mutation-selected-metastatic-castration-resistant-prostate-cancer-met-primary-endpoint-07082019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/tagrisso-significantly-improves-overall-survival-in-the-phase-iii-flaura-trial-for-1st-line-egfr-mutated-non-small-cell-lung-cancer-09082019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/calquence-granted-us-breakthrough-therapy-designation-for-chronic-lymphocytic-leukaemia-14082019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-phase-iii-paola-1-trial-met-primary-endpoint-as-1st-line-maintenance-treatment-with-bevacizumab-for-advanced-ovarian-cancer-14082019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/farxiga-met-primary-endpoint-in-landmark-phase-iii-dapa-hf-trial-for-the-treatment-of-patients-with-heart-failure-20082019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/update-on-the-phase-iii-neptune-trial-of-imfinzi-plus-tremelimumab-in-stage-iv-non-small-cell-lung-cancer-21082019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-agrees-to-buy-us-fda-priority-review-voucher-from-sobi-22082019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/roxadustat-approved-in-china-for-the-treatment-of-anaemia-in-non-dialysis-dependent-patients-with-chronic-kidney-disease-22082019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/fda-grants-fast-track-designation-for-farxiga-in-chronic-kidney-disease-27082019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/breztri-aerosphere-phase-iii-ethos-trial-met-its-primary-endpoint-in-chronic-obstructive-pulmonary-disease-28082019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/fasenra-granted-us-orphan-drug-designation-for-eosinophilic-oesophagitis-28082019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/anifrolumab-phase-iii-trial-meets-primary-endpoint-in-systemic-lupus-erythematosus-29082019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-to-present-data-at-esc-congress-2019-that-potentially-redefines-the-treatment-of-heart-failure-29082019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/detailed-results-from-phase-iii-dapa-hf-trial-showed-farxiga-significantly-reduced-both-the-incidence-of-cardiovascular-death-and-the-worsening-of-heart-failure-01092019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/brilinta-reduced-the-risk-of-cardiovascular-events-in-patients-with-coronary-artery-disease-and-type-2-diabetes-in-phase-iii-themis-trial-01092018.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/tagrisso-approved-in-china-as-a-1st-line-treatment-for-egfr-mutated-non-small-cell-lung-cancer-04092019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/rns1.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-redefines-cancer-treatment-with-practice-changing-data-at-esmo-2019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/fda-grants-fast-track-designation-for-farxiga-in-heart-failure.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-amends-collaboration-with-ironwood-for-linzess-in-china.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/qtrilmet-recommended-for-approval-in-eu-by-chmp-for-the-treatment-of-type-2-diabetes-23092019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-to-present-next-wave-of-science-in-respiratory-disease-at-ers-international-congress-25092019.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/tagrisso-is-the-only-1st-line-treatment-for-egfr-mutated-non-small-cell-lung-cancer-to-deliver-a-median-overall-survival-of-more-than-three-years.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-improved-the-time-women-lived-without-disease-progression-to-22-months-in-the-broad-population-and-to-37-months-in-hrd-positive-patients.html
- https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-more-than-doubled-the-time-without-disease-progression-in-patients-with-brca1-2-atm-mutated-metastatic-castration-resistant-prostate-cancer-30092019.html
- https://www.astrazeneca.com/media-centre/press-releases/2018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/lokelma-approved-in-the-eu-for-the-treatment-of-adults-with-hyperkalaemia-22032018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-receives-eu-approval-of-fasenra-for-severe-eosinophilic-asthma-10012018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/lynparza-approved-by-us-fda-in-germline-brca-mutated-metastatic-breast-cancer-12012018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/fasenra-recieves-approval-in-japan-19012018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/lynparza-receives-approval-in-japan-for-the-treatment-of-advanced-ovarian-cancer-19012018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-listed-as-one-of-the-worlds-top-100-most-sustainable-companies-and-recognised-for-its-three-fold-increase-in-renewable-energy-usage-23012018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-reports-top-line-phase-iii-kronos-trial-results-for-pt010-triple-combination-therapy-in-chronic-obstructive-pulmonary-disease-26102018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/full-year-2017-results.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/brilinta-significantly-reduces-cv-events-and-coronary-death-beyond-one-year-in-heart-attack-survivors-with-multi-vessel-disease-07022018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/selumetinib-granted-orphan-drug-designation-by-the-us-fda-for-neurofibromatosis-type-1-15022018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/us-fda-approves-imfinzi-for-unresectable-stage-iii-non-small-cell-lung-cancer-180202018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/lynparza-receives-positive-eu-chmp-opinion-in-platinum-sensitive-relapsed-ovarian-cancer-23022018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/medimmune-to-create-stand-alone-company-for-early-stage-inflammation-and-autoimmunity-biologics-28022018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/the-european-medicines-agency-accepts-regulatory-submission-for-forxiga-in-adults-with-type-1-diabetes-05032018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-aims-to-advance-clinical-practice-in-cv-risk-management-with-new-data-at-acc-2018-05032018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-provides-update-on-mystic-trial-timeline-12032018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/new-data-from-landmark-cvd-real-study-of-patients-with-type-2-diabetes-confirms-cv-benefits-associated-with-sglt-2-inhibitors-12032018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/us-fda-accepts-biologics-license-application-for-moxetumomab-pasudotox-in-hairy-cell-leukaemia-03042018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/the-european-medicines-agency-accepts-regulatory-submission-for-lynparza-in-brca-mutated-her2-negative-metastatic-breast-cancer-03042018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/astrazenecas-early-and-late-stage-oncology-portfolio-showcased-at-aacr-annual-meeting-and-elcc-04042018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/1st-line-tagrisso-demonstrates-sustained-benefit-post-progression-in-patients-with-egfr-mutated-non-small-cell-lung-cancer-13042018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/updated-overall-survival-data-for-lynparza-in-brca-mutated-her2-negative-metastatic-breast-cancer-presented-at-aacr-16042018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/us-fda-approves-tagrisso-as-1st-line-treatment-for-EGFR-mutated-non-small-cell-lung-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-reports-results-from-the-arctic-trial-in-third-line-non-small-cell-lung-cancer-24042018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/tagrisso-receives-positive-eu-chmp-opinion-for-1st-line-treatment-of-egfr-mutated-non-small-cell-lung-cancer27042018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/lynparza-tablets-receive-eu-approval-for-the-treatment-of-platinum-sensitive-relapsed-ovarian-cancer08052018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-and-luye-pharma-group-enter-agreement-for-rights-to-seroquel-and-seroquel-xr-in-the-uk-china-and-other-international-markets.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-provides-update-on-galathea-phase-iii-trial-for-fasenra-in-chronic-obstructive-pulmonary-disease-11052018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-is-advancing-clinical-practice-in-respiratory-medicine-with-new-data-at-the-american-thoracic-society-2018-international-congress.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/new-england-journal-of-medicine-publishes-two-trials-for-symbicort-as-an-anti-inflammatory-reliever-therapy-as-needed-in-mild-asthma16052018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/q1-2018-results.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/regulatory-submission-in-japan-for-forxiga-in-type-1-diabetes-21052018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/lokelma-approved-in-the-us-for-the-treatment-of-adults-with-hyperkalaemia-21052018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-heads-to-2018-asco-annual-meeting-with-its-diversified-oncology-portfolio-and-next-generation-pipeline24052018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/imfinzi-significantly-improves-overall-survival-in-the-phase-iii-pacific-trial-for-unresectable-stage-iii-non-small-cell-lung-cancer-25052018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/update-on-terranova-phase-iii-trial-for-fasenra-in-chronic-obstructive-pulmonary-disease-30052018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/moxetumomab-pasudotox-pivotal-data-in-patients-with-previously-treated-hairy-cell-leukaemia-presented-at-the-2018-asco-meeting-04062018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/lynparza-in-combination-with-abiraterone-delayed-disease-progression-in-metastatic-castration-resistant-prostate-cancer-04062018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/the-eu-approves-tagrisso-for-1st-line-treatment-of-egfr-mutated-non-small-cell-lung-cancer-08062018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/update-on-phase-iii-clinical-trials-of-lanabecestat-for-alzheimers-disease-12062018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-to-share-latest-data-from-an-industry-leading-portfolio-that-aims-to-advance-clinical-understanding-of-diabetes-and-cv-risk-management-at-ada-2018-19062018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/lynparza-significantly-delays-disease-progression-in-phase-iii-1st-line-solo-1-trial-for-ovarian-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/bydureon-receives-positive-eu-chmp-opinion-for-new-bcise-device-for-patients-with-type-2-diabetes-29062018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/lynparza-approved-in-japan-for-brca-mutated-metastatic-breast-cancer-02072018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/imfinzi-approved-in-japan-for-unresectable-stage-iii-non-small-cell-lung-cancer-02072018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/Atacand-to-be-divested-to-Cheplapharm-in-Europe24072018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/h1-2018-results-25072018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/imfinzi-receives-positive-eu-chmp-opinion-for-locally-advanced-unresectable-non-small-cell-lung-cancer-27072018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/selumetinib-granted-orphan-designation-in-europe-for-neurofibromatosis-type-1-03082018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-is-advancing-understanding-of-cardio-renal-metabolic-interconnectivity-with-new-evidence-at-esc-2018-20082018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/tagrisso-approved-in-japan-for-1st-line-treatment-of-egfr-mutated-non-small-cell-lung-cancer-21082018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/european-commission-approves-new-easy-to-use-once-weekly-bydureon-bcise-device-for-patients-with-type-2-diabetes30082018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/update-on-tulip-1-phase-iii-trial-for-anifrolumab-in-systemic-lupus-erythematosus-31082018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-provides-update-on-aeristo-phase-iiib-trial-for-bevespi-aerosphere-in-chronic-obstructive-pulmonary-disease23082018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/tezepelumab-granted-breakthrough-therapy-designation-by-us-fda-07092018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-to-present-fasenra-long-term-safety-and-efficacy-data-at-european-respiratory-society-international-congress-2018-13092018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/new-data-on-mechanisms-of-acquired-resistance-after-1st-line-tagrisso-in-nsclc-support-initiation-of-orchard-trial-to-explore-post-progression-treatment-options-19102018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/us-fda-approves-lumoxiti-moxetumomab-pasudotox-tdfk-for-certain-patients-with-relapsed-or-refractory-hairy-cell-leukaemia.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/the-lancet-respiratory-medicine-publishes-first-phase-iii-trial-for-pt010-triple-combination-therapy-in-moderate-to-very-severe-chronic-obstructive-pulmonary-disease-16092018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/fasenra-shows-consistent-safety-and-sustained-efficacy-in-long-term-phase-iii-bora-trial-in-severe-eosinophilic-asthma-18092018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-presents-further-data-showing-the-interconnectivity-between-cardiovascular-and-renal-risks-in-diabetes-at-easd-2018-20092018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/bydureon-receives-positive-eu-chmp-opinion-for-exscel-cardiovascular-outcomes-data-25092018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/european-commission-approves-imfinzi-for-locally-advanced-unresectable-nsclc-24092018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/farxiga-achieved-a-positive-result-in-the-phase-iii-declare-timi-58-trial-a-large-cardiovascular-outcomes-trial-in-17000-patients-with-type-2-diabetes-24092018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/imfinzi-is-the-first-immunotherapy-to-demonstrate-significant-overall-survival-benefit-in-unresectable-stage-iii-lung-cancer25092018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-presents-advances-in-improving-treatment-options-for-ovarian-and-lung-cancer-patients-at-esmo-2018-09102018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/us-fda-grants-lynparza-orphan-drug-designation-for-pancreatic-cancer-16102018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/chmp-issues-a-positive-opinion-for-bevespi-aerosphere-for-the-treatment-of-chronic-obstructive-pulmonary-disease-19102018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-to-present-new-data-demonstrating-breadth-of-research-portfolio-in-renal-disease-at-asn-kidney-week-22102018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-strengthens-and-expands-oncology-development-and-commercialisation-collaboration-with-innate-pharma23102018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/agreement-with-grunenthal-for-rights-to-nexium-in-europe-and-vimovo-worldwide-ex-us-30102018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/us-fda-accepts-regulatory-submission-for-lynparza-maintenance-therapy-in-newly-diagnosed-brca-mutated-advanced-ovarian-cancer-and-grants-priority-review-12112018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/year-to-date-and-q3-2018-results-08112018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/the-landmark-declare-timi-58-cardiovascular-outcomes-trial-of-farxiga-in-patients-with-type-2-diabetes-to-be-featured-at-aha-01112018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/solo-1-phase-III-trial-demonstrates-lynparza-maintenance-therapy-cut-risk-of-disease-progression-or-death-by-70-percent-in-patients-with-newly-diagnosed-advanced-brca-mutated-ovarian-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/phase-iii-harmonize-global-trial-of-lokelma-confirms-efficacy-in-maintaining-normal-potassium-levels-in-asian-patients-with-hyperkalaemia-25102018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/divestment-of-rights-to-alvescoomnaris-and-zetonna-to-covis-pharma06112018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/farxiga-significantly-reduced-hospitalisation-for-heart-failure-or-cv-death-in-a-broad-patient-population-with-type-2-diabetes-in-the-landmark-declare-timi-58-trial.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-to-divest-us-synagis-rights-to-sobi131120180.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-provides-update-on-the-phase-iii-mystic-trial-of-imfinzi-and-tremelimumab-in-stage-iv-non-small-cell-lung-cancer16112018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/update-on-the-phase-iii-eagle-trial-of-imfinzi-and-tremelimumab-in-advanced-head-and-neck-cancer-07122018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-and-cancer-research-uk-launch-functional-genomics-centre-to-accelerate-the-discovery-of-new-medicines-10122018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/us-fda-grants-fasenra-orphan-drug-designation-for-eosinophilic-granulomatosis-with-polyangiitis-26112018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/phase-iii-olympus-and-rockies-trials-for-roxadustat-met-their-primary-endpoints-in-chronic-kidney-disease-patients-with-anaemia20122018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-presents-clinical-research-advances-for-blood-cancer-patients-at-2018-american-society-of-hematology-annual-meeting-27112018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/roxadustat-approved-in-china-for-the-treatment-of-anaemia-in-chronic-kidney-disease-patients-on-dialysis18122018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/lynparza-meets-primary-endpoint-in-phase-iii-solo-3-trial-for-the-treatment-of-relapsed-brca-mutated-advanced-ovarian-cancer20122018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/new-long-term-data-on-calquence-presented-at-ash-2018-03122018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/lynparza-approved-by-us-fda-for-1st-line-maintenance-therapy-in-brca-mutated-advanced-ovarian-cancer19122018.html
- https://www.astrazeneca.com/media-centre/press-releases/2018/bevespi-aerosphere-approved-in-the-eu-for-chronic-obstructive-pulmonary-disease-20122018.html
- https://www.astrazeneca.com/media-centre/press-releases/2017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-and-pieris-pharmaceuticals-collaborate-to-develop-and-commercialise-anticalin-based-inhaled-treatments-for-respiratory-diseases-03052017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-expands-1st-line-lung-cancer-immuno-oncology-programme-opportunities-17012017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/symbicort-granted-paediatric-exclusivity-in-the-us-26012017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/full-year-and-q4-2016-results-02022017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/Siliq-brodalumab-approved-by-the-US-FDA-for-adult-patients-with-moderate-to-severe-plaque-psoriasis-160220170.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/lynparza-meets-primary-endpoint-in-phase-iii-trial-in-brca-mutated-metastatic-breast-cancer-17022017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/updated-durvalumab-monotherapy-data-confirm-results-in-urothelial-bladder-cancer-17022017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-enters-agreement-with-tersera-therapeutics-for-zoladex-in-the-us-and-canada-20022017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/zs-9-sodium-zirconium-cyclosilicate-receives-positive-chmp-opinion-for-the-treatment-of-hyperkalaemia-24022017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/fda-approves-once-daily-qtern-dapagliflozin-and-saxagliptin-tablets-for-adults-with-type-2-diabetes-240217.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/medimmune-and-sanofi-pasteur-form-alliance-to-develop-and-commercialise-potential-next-generation-respiratory-syncytial-virus-antibody-medi8897-030317.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/lynparza-phase-iii-solo-2-data-demonstrate-progression-free-survival-benefit-in-brca-mutated-ovarian-cancer-as-maintenance-therapy-14032017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-receives-complete-response-letter-from-us-fda-for-zs-sodium-zirconium-cyclosilicate-for-hyperkalaemia-17032017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-and-circassia-enter-strategic-collaboration-in-respiratory-disease-17032017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-s-cvd-real-study-shows-sglt-2-inhibitors-significant-reduced-death-and-hospitalisations-for-heart-failure-versus-other-type-2-diabetes-medicines-19032017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/tagrisso-approved-in-china-as-first-in-class-treatment-for-egfr-t790m-mutation-positive-metastatic-non-small-cell-lung-cancer-27032017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-to-share-its-robust-early-science-in-oncology-with-the-medical-community-at-aacr-28032017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/astrazenecas-potential-medicine-for-neuromyelitis-optica-spectrum-disorder-receives-orphan-designation-in-europe-29032017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/tagrisso-osimertinib-receives-us-fda-full-approval-31032017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-marks-a-key-milestone-with-the-topping-out-of-new-global-r-and-d-centre-and-hq-in-cambridge-uk-25042017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/tagrisso-receives-full-approval-in-the-eu-25042017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/q1-2017-results.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/astrazenecas-imfinzi-durvalumab-receives-us-fda-accelerated-approval-for-previously-treated-patients-with-advanced-bladder-cancer-01052017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-provides-update-on-stratos-1-phase-iii-trial-of-tralokinumab-in-severe-uncontrolled-asthma-100517.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/imfinzi-significantly-reduces-the-risk-of-disease-worsening-or-death-in-the-phase-iii-pacific-trial-for-stage-iii-unresectable-lung-cancer-12052017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-to-present-scientific-advancements-from-growing-respiratory-portfolio-at-the-american-thoracic-society-conference-2017-18052017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/brodalumab-receives-positive-chmp-opinion-for-the-treatment-of-adult-patients-with-moderate-to-severe-plaque-psoriasis-19052017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-enters-agreement-with-recordati-for-seloken-in-europe-22052017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/phase-iii-zonda-trial-for-benralizumab-shows-ability-to-reduce-oral-steroid-use-in-severe-asthma-patients-22052017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/bydureon-exscel-trial-meets-primary-safety-objective-in-type-2-diabetes-patients-at-wide-range-of-cardiovascular-risk-23052017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-delivers-new-data-on-expanding-portfolio-of-cancer-medicines-at-2017-american-society-of-clinical-oncology-(asco)-annual-meeting-26052017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-appoints-professor-nazneen-rahman-to-its-board-of-directors-and-science-committee-31052017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/lynparza-significantly-reduces-the-risk-of-disease-worsening-or-death-in-patients-with-BRCA-mutated-metastatic-breast-cancer-04062017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-enters-agreement-with-grunenthal-to-divest-rights-to-migraine-treatment-zomig-07062017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-to-present-scientific-advances-in-cardiovascular-and-metabolic-diseases-at-2017-ada-scientific-sessions-08062017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-presents-new-data-underpinning-safety-profile-and-real-world-cv-outcomes-of-farxiga-at-ada-2017-12062017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/faslodex-fulvestrant-receives-positive-chmp-opinion-for-use-in-1st-line-hormone-receptor-positive-advanced-breast-cancer-23062017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/kyntheum-approved-in-the-eu-for-the-treatment-of-adults-with-moderate-to-severe-plaque-psoriasis-20072017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/faslodex-receives-eu-approval-as-first-line-therapy-for-advanced-breast-cancer-26072017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/h1-2017-results.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-and-merck-establish-strategic-oncology-collaboration-27072017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-reports-initial-results-from-the-ongoing-mystic-trial-in-stage-iv-lung-cancer-27072017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/tagrisso-significantly-improves-progression-free-survival-in-the-phase-iii-flaura-trial-for-lung-cancer-27072017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/imfinzi-granted-breakthrough-therapy-designation-by-us-fda-for-patients-with-locally-advanced-unresectable-non-small-cell-lung-cancer-31072017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/acalabrutinib-granted-breakthrough-therapy-designation-by-us-fda-for-the-treatment-of-patients-with-mantle-cell-lymphoma-01082017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/us-fda-accepts-regulatory-submission-for-acalabrutinib-and-grants-priority-review-02082017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/lynparza-receives-additional-and-broad-approval-in-the-us-for-ovarian-cancer-17082017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/extended-treatment-with-brilinta-reduces-risk-of-cardiovascular-death-by-29-percent-in-patients-with-history-of-heart-attack-24082017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-and-takeda-establish-collaboration-to-develop-and-commercialise-medi1341-for-parkinsons-disease-25082017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/faslodex-receives-us-fda-approval-as-monotherapy-for-expanded-use-in-breast-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-highlights-latest-advances-in-lung-cancer-at-the-esmo-2017-congress-31082017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-to-present-data-on-next-generation-of-biologics-at-european-respiratory-society-international-congress-04092017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/tezepelumab-significantly-reduced-asthma-exacerbations-for-a-broad-population-of-patients-with-severe-uncontrolled-asthma-06092017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/duaklir-significantly-improves-lung-function-in-copd-patients-07092017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/celgene-and-astrazeneca-provide-update-on-the-fusion-clinical-trial-programme-07092017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-tagrisso-shows-potential-as-a-new-standard-of-care-in-1st-line-egfr-mutated-lung-cancer-at-esmo-2017-congress-08092017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-presents-superior-progression-free-survival-for-imfinzi-in-the-pacific-trial-of-patients-with-locally-advanced-unresectable-lung-cancer-at-esmo-2017-congress-08092017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-presents-new-results-identifying-severe-asthma-patients-who-would-benefit-most-from-benralizumab-11092017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-and-aspen-enter-agreement-for-remaining-rights-to-anaesthetics-medicines14092017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/bydureon-exscel-trial-demonstrates-favourable-cardiovascular-cv-safety-profile-and-fewer-cv-events-in-patients-with-type-2-diabetes-at-wide-range-of-cv-risk14092017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/bevespi-aerosphere-demonstrates-statistically-significant-improvement-in-lung-function-in-patients-with-copd-25092017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/the-european-medicines-agency-accepts-marketing-authorisation-application-for-imfinzi-in-locally-advanced-unresectable-non-small-cell-lung-cancer-09102017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/tagrisso-granted-breakthrough-therapy-designation-by-us-fda-for-the-1st-line-treatment-of-patients-with-egfr-mutation-positive-non-small-cell-lung-cancer-09102017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-shares-its-comprehensive-scientific-approach-at-the-world-conference-on-lung-cancer-2017-16102017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/us-fda-accepts-supplemental-biologics-license-application-for-imfinzi-in-locally-advanced-unresectable-non-small-cell-lung-cancer-171017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/us-fda-accepts-regulatory-submission-for-lynparza-in-metastatic-breast-cancer-and-grants-priority-review-18102017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/us-fda-approves-new-easy-to-use-once-weekly-bydureon-bcise-injectable-medicine-for-patients-with-type-2-diabetes-231017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-and-msd-rapidly-advance-lynparza-in-japan-with-a-second-regulatory-submission-231017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/us-fda-approves-astrazenecas-calquence-acalabrutinib-for-adult-patients-with-previously-treated-mantle-cell-lymphoma-24102017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-and-incyte-enter-clinical-trial-collaboration-in-early-lung-cancer-31102017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-provides-update-on-tralokinumab-phase-iii-programme-in-severe-uncontrolled-asthma-01112017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-shares-scientific-updates-from-its-extensive-cardiovascular-renal-and-metabolic-diseases-cvmd-portfolio-at-aha-2017-08112017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/year-to-date-and-q3-2017-results.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/benralizumab-receives-positive-eu-chmp-opinion-for-severe-uncontrolled-eosinophilic-asthma-10112017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/fasenra-benralizumab-receives-us-fda-approval-for-severe-uncontrolled-eosinophilic-asthma-14112017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/faslodex-receives-us-fda-approval-for-the-treatment-of-advanced-breast-cancer-in-combination-with-abemaciclib-15112017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/the-european-medicines-agency-accepts-regulatory-submission-for-tagrisso-in-1st-line-egfr-mutated-non-small-cell-lung-cancer-24112017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-and-chinese-future-industry-investment-fund-establish-joint-venture-to-develop-new-medicines-in-china-27112017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-makes-regulatory-submission-for-tagrisso-in-1st-line-egfr-mutated-non-small-cell-lung-cancer-in-japan-27112017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/tudorza-reduces-exacerbations-and-demonstrates-cardiovascular-safety-in-copd-patients-041217.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-to-highlight-its-commitment-to-blood-cancers-at-the-2017-american-society-of-hematology-annual-meeting-06122017.html
- https://www.astrazeneca.com/media-centre/press-releases/2017/us-fda-accepts-regulatory-submission-for-tagrisso-in-1st-line-egfr-mutated-non-small-cell-lung-cancer-18122017.html
- https://www.astrazeneca.com/media-centre/press-releases/2016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-head-and-neck-cancer-trials-27102016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/q3-2016-results.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/fda-accepts-for-review-new-drug-application-for-sodium-zirconium-18102016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/lynparza-phase-iii-solo-2-trial-shows-significant-progression-free-survival-benefit-261020161.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-completes-acquisition-of-takedas-respiratory-business.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-enters-licensing-agreements-with-leo-pharma-in-skin-diseases-01072016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/Tagrisso-met-primary-endpoint-in-phase-III-2nd-line-lung-cancer-trial-18072016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/AstraZeneca-receives-approval-in-the-EU-for-Qtern-saxagliptin-and-dapagliflozin-for-treatment-of-Type-2-diabetes.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/AstraZenecas-antibiotic-Zavicefta-met-primary-endpoints-in-Phase-III-trial-for-treatment-of-hospital-acquired-pneumonia-21072016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/AstraZeneca-files-first-clinical-trial-application-in-Moderna-messenger-RNA-collaboration-26072016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/h1-2016-results.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/AstraZeneca-provides-update-on-Phase-III-trial-of-Selumetinib-in-non-small-cell-lung-cancer-09082016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-and-lilly-receive-fda-fast-track-designation-for-azd3293-as-potential-treatment-for-early-alzheimers-disease-22082016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/AstraZeneca-to-sell-small-molecule-antibiotics-business-to-Pfizer-24082016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-to-present-new-data-highlighting-its-growing-respiratory-portfolio-ERS-30082016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/AstraZeneca-completes-commercialisation-agreement-with-Aspen-for-anaesthetics-portfolio-01092016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/benralizumub-phase-III-trials-show-positive-results-in-severe-asthma-05092016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/pepfar-and-astrazeneca-launch-partnership-across-hiv-and-hypertension-services-in-africa-080920161.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-announces-two-new-phase-IIIb-trials-for-Forxiga-in-chronic-kidney-disease-and-chronic-heart-failure-120920161.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/phase-III-combination-trial-of-bydureon-and-forxiga-shows-significant-benefits-in-patients-with-type-2-diabetes-1609201611.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-provides-update-on-cediranib-eu-marketing-authorisation-application-21092016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/AstraZeneca-presents-new-data-on-Faslodex-in-breast-cancer-and-provides-immuno-oncology-update-at-ESMO-2016-congress-30092016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/medimmune-out-licenses-potential-medicine-for-inflammatory-diseases-to-allergan-03102016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-reports-top-line-results-from-the-brilinta-euclid-trial-in-patients-with-peripheral-artery-disease-04102016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-enters-agreement-with-aralez-for-beta-blocker-medicine-in-the-us-04102016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-enters-agreement-with-cilag-gmbh-international-to-divest-rights-to-rhinocort-aqua-outside-the-us-071020161.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/MedImmune-completes-out-licensing-agreement-with-Allergan-for-MEDI2070-17112016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/AstraZeneca-and-Moderna-Therapeutics-announce-new-collaboration-to-co-develop-and-co-commercialise-immuno-oncology-mRNA-therapeutics-11012016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-and-incyte-announce-new-lung-cancer-clinical-trial-collaboration-11012016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/AstraZeneca-partners-with-peers-and-academia-to-establish-translational-research-fund.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/Lynparza-Olaparib-granted-Breakthrough-Therapy-Designation-by-US-FDA-for-treatment-of-BRCA1-2-or-ATM-gene-mutated-metastatic-Castration-Resistant-Prostate-Cancer-28012016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-completes-transaction-for-majority-equity-stake-investment-in-acerta-pharma-01022016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/tagrisso-osimertinib-approved-in-eu-as-first-in-class-treatment-for-lung-cancer-03022016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/full-year-and-q4-2015-results-04022016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/AstraZeneca-and-Medimmune-enter-consortium-to-deliver-new-treatments-for-chronic-kidney-disease-11022016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/Durvalumab-granted-Breakthrough-Therapy-designation-by-US-FDA-for-treatment-of-patients-with-PD-L1-positive-urothelial-bladder-cancer-17022016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/zurampic-lesinurad-approved-in-the-european-union-for-patients-with-gout-19022016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/Brilique-ticagrelor-approved-in-EU-for-extended-treatment-of-patients-with-history-of-heart-attack-19022016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/acalabrutinib-recommended-for-orphan-drug-designation-in-europe-for-three-indications-25022016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/AstraZeneca-enters-licensing-agreement-with-China-Medical-System-Holdings-for-hypertension-medicine-29022016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-reports-top-line-result-of-tremelimumab-monotherapy-trial-in-mesothelioma-29022016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-enters-into-agreement-with-prostrakan-for-rights-to-moventig-in-europe-03012016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/Medimmune-receives-fast-track-designation-in-the-US-for-MEDI8852-for-treatment-of-patients-hospitalised-with-influenza-A-07032016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/astrazenecas-potential-medicine-for-neuromyelitis-optica-receives-fda-orphan-drug-designation-09032016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-reports-top-line-results-from-the-brilinta-socrates-trial-in-stroke-23032016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/tagrisso-approved-in-japan-for-patients-with-egfr-t790m-mutation-positive-metastatic-non-small-cell-lung-cancer-29032016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/brilinta-preferred-over-clopidogrel-in-updated-american-college-of-cardiology-and-american-heart-association-guideline-in-acute-coronary-syndrome-31032016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/pandemic-influenza-vaccine-receives-positive-chmp-opinion-01042016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/AstraZeneca-to-showcase-clinical-and-scientific-leadership-in-lung-cancer-at-ELCC-2016-06042016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/AstraZeneca-and-Eli-Lilly-and-company-announce-continuation-of-pivotal-clinical-trial-for-people-with-early-alzheimers-disease-08042016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-showcases-breadth-of-oncology-portfolio-at-aacr-2016-annual-meeting-14042016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/AstraZeneca-launches-integrated-genomics-approach-to-transform-drug-discovery-and-development-22042016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/bevespi-aerosphere-approved-by-the-us-fda-for-patients-with-copd-25042016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-enters-into-us-licensing-agreement-with-ironwood-pharmaceuticals-for-lesinurad-26042016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/q1-2016-results.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/positive-chmp-opinion-for-caz-avi-in-the-eu-for-serious-bacterial-infections-29042016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-completes-divestment-of-imdur-to-china-medical-system-holdings-03052016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/selumetinib-granted-orphan-drug-designation-in-the-US-for-adjuvant-treatment-of-differentiated-thyroid-cancer-12052016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-to-highlight-the-breadth-of-its-respiratory-medicines-at-american-thoracic-society-2016-international-conference-12052016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-announces-positive-results-from-benralizumab-phase-iii-programme-in-severe-asthma-17052016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-provides-top-line-results-from-lynparza-gold-trial-in-advanced-gastric-cancer-1805206.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-highlights-continued-progress-of-oncology-pipeline-at-asco-2016-19052016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/astrazenecas-faslodex-met-primary-endpoint-in-first-line-treatment-of-advanced-breast-cancer.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-receives-complete-response-letter-from-us-fda-for-sodium-zirconium-cyclosilicate-zs-9-for-oral-suspension-for-treatment-of-hyperkalaemia-27052016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/positive-chmp-opinion-in-eu-for-saxa-dapa-for-adults-with-type-2-diabetes-27052016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/AstraZeneca-licenses-Zurampic-to-Grunenthal-GmbH-in-Europe-and-Latin-America-02062016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-completes-us-licensing-agreement-with-ironwood-pharmaceuticals-for-lesinurad-03062016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/AstraZeneca-and-Foundation-Medicine-enter-strategic-collaboration-for-Lynparza-companion-diagnostic-assay-04062016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-enters-commercialisation-agreement-with-aspen-for-anaesthetic-medicines-portfolio-08062016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-provides-update-on-flumist-quadrivalent-vaccine-in-the-us-for-the-2016-17-influenza-season-23062016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/New-antibiotic-Zavicefta-approved-in-the-European-Union-for-patients-with-serious-bacterial-infections-28062016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-head-and-neck-cancer-trials-resume-new-patient-enrolment-as-fda-lifts-partial-clinical-hold-22112016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-takes-latest-scientific-advances-in-oncology-to-major-us-and-european-congresses29112016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-completes-agreement-with-cilag-gmbh-international-for-rights-to-rhinocort-aqua-outside-the-us-05122016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/tagrisso-demonstrates-superiority-over-chemotherapy-in-egfr-t790m-mutation-positive-non-small-cell-lung-cancer-06122016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/Astrazeneca-and-Lilly-to-develop-second-potentially-disease-modifying-treatment-for-alzheimers-disease-09122016.html
- https://www.astrazeneca.com/media-centre/press-releases/2016/US-FDA-accepts-first-biologics-license-application-for-AstraZenecas-durvalumab-in-bladder-cancer-09122016.html
- https://www.astrazeneca.com/media-centre/press-releases/2015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-archaeological-dig-cambridge-biomedical-campus-11062015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-pam-cheng-executive-vice-president-operations-16062015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-oncology-research-european-cancer-congress-2015-24092015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/real-world-data-saxagliptin-sitagliptin-heart-failure-risk-08062015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-type-2-diabetes-triple-therapy-treatment-data-06062015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-diabetes-data-american-diabetes-association-scientific-sessions-03062015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-immuno-oncology-combinations-development-programme-asco-2015-02062015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-medimmune-positive-immuno-oncology-combination-data-asco-30052015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-lilly-immuno-oncology-clinical-trial-solid-tumours-29052015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-brodalumab-development-programme-psoriasis-arthritis-22052015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-biologics-manufacturing-sodertalje-sweden-18052015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-immuno-oncology-pipeline-combination-treatments-asco-2015-13052015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-abbott-companion-diagnostic-tests-tralokinumab-severe-asthma-13052015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-montreal-heart-institute-cardiovascular-diabetes-genetic-screening-13052015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/us-fda-priority-review-brilinta-heart-attack-history-patients-29042015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-plc-first-quarter-results-2015-24042015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-celgene-corporation-immuno-oncology-collaboration-blood-cancers-24042015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-innate-pharma-global-collaboration-immuno-oncology-24042015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-non-small-cell-lung-cancer-medicine-data-european-lung-cancer-congress-17042015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/selumetinib-orphan-drug-designation-us-fda-uveal-melanoma-treatment-17042015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/medimmune-immunocore-immuno-oncology-combination-trials-melanoma-16042015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/tremelimumab-orphan-drug-designation-us-fda-malignant-mesothelioma-treatment-15042015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/fda-advisory-committee-reviews-saxagliptin-type-2-diabetes-14042015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-patientslikeme-research-oncology-diabetes-lupus-respiratory-disease-13042015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-oncology-science-american-association-cancer-research-annual-meeting-2015-13042015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-genomics-england-consortium-26032015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-harvard-stem-cell-institute-diabetes-25032015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-daiichi-sankyo-commercialise-movantik-19032015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-pt003-results-chronic-obstructive-pulmonary-disease-18032015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/pegasus-timi-54-study-brilinta-long-term-treatment-reduces-cardiovascular-thrombotic-events-14032015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-us-fda-endocrinologic-metabolic-drugs-advisory-committee-04032015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-actavis-respiratory-portfolio-chronic-obstructive-pulmonary-disease-03032015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-board-annual-general-meeting-17022015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/us-district-court-decision-pulmicort-respulses-patent-litigation-13022015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-actavis-aclidinium-respiratory-franchise-05022015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-plc-fourth-quarter-full-year-results-2014-05022015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-research-development-centre-corporate-headquarters-cambridge-uk-04022015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-crispr-technology-genome-editing-29012015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/lesinurad-gout-treatment-european-medicines-agency-22012015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/pegasus-timi-54-study-brilinta-reduction-cardiovascular-thrombotic-events-14012015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/medimmune-omnis-pharmaceuticals-oncolytic-viruses-immuno-oncology-12012015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-daiichi-sankyo-flumist-influenza-vaccine-02092015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-valeant-pharmaceuticals-brodalumab-dermatology-psoriasis-01092015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-peregrine-pharmaceuticals-immuno-oncology-combination-clinical-trial-24082015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/medimmune-mirati-therapeutics-immuno-oncology-combination-lung-cancer-05082015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-heptares-therapeutics-immuno-oncology-treatments-06082015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/medimmune-inovio-pharmaceuticals-cancer-vaccine-10082015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-isis-pharmaceuticals-antisense-drugs-cardiovascular-metabolic-renal-diseases-03082015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-genzyme-rare-disease-medicine-caprelsa-27072015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-tillotts-pharma-entocort-gastroenterology-medicine-17072015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-kyowa-hakko-kirin-benralizumab-asthma-chronic-obstructive-pulmonary-disease-16072015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-tillotts-pharma-entocort-gastroenterology-09072015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/iressa-fda-approved-non-small-cell-lung-cancer-treatment-13072015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-selumetinib-uveal-melanoma-oncology-22072015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-plc-h1-results-2015-30072015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-dr-sean-bohen-chief-medical-officer-24082015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-cardiovascular-events-prevention-esc-congress-2015-29082015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/pegasus-timi-54-brilinta-treatment-following-heart-attack-31082015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/antibiotic-medicine-caz-avi-complicated-urinary-tract-infections-02092015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/us-fda-approves-brilinta-long-term-use-heart-attack-history-patients-03092015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-lung-cancer-portfolio-world-conference-lung-cancer-2015-04092015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-university-manchester-clinical-oncology-bioinformatics-collaboration-08092015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-biologics-manufacturing-boulder-colorado-11092015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-diabetes-data-pre-clinical-research-easd-2015-11092015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-respiratory-disease-data-european-respiratory-society-international-congress-2015-22092015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/new-england-journal-medicine-brodalumab-ustekinumab-psoriasis-30092015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-orca-pharmaceuticals-rory-inhibitors-auto-immune-diseases-treatment-25022015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-cambridge-judge-business-school-biotech-start-ups-03032015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-singapore-research-organisations-heart-failure-11032015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-scientific-review-board-clinical-trial-data-transparency-19032015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-bina-genomic-management-solution-21042015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-mene-pangalos-fellowship-academy-medical-sciences-11052015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-university-michigan-chronic-kidney-disease-treatments-17062015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-inserm-type-2-diabetes-chronic-kidney-disease-studies-17062015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-university-cambridge-phd-clinical-research-scholarships-30062015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-crowd-sourcing-challenge-combination-therapies-cancer-22092015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-receives-complete-response-letter-from-us-16102015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-opens-new-manufacturing-facility-to-support-continued20102015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-and-lilly-expand-immuno-oncology-research-collaborat-22102015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/-fda-advisory-committee-recommends-the-approval-of-lesinurad-for-gout-patients-23102015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/Year-To-Date-and-Q3-2015-Results-05112015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/AstraZeneca-strengthens-Cardiovascular-and-Metabolic-disease-portfolio-with-acquisition-of-ZS-Pharma-06112015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/AstraZeneca-presents-positive-new-data-on-anifrolumab-in-lupus-at-American-College-of-Rheumatology-Annual-Scientific-Meeting-10112015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/TAGRISSO-AZD9291-approved-by-the-US-FDA-for-patients-with-EGFR-T790M-mutation-positive-metastatic-non-small-cell-lung-cancer-13112015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/AstraZeneca-expands-technological-investment-in-new-Cambridge-lead-discovery-centre-20112015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/AstraZeneca-and-Sanofi-exchange-over-200000-chemical-compounds-20112015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/AstraZeneca-enters-into-agreement-with-Perrigo-for-rights-to-Entocort-in-the-US.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/AstraZeneca-and-Voluntis-to-test-companion-mobile-app-in-ovarian-cancer-studies-07122015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-stand-alone-company-small-molecule-early-stage-antibiotic-research-development-26022015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/AstraZeneca-presents-positive-pooled-analysis-demonstrating-the-effect-of-dapagliflozin-on-albuminuria-in-hypertensive-patients-with-type-2-diabetes-17092015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/AstraZeneca-announces-new-tolerability-long-term-efficacy-and-real-world-adherence-data-for-exenatide-once-weekly-in-patients-with-type-2-diabetes-15092015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/AstraZeneca-to-harness-power-of-the-Secretome-and-develop-next-generation-biologics-11122015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/Discussions-with-Acerta-Pharma-BV-14122015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/AstraZeneca-completes-agreement-with-Perrigo-for-rights-to-Entocort-in-the-US-15122015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/AstraZeneca-continues-strategic-investment-in-China-to-accelerate-delivery-of-innovative-biologics-and-targeted-medicines-16122015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/AstraZeneca-to-strengthen-therapy-area-franchise-through-acquisition-of-Takedas-respiratory-business-16122015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/AstraZeneca-enhances-long-term-growth-through-Oncology-investment-in-Acerta-Pharma.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/AstraZeneca-completes-acquisition-of-ZS-Pharma-17122015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/Durvalumab-ATLANTIC-trial-supports-clinical-activity-and-AstraZenecas-overall-immuno-oncology-strategy.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/CHMP-issues-positive-opinion-on-lesinurad-for-Gout18122015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/tagrisso-osimertinib--receives-positive-chmp-opinion-18122015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/BRILIQUE-ticagrelor-receives-positive-European-Union-CHMP-opinion-for-extended-treatment-18122015.html
- https://www.astrazeneca.com/media-centre/press-releases/2015/ZURAMPIC-lesinurad-approved-by-US-FDA-for-patients-with-gout-22122015.html
- https://www.astrazeneca.com/media-centre/press-releases/2014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/medimmune-immunocore-immunotherapy-novel-cancer-therapies-08012014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-bristol-myers-squibb-farxiga-us-fda-approval-08012014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/us-fda-approved-farxiga-treatment-type-2-diabetes-patients-13012014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazenca-scientific-leadership-growth-jp-morgan-healthcare-conference-14012014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/xigduo-approved-european-union-type-2-diabetes-21012014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-aquisition-bristol-myers-squibb-global-diabetes-alliance-03022014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-plc-fourth-quarter-full-year-results-2013-06022014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/us-fda-approved-myalept-lepti-deficiency-treatment-25022014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/us-fda-approved-bydureon-pen-treatment-type-2-diabetes-03032014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-alderley-park-site-cheshire-uk-sale-11032014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-board-non-executive-director-ann-cairns-20032014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/forxiga-approval-japan-type-2-diabetes-treatment-24032014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-sumitomo-chemicals-astrazeneca-kk-japan-26032014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-mrc-early-drug-discovery-centre-cambridge-uk-31032014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-plc-first-quarter-results-2014-24042014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-statement-regarding-pfizer-announcement-28042014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-statement-regarding-pfizer-proposal-announcement-02052014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-board-rejects-pfizer-proposal-02052014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/us-fda-approved-epanova-severe-hypertriglyceridaemia-treatment-06052014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-updated-strategy-value-for-shareholders-06052014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-immunotherapy-study-medi4736-lung-cancer-patients-08052014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-amgen-brodalumab-study-results-plaque-psoriasis-patients-09052014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-respiratory-data-ats-2014-international-conference-12052014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-medimmune-mavrilimumab-sifalimumab-studies-rheumatoid-arthritis-global-disease-12052014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-saxagliptin-dapagliflozin-combination-type-2-diabetes-patients-13052014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-updated-statement-regarding-pfizer-announcement-13052014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/medimmune-incyte-immuno-oncology-combination-clinical-trial-14052014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-oncology-pipeline-acceleration-asco-2014-14052014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-mrc-laboratory-molecular-biology-joint-research-fund-15052014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-late-stage-pipeline-acceleration-strategy-15052014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-board-rejects-pfizers-final-proposal-19052014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-clarification-regarding-pfizer-statement-20052014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-statement-regarding-pfizer-withdrawal-26052014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-olaparib-cediranib-combination-data-ovarian-cancer-treatment-31052014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-oncology-pipeline-progress-asco-2014-03062014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-novel-antibiotic-azd0914-us-fda-fast-track-03062014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-diabetes-data-american-diabetes-association-scientific-sessions-11062014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/brodalumab-treatment-psoriatic-arthritis-study-new-england-journal-medicine-11062014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-synairgen-sng001-novel-immuno-modulatory-therapy-asthma-12062014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/us-fda-advisory-committee-movantik-cardiovascular-safety-12062014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/fda-advisory-committee-olaparib-ovarian-cancer-treatment-25062014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-global-research-development-centre-corporate-headquarters-cambridge-uk-18072014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/medimmune-and-advaxis-partner-on-immuno-oncology-combination-clinical-trial-22072014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-qiagen-lung-cancer-diagnostic-test-iressa-treatment-28072014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-roche-azd9291-companion-diagnostic-test-lung-cancer-28072014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-kyowa-hakko-kirin-immuno-oncology-clinical-study-30072014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-almirall-respiratory-disease-30072014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-second-quarter-half-year-results-2014-31072014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-lesinurad-xanthine-oxidase-results-gout-patients-13082014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-tralokinumab-treatment-severe-asthma-14082014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/united-states-department-justice-closes-investigation-plato-clinical-trial-brilinta-19082014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-caz-avi-results-complicated-intra-abdominal-infections-19082014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-illumina-gene-sequencing-panel-companion-diagnostic-tests-oncology-21082014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/brilinta-brilique-stemi-patients-cardiology-01092014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/benralizumab-study-lancet-respiratory-medicine-08092014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-diabetes-research-2014-meeting-european-association-study-of-diabetes-10092014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-lilly-bace-inhibitor-azd3293-alzheimers-disease-16092014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/fda-approved-movatnik-opioid-induced-constipation-chronic-non-cancer-pain-patients-16092014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-exenatide-study-results-byetta-type-2-diabetes-patients-19092014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/medimmune-cancer-research-uk-cruk-media-alliance-laboratory-biologic-cancer-medicines-25092014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/iressa-chmp-positive-opinion-blood-based-diagnostic-testing-european-label-26092014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/moventig-naloxegol-chmp-positive-opinion-opioid-induced-constipation-treatment-26092014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-oncology-pipeline-progress-esmo-2014-congress-27092014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/benralizumab-study-positive-results-severe-asthma-lancet-respiratory-medicine-09102014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-university-cambridge-partnership-16102014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/lynparza-positive-chmp-opinion-ovarian-cancer-treatment-24102014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/us-fda-approved-xigduo-type-2-diabetes-patients-30102014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-healthy-heart-africa-programme-hypertension-28102014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-almirall-respiratory-disease-transaction-complete-03112014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-pharmacyclics-oncology-clinical-trial-collaborations-04112014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-pharmacyclics-janssen-immuno-oncology-combination-trials-haematological-cancers-04112014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/medimmune-immuno-oncology-capabilities-definiens-04112014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-myalept-aegerion-leptin-deficiency-06112014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-plc-third-quarter-nine-months-results-2014-06112014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-inflammation-autoimmunity-pipeline-data-american-college-rheumatology-2014-annual-meeting-11112014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-amgen-brodalumab-study-positive-results-plaque-psoriasis-patients-11112014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-isis-pharmaceuticals-oligonucleotide-oncology-cardiovascular-metabolic-diseases-13112014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-brilinta-development-programme-cardiovascular-13112014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-strategy-update-institutional-investors-financial-analysts-18112014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-successful-pricing-euro-medium-term-notes-19112014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/duaklir-genuiar-approved-european-union-chronic-obstructive-pulmonary-disease-24112014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-amgen-brodalumab-final-study-positive-results-plaque-psoriasis-25112014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/medimmune-definiens-aquisition-tissue-phenomics-26112014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-eli-lilly-clinical-trial-early-alzheimers-disease-patients-01122014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/us-fda-accept-new-drug-application-iressa-lung-cancer-02122014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-nexium-antitrust-litigation-jury-verdict-05122014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/moventig-approved-european-union-opioid-induced-constipation-09122014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-amgen-amagine-1-results-brodalumab-plaque-psoriasis-11122014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/lynparza-approved-european-union-brca-mutated-ovarian-cancer-treatment-18122014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/lynparza-approved-us-fda-brca-mutated-ovarian-cancer-treatment-19122014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-max-planck-institute-satellite-chemistry-unit-cardiovascular-metabolic-diseases-08072014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-mitsubishi-tanabe-pharma-corporation-diabetic-nephropathy-20082014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-scientists-cancer-research-uk-cambridge-institute-17022014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-shanghai-institutes-biological-sciences-cardiovascular-metabolic-diseases-research-23012014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-korea-health-industry-development-institute-oncology-research-programme-06032014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/new-open-innovation-platform-compound-bank-partnering-programmes-25032014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-shenzhen-university-health-science-center-chronic-kidney-disease-27032014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-tianjin-medical-university-cardiovascular-research-china-15052014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/nobel-laureate-tim-hunt-nobel-prize-inspiration-initiative-astrazeneca-china-03062014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-addc-novel-drug-development-academic-research-community-17062014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-mrc-technology-novel-targets-discovery-research-03072014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/pharma-companies-astrazeneca-virtual-library-pharmaceutical-compounds-22072014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-redx-pharma-genetic-drivers-tumour-growth-research-03092014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/medimmune-fda-medi3902-nosocomial-pneumonia-prevention-23092014.html
- https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-cancer-research-uk-new-cancer-medicine-screening-mrc-uk-centre-lead-discovery-28112014.html
- https://www.astrazeneca.com/media-centre/press-releases/2013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-shionogi-crestor-licence-agreement26122013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-bristol-myers-squibb-global-diabetes-alliance-assets-19122013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-statement-esomeprazole-strontium-product-launch-17122013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-lesinurad-study-results-gout-patients-13122013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/fda-advisory-committee-recommends-dapagliflozin-type-2-diabetes-treatment-12122013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/fda-advisory-committee-metreleptin-lipodystrophy-treatment-12122013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-brixham-environmental-laboratory-plymouth-university-09122013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/fluenz-tetra-european-commission-approval-seasonal-influenza-prevention-children-06122013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-prilosec-patent-litigation-ruling-03122013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/xigduo-chmp-positive-opinion-european-union-type-2-diabetes-treatment-22112013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-research-development-centre-corporate-headquarters-cambridge-uk-herzog-meuron-architect-19112013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/us-fda-new-drug-application-naloxegol-opioid-induced-constipation-treatment-19112013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-manufacturing-facility-macclesfield-zoladex-prostate-cancer-treatment-11112013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-plc-third-quarter-nine-months-results-2013-31102013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/marc-dunoyer-new-chief-financial-officer-astrazeneca-31102013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/us-appeals-court-pulmicort-respules-patent-litigation-decision-30102013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-medimmune-benralizumab-severe-asthma-treatment-30102013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-brixham-environmental-laboratory-closing-24102013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-selumetinib-non-small-cell-lung-cancer-treatment-22102013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-oncology-medimmune-spirogen-acquisition-15102013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-janssen-japan-prostate-cancer-treatment-11102013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/medimmune-amplimmune-aquisition-07102013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/us-appeals-court-lifts-temporary-injunction-hanmi-505b2-nda-esomeprazole-strontium-02102013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-alderley-park-biohub-research-development-centre-01102013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/olaparib-european-medicines-agency-brca-mutated-ovarian-cancer-treatment-27092013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/naloxegol-european-medicines-agency-opioid-induced-constipation-treatment-27092013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/onglyza-hypoglycemia-pancreatitis-subanalyses-savor-cardiovascular-trial-outcomes-easd-26092013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/dapagliflozin-hba1c-type-2-diabetes-patients-metformin-sulfonylurea-24092013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/fluenz-tetra-nasal-spray-vaccine-eu-chmp-positive-opinion-seasonal-influenza-prevention-children-20092013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/fda-new-drug-application-epanova-severe-hypertriglyceridaemia-treatment-18092013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/us-appeals-court-temporary-injunction-hanmi-505b2-nda-esomeprazole-strontium-13092013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-merck-wee1-kinase-inhibitor-therapy-cancer-11092013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-olaparib-clinical-programme-brca-mutated-ovarian-cancer-treatment-04092013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/onglyza-saxagliptin-safety-cardiovascular-heart-attack-stroke-02092013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/medimmune-immune-mediated-cancer-therapy-amplimmune-26082013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-plc-second-quarter-half-year-results-2013-01082013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-fibrogen-fg4592-anaemia-treatment-chronic-kidney-disease-renal-disease-31072013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/us-fda-new-drug-application-dapagliflozin-type-2-diabetes-treatment-25072013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-bristol-myers-squibb-dapagliflozin-type-2-diabetes-treatment-25072013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-chief-financial-officer-simon-lowth-15072013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-university-cambridge-cancer-research-09072013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-pearl-therapeutics-acquisition-28062013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-bristol-myers-squibb-savor-timi-53-results-onglyza-cardiovascular-trial-outcomes-19062013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-new-global-research-development-centre-corporate-headquarters-cambridge-uk-18062013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-medimmune-ngm-biopharamaceuticals-diabetes-obesity-therapies-17062013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-pearl-therapeutics-respiratory-disease-10062013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-oskira-trials-fostamatinib-results-04062013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-hanmi-pharmaceuticals-amneal-pharmaceuticals-us-nexium-patent-litigation-03062013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-omthera-pharmaceuticals-dyslipidemia-treatment-cardiovascular-28052013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/us-appeals-court-temporary-injunction-pulmicort-respules-25052013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-accelerated-oncology-pipeline-2013-asco-annual-meeting-16052013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-alderley-park-cheshire-future-29042013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-plc-first-quarter-results-2013-25042013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-bind-therapeutics-cancer-nanomedicine-accurin-22042013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-oskira-1-study-results-fostamatinib-rheumatoid-arthritis-05042013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-medimmune-alphacore-pharma-biologics-03042013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/us-district-court-pulmicort-respules-patent-invalid-02042013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-crestor-patent-litigation-settled-25032013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-marc-dunoyer-executive-vice-president-global-portfolio-product-strategy-21032013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-growth-scientific-leadership-strategy-21032013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-karolinska-institutet-research-centre-cardiovascular-metabolic-disease-regnerative-medicine-21032013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-moderna-therapeutics-cardiometabolic-diseases-cancer-treatment-21032013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/copd-medicines-pathos-study-journal-internal-medicine-19032013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-research-development-centres-innovation-pipeline-18032013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-research-development-centre-global-headquarters-cambridge-18032013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/australia-federal-court-crestor-patents-05032013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-naloxegol-long-term-safety-opioid-induced-constipation-patients-26022013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/us-court-appeals-seroquel-patent-descision-15022013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-plc-fourth-quarter-full-year-results-2012-31012013.html
- https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-senior-executive-team-15012013.html
- https://www.astrazeneca.com/media-centre/press-releases/2012.html
- https://www.astrazeneca.com/media-centre/press-releases/2012/astrazeneca-reaffirms-december-2011-financial-guidance-for-2011-.html
- https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-and-IMS-Health-announce-real-world-evidence-collaboration-in-Europe-11012015.html
- https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-and-Bristol-Myers-Squibb-receive-complete-response-letter-from-US-Food-and-Drug-Administration-for-dapagliflozin-19012012.html
- https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-PLC-Fourth-quarter-and-full-year-results-2011-02022012.html
- https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZenecas-new-restructuring-initiatives-to-drive-productivity-and-support-innovation-02022012.html
- https://www.astrazeneca.com/media-centre/press-releases/2012/European-Commission-approves-CAPRELSA-vandetanib-for-patients-with-advanced-medullary-thyroid-cancer-21022012.html
- https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-announces-Non-Executive-changes-retirement-of-Chairman-and-appointment-of-successor-01032012.html
- https://www.astrazeneca.com/media-centre/press-releases/2012/FDA-approves-first-four-strain-flu-vaccine-01032012.html
- https://www.astrazeneca.com/media-centre/press-releases/2012/FDA-responds-AstraZeneca-Citizen-Petitions-quetiapine-product-labelling-09032012.html
- https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-files-against-the-fda-for-decision-on-quetiapine-13032012.html
- https://www.astrazeneca.com/media-centre/press-releases/2012/Remaining-TC-5214-Phase-III-efficacy-studies-do-not-meet-endpoint-regulatory-filing-will-not-be-pursued-20032012.html
- https://www.astrazeneca.com/media-centre/press-releases/2012/UK-court-finds-SEROQUEL-XR-formulation-patent-invalid-22032012.html
- https://www.astrazeneca.com/media-centre/press-releases/2012/US-court-denies-preliminary-injunction-application-against-the-FDA-and-dismisses-AstraZenecas-lawsuit-without-prejudice-26032012.html
- https://www.astrazeneca.com/media-centre/press-releases/2012/US-District-Court-finds-SEROQUEL-XR-formulation-patent-valid-and-infringed-30032012.html
- https://www.astrazeneca.com/media-centre/press-releases/2012/astrazeneca-and-amgen-announce-collaboration-02042012.html
- https://www.astrazeneca.com/media-centre/press-releases/2012/FORXIGA-dapagliflozin-receives-positive-CHMP-opinion-in-the-European-Union-for-the-treatment-of-type-2-diabetes-20042012.html
- https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-to-acquire-Ardea-Biosciences-for-1-billion-23042012.html
- https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-and-The-Medicines-Company-announce-global-collaboration-in-acute-ischaemic-heart-disease-25042012.html
- https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-PLC-First-quarter-results-2012-26042012.html
- https://www.astrazeneca.com/media-centre/press-releases/2012/David-Brennan-to-retire-as-AstraZenecas-Chief-Executive-Officer-26042012.html
- https://www.astrazeneca.com/media-centre/press-releases/2012/Innovative-public-private-collaboration-launches-to-tackle-antibiotic-research-24052012.html
- https://www.astrazeneca.com/media-centre/press-releases/2012/Investigational-compound-dapagliflozin-demonstrated-significant-reductions-in-blood-sugarlevels-09062012.html
- https://www.astrazeneca.com/media-centre/press-releases/2012/Zinforo-ceftaroline-fosamil-receives-positive-CHMP-opinion-in-the-European-Union-for-the-treatment-of-patients-with-serious-skin-infections-or-community-acquired-pneumonia-22062012.html
- https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-and-Merck-agree-to-amend-second-option-27062012.html
- https://www.astrazeneca.com/media-centre/press-releases/2012/Bristol-Myers-Squibb-and-AstraZeneca-expand-diabetes-alliance-30062012.html
- https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-completes-sale-of-Aptium-Oncology-assets-06072012.html
- https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-reports-terms-of-David-Brennans-retirement-16072012.html
- https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-PLC-Second-quarter-and-half-year-results-2012-26072012.html
- https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-and-Bristol-Myers-Squibb-complete-expansion-of-diabetes-alliance-through-Bristol-Myers-Squibbs-acquisition-of-Amylin-Pharmaceuticals-09082012.html
- https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-and-Pfizer-enter-agreement-for-over-the-counter-NEXIUM-AstraZeneca-raises-2012-guidance-13082012.html
- https://www.astrazeneca.com/media-centre/press-releases/2012/Pascal-Soriot-appointed-Chief-Executive-Officer-of-AstraZeneca-28082012.html
- https://www.astrazeneca.com/media-centre/press-releases/2012/European-Commission-approves-ZINFORO-ceftaroline-fosamil-for-adult-patients-with-serious-skin-infections-or-community-acquired-pneumonia-28082012.html
- https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-prices-a-2-billion-bond-issue-12092012.html
- https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-suspends-share-repurchase-programme-01102012.html
- https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-and-Ardelyx-announce-worldwide-licensing-deal-for-NHE3-inhibitor-programme-for-complications-of-renal-disease-including-diabetes-induced-renal-disease-08102012.html
- https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-and-Ironwood-announce-Linaclotide-collaboration-23102012.html
- https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-PLC-Third-quarter-and-nine-months-results-2012-25102012.html
- https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-announces-details-of-Chief-Executive-Officer-Pascal-Soriot-remuneration-29102012.html
- https://www.astrazeneca.com/media-centre/press-releases/2012/Alzheimers-cancer-and-rare-disease-research-to-benefit-from-landmark-MRC-AstraZeneca-compound-collaboration-31102012.html
- https://www.astrazeneca.com/media-centre/press-releases/2012/Definition-of-Core-Financial-Measures-12112012.html
- https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-announces-top-line-phase-III-results-from-naloxegol-pivotal-trials-in-patients-with-opioid-induced-constipation-12112012.html
- https://www.astrazeneca.com/media-centre/press-releases/2012/Court-in-Germany-finds-SEROQUEL-XR-formulation-patent-invalid-13112012.html
- https://www.astrazeneca.com/media-centre/press-releases/2012/FORXIGA-dapagliflozin-now-approved-in-European-Union-for-treatment-of-type-2-diabetes-14112012.html
- https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-and-Isis-Pharmaceuticals-form-strategic-alliance-on-RNA-therapeutics-for-cancer-11122012.html
- https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-announces-top-line-results-of-OSKIRA-4-Phase-IIb-study-of-fostamatinib-as-a-monotherapy-for-rheumatoid-arthritis-13122012.html
- https://www.astrazeneca.com/media-centre/press-releases/2012/CRESTOR-US-patent-upheld-by-Court-of-Appeals-for-the-Federal-Circuit-14122012.html
- https://www.astrazeneca.com/media-centre/press-releases/2011.html
- https://www.astrazeneca.com/media-centre/press-releases/2011/us-food-and-drug-administration-extend-review-timeline-for-vand-07012011.html
- https://www.astrazeneca.com/media-centre/press-releases/2011/astrazeneca-replies-to-the-us-fda-complete-response-letter-for-b-21012011.html
- https://www.astrazeneca.com/media-centre/press-releases/2011/astrazeneca-plc-fourth-quarter-and-full-year-results-2010-27012011.html
- https://www.astrazeneca.com/media-centre/press-releases/2011/AstraZeneca-approves-nasal-spray-vaccine-Fluenz-for-flu-01022011.html
- https://www.astrazeneca.com/media-centre/press-releases/2011/US-FDA-Assigns-new-PDUFA-date-for-BRILINTA-ticagrelor-tablets-04022011.html
- https://www.astrazeneca.com/media-centre/press-releases/2011/astrazeneca-halts-phase-iii-trial-of-zibotentan-in-non-metastatic-castrate-resistant-07022011.html
- https://www.astrazeneca.com/media-centre/press-releases/2011/astrazeneca-and-targacept-initiate-phase-iib-clinical-trial-of-tc-5214-07022011.html
- https://www.astrazeneca.com/media-centre/press-releases/2011/onglyza_-us-label-update-provides-further-evidence-regarding-use-23022011.html
- https://www.astrazeneca.com/media-centre/press-releases/2011/astrazeneca-to-discontinue-production-of-pulmicort--pmdi--other-07032011.html
- https://www.astrazeneca.com/media-centre/press-releases/2011/Onglyza-is-first-DPP4-Inhibitor-for-Type-2-Diabetes-04032011.html
- https://www.astrazeneca.com/media-centre/press-releases/2011/-fda-accepts-new-drug-application-for-investigational-compound-08032011.html
- https://www.astrazeneca.com/media-centre/press-releases/2011/astrazeneca-initiates-phase-iii-clinical-programme-evaluating-nk-15032011.html
- https://www.astrazeneca.com/media-centre/press-releases/2011/uk-and-us-governments-reach-agreement-over-astrazeneca-tax-matte-28032011.html
- https://www.astrazeneca.com/media-centre/press-releases/2011/fda-approves-orphan-drug-vandetanib-07042011.html
- https://www.astrazeneca.com/media-centre/press-releases/2011/AstraZeneca-PLC-First-Quarter-Results-2011-28042011.html
- https://www.astrazeneca.com/media-centre/press-releases/2011/health-economics-substudy-of-plato-shows-brilique-to-be-cost-effective-09052011.html
- https://www.astrazeneca.com/media-centre/press-releases/2011/astrazeneca-signs-agreement-in-japan-with-daiichi-sankyo-to-co-promote-24052011.html
- https://www.astrazeneca.com/media-centre/press-releases/2011/health-canada-approves-brilinta--ticagrelor-tablets-01062011.html
- https://www.astrazeneca.com/media-centre/press-releases/2011/astrazeneca-extends-its-investment-in-russia-with-new-predictive-science-centre-16062011.html
- https://www.astrazeneca.com/media-centre/press-releases/2011/AstraZeneca-to-sell-AstraTech-to-DENTSPLY-International-22062011.html
- https://www.astrazeneca.com/media-centre/press-releases/2011/Bristol-Myers-Squibb-and-AstraZeneca-ph3-study-on-DAPAGLIFLOZIN-27062011.html
- https://www.astrazeneca.com/media-centre/press-releases/2011/astrazeneca-s-nexium-receives-first-regulatory-approval-in-japan-01072011.html
- https://www.astrazeneca.com/media-centre/press-releases/2011/fda-advisory-committee-makes-recommendation-on-investigational-compound-20072011.html
- https://www.astrazeneca.com/media-centre/press-releases/2011/fda-approves-new-medicine-brilinta--ticagrelor--for-use-in-the-us-20072011.html
- https://www.astrazeneca.com/media-centre/press-releases/2011/astrazeneca-plc-second-quarter-and-half-year-results-2011-28072011.html
- https://www.astrazeneca.com/media-centre/press-releases/2011/positive-agreement-received-for-approval-of-axanum-in-europe-02082011.html
- https://www.astrazeneca.com/media-centre/press-releases/2011/sale-of-astra-tech-to-dentsply-international-complete-31082011.html
- https://www.astrazeneca.com/media-centre/press-releases/2011/astrazeneca-announces-top-line-results-from-saturn-study-020920111.html
- https://www.astrazeneca.com/media-centre/press-releases/2011/astrazeneca-announces-top-line-results-from-saturn-study-02092011.html
- https://www.astrazeneca.com/media-centre/press-releases/2011/KOMBOGLYZE-saxagliptin-and-metformin-HCl-immediate-release-receives-positive-CHMP-opinion-in-the-European-Union-for-the-treatment-of-type-2-diabetes-23092011.html
- https://www.astrazeneca.com/media-centre/press-releases/2011/AstraZeneca-announces-first-approval-of-FASLODEX-fulvestrant-in-Japan-26092011.html
- https://www.astrazeneca.com/media-centre/press-releases/2011/AstraZeneca-enters-into-a-settlement-agreement-with-Handa-Pharmaceuticals-regarding-US-SEROQUEL-XR-patent-litigation-29092011.html
- https://www.astrazeneca.com/media-centre/press-releases/2011/BRILIQUE-receives-a-positive-preliminary-medical-benefit-assessment-for-the-majority-of-ACS-patients-in-Germany-as-part-of-new-AMNOG-review-process-04102011.html
- https://www.astrazeneca.com/media-centre/press-releases/2011/AstraZeneca-enters-into-a-settlement-agreement-with-Accord-Healthcare-Inc-and-Intas-Pharmaceuticals-Ltd-regarding-US-SEROQUEL-XR-patent-litigation-05102011.html
- https://www.astrazeneca.com/media-centre/press-releases/2011/AstraZeneca-increases-investment-in-China-with-new-200-million-manufacturing-facility-10102011.html
- https://www.astrazeneca.com/media-centre/press-releases/2011/AstraZeneca-and-Forest-Laboratories-to-initiate-phase-III-clinical-trials-for-ceftazidime-avibactam-to-treat-serious-Gram-negative-bacterial-infections-18102011.html
- https://www.astrazeneca.com/media-centre/press-releases/2011/AstraZeneca-to-present-new-healthcare-economics-data-demonstrating-cost-effectiveness-of-BRILIQUE-at-ISPOR-EU-21102011.html
- https://www.astrazeneca.com/media-centre/press-releases/2011/US-Food-and-Drug-Administration-extends-action-date-for-dapagliflozin-by-three-months-26102011.html
- https://www.astrazeneca.com/media-centre/press-releases/2011/AstraZeneca-PLC-Third-quarter-and-nine-months-results-2011-27102011.html
- https://www.astrazeneca.com/media-centre/press-releases/2011/AstraZeneca-and-Targacept-announce-first-top-line-Phase-III-results-for-TC-5214-as-an-adjunct-treatment-in-patients-with-major-depressive-disorder-08112011.html
- https://www.astrazeneca.com/media-centre/press-releases/2011/SATURN-demonstrated-effect-of-intensive-statin-treatment-on-reducing-atherosclerosis-15112011.html
- https://www.astrazeneca.com/media-centre/press-releases/2011/CAPRELSA-vandetanib-receives-positive-CHMP-opinion-in-the-European-Union-for-treating-advanced-medullary-thyroid-cancer-18112011.html
- https://www.astrazeneca.com/media-centre/press-releases/2011/AstraZeneca-commits-100-million-MedImmune-Ventures-28112011.html
- https://www.astrazeneca.com/media-centre/press-releases/2011/KOMBOGLYZE-receives-marketing-authorisation-in-the-European-Union-for-adult-patients-with-Type-2-diabetes-29112011.html
- https://www.astrazeneca.com/media-centre/press-releases/2011/Groundbreaking-scientific-collaboration-gives-UK-academia-access-to-compounds-to-advance-medical-research-05122011.html
- https://www.astrazeneca.com/media-centre/press-releases/2011/AstraZeneca-to-streamline-US-sales-organisation-07122011.html
- https://www.astrazeneca.com/media-centre/press-releases/2011/AstraZeneca-to-acquire-generics-company-to-broaden-patient-access-to-medicines-in-China-08122011.html
- https://www.astrazeneca.com/media-centre/press-releases/2011/G-BA-issues-positive-final-medical-benefit-assessment-for-BRILIQUE-in-Germany-15122011.html
- https://www.astrazeneca.com/media-centre/press-releases/2011/AstraZeneca-updates-on-olaparib-and-TC-5214-development-programmes-20122010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-Reaches-Agreements-With-Teva-Pharmaceuticals-Regarding-Nexium-And-Prilosec-US-Patent-Litigations-07012010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-PLC-Fourth-Quarter-and-Full-Year-Results-2009-28012010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/US-FDA-Approves-New-Indication-for-Crestor-Rosuvastatin-Calcium-09022010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-and-Rigel-Pharmaceuticals-Sign-Worldwide-License-Agreement-for-Late-Stage-Development-Product-Fostamatinib-Disodium-R788-for-the-Treatment-of-Rheumatoid-Arthritis-16022010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-Reaches-Agreement-With-UK-Tax-Authorities-Over-Transfer-Pricing-23022010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-Provides-An-Update-On-The-Status-Of-Its-Arrangements-With-Merck-01032010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/RECENTIN-did-not-meet-primary-endpoint-in-Horizon-III-study-in-metastatic-colorectal-cancer-08032010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-Comments-On-FDA-Joint-Advisory-Committee-Meeting-On-Post-Marketing-Safety-Studies-For-The-Use-Of-LABAs-In-Asthma-11032010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-Extends-Branded-Generics-Capability-With-Torrent-Agreement-11032010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/New-PLATO-Sub-Analysis-of-CABG-Patients-Presented-at-ACC-16032010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/Jury-Rules-In-Favour-Of-AstraZeneca-In-First-US-Seroquel-Product-Liability-Trial-18032010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-and-Abbott-receive-FDA-complete-response-letter-on-CERTRIAD-new-drug-application-30032010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/Seroquel-XR-Recommended-For-Approval-In-EU-as-an-Add-On-Treatment-Of-Major-Depressive-Disorder-23042010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-Finalises-US-Agreement-On-SEROQUEL-Marketing-27042010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/Crestor-Gains-New-EU-Indication-to-Prevent-Major-Cardiovascular-Events-in-High-Risk-Patients-27042010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-First-Quarter-Results-2010-29042010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/FDA-approved-VIMOVO-for-arthritis-patients-at-risk-of-developing-NSAID-associated-gastric-ulcers-30042010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-Reaches-US-Agreement-With-Teva-Pharmaceuticals-Regarding-Entocort-EC-Capsules-18052010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/Martin-Mackay-to-Lead-AstraZenecas-Research-and-Development-Organisation-26052010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/NOTICE-Advisory-Committee-Briefing-Materials-for-Motavizumab-BLA-Available-on-US-FDA-Web-Site-28052010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-Announces-Results-of-Recentin-HORIZON-II-Phase-III-Trial-in-Metastatic-Colorectal-Cancer-28052010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-Receives-FDA-Complete-Response-Letter-for-AXANUM-New-Drug-Application-01062010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/FDA-updates-US-product-labels-for-LABA-containing-medications-including-AstraZenecas-SYMBICORT-02062010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/FDA-Advisory-Committee-Reviews-MedImmunes-Motavizumab-02062010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-Submits-Marketing-Authorisation-Application-To-European-Union-For-Cardiovascular-Drug-Axanum-04062010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/Federal-Court-of-Canada-Rules-on-Applications-for-Generic-Esomep-17062010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-and-Targacept-Initiate-Phase-3-Clinical-Development-23062010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/FDA-Resets-its-Decision-Date-For-Motavizumab-25062010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-and-MMV-Join-Efforts-in-the-Fight-Against-Malaria-28072010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/CRESTOR-Patent-Upheld-By-US-Court-30072010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-and-MRC-Technology-Form-Strategic-Alliance-05072010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/Advisory-Committee-Briefing-Materials-For-Brilinta-Ticagrelor-26072010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-PLC-Appoints-New-NonExecutive-Director-29072010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-Second-Quarter-and-Half-Year-Results-2010-29072010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/FDA-Advisory-Committee-recommends-US-FDA-approval-of-Brilinta-29072010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-Announces-Agreements-in-Principle-in-Seroquel-09082010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/Genetic-substudy-shows-fewer-major-cardiovascular-events-with-ticagrelor-brilinta-29082010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/MedImmune-receives-complete-response-letter-on-motavizumab-30082010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/European-Commission-Issues-Positive-Decision-for-Approval-of-Seroquel-XR-as-an-Add-On-Treatment-of-Major-Depressive-Disorder-02092010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/US-FDA-Extends-Review-Timeline-For-BRILINTA-15092010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/24-Week-Phase-3-Study-Found-Investigational-Drug-Dapagliflozin-Improved-Glycosylated-Hemoglobin-HbA1c-When-Added-to-Glimepiride-in-Adults-with-Type-2-Diabetes-Mellitus-20092010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/US-and-EU-regulatory-submissions-for-VANDETANIB-in-advanced-medullary-thyroid-cancer-23092010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/52Week-Phase-3-Study-Found-Investigational-Drug-Dapagliflozin-24092010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/BRILIQUE-ticagrelor-receives-positive-opinion-from-European-CHMP-for-the-treatment-of-Acute-Coronary-Syndromes-24092010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/Results-of-Zibotentan-Phase-III-trial-in-castration-resistant-prostate-cancer-27092010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-initiates-phase-III-clinical-development-of-fostamatinib-29092010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/New-outcomes-study-for-ticagrelor-BRILINTA-01102010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/Positive-agreement-received-for-approval-of-VIMOVO-in-Europe-11102010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/European-regulator-backs-nasal-spray-vaccine-FLUENZ-22102010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-initiates-phase-IIB-study-for-AZD9773-CytoFab-25102010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-Third-Quarter-and-Nine-Months-Results-2010-28102010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-announces-copromotion-agreement-with-Daiichi-Sankyo-29102010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/US-Appeal-Court-affirms-preliminary-injunction-against-Apotex-02112010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/KOMBIGLYZE-XR-tablets-approved-in-the-US-05112010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-commences-review-of-strategic-options-for-Astra-Tech-19112010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/US-FDA-Advisory-Committee-Makes-Recommendation-on-New-Drug-Application-for-Vandetanib-in-Advanced-Medullary-Thyroid-Cancer-02122010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/Public-believe-China-and-India-set-to-become-World-leaders-for-innovation-survey-shows-06122010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/European-Commission-Approves-Brilique-06122010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-PLC-appoints-new-Non-Executive-Director-17122010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-receives-complete-response-letter-from-US-FDA-for-BRILINTA-ticagrelor-tablets-17122010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-discontinues-motavizumab-RSV-21122010.html
- https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-ends-agreement-with-Abbott-for-Certriad-22122010.html
- https://www.astrazeneca.com/media-centre/press-releases/2009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/MedImmune-Submits-Marketing-Authorisation-Application-06012009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-PLC-Fourth-Quarter-and-Full-Year-Results-2008-29012009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZenecas-Partner-POZEN-Informed-By-FDA-That-Gastric-Ulcers-Are-Valid-29062009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZenecas-partner-MAP-pharmaceuticals-Announces-24022009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-To-Participate-In-Tentative-FDA-Psychopharmacologic-Drugs-25022009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-PLC-Board-Change-27022009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-Receives-FDA-Complete-Response-Letter-On-Seroquel-27022009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/FDA-Approves-Symbicort-for-Chronic-Obstructive-Pulmon-02032009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-Issues-2008-Annual-Report-04032009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-to-Participate-in-Tentative-FDA-Psychopharmacologic-Drugs-Advisory-Committee-30032009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/ONGLYZA-Saxagliptin-Cardiovascular-Profile-Acceptable-02042009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/David-Brennan-elected-board-chairman-of-the-Pharmaceutical-03042009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-Receives-FDA-Complete-Response-Letter-on-Symbicort-06042009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/Sale-of-AstraZeneca-OTC-Product-Portfolio-Cleared-06042009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-Files-Suit-Against-Apotex-for-a-Declaratory-Judgment-07042009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/FDA-Advisory-Committee-Recommendation-on-Seroquel-XR-09042009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/Court-Grants-AstraZeneca-Temporary-Restraining-Order-17042009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/IRESSA-Gefitinib-Recommended-for-Approval-23042009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/US-Food-and-Drug-Administration-Extends-Review-Timeline-23042009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-PLC-First-Quarter-Results-2009-23042009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-Announces-Top-Line-Results-From-Pivotal-11052009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/Court-Grants-AstraZeneca-Preliminary-Injunction-Again-20052009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-Regulatory-Update-on-Seroquel-XR-29052009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-and-Merck-and-Co-Inc-Form-Pioneering-Collaboration-01062009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-and-Abbott-Submit-New-Drug-Application-04062009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-and-Abbott-Extend-Relationship-to-Include-04062009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/Favourable-Vote-from-FDA-Advisory-Committee-on-Seroquel-10062009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/ONGLYZA-saxagliptin-Receives-Positive-Opinion-in-Europe-25062009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-Development-Partner-Pozen-Inc-Submits-New-Drugs-30062009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/IRESSA-Gefitinib-Receives-Marketing-Authorisation-01072009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-to-Advance-AZD3480-in-ADHD-08072009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-Terminates-License-Agreement-with-MAP-09072009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-PLC-Second-Quarter-and-Half-Year-Results-2009-30072009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/FDA-Approves-ONGLYZA-For-The-Treatment-Of-Type-2-Diabetes-01082009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-And-Astellas-Enter-Agreement-for-CoPromo-04082009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-and-Forest-Laboratories-to-CoDevelop-and-Commercialise-12082009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/Phase-III-Head-to-Head-Trial-Showed-Ticagrelor-Reduce-30082009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-Announces-FDA-Acceptance-of-New-Drug-Application-31082009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-and-Nektar-Sign-Worldwide-Agreement-for-Nektar-21092009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/US-Court-of-Appeals-Affirms-Summary-Judgment-Decision-25092009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/Brilinta-Reduced-Cardiovascular-Deaths-and-Heart-Attacks-25092009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/Seroquel-XR-and-Seroquel-Approved-in-Europe-for-Prevention-29092009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/ONGLYZA-saxagliptin-Receives-Marketing-Authorisation-05102009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/Study-Finds-That-ONGLYZA-saxagliptin-When-Added-to-Metformin-05102009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/US-Food-and-Drug-Administration-Approves-CRESTOR-16102009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-Submits-Marketing-Authorisation-Application-16102009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/Patients-Taking-VIMOVOTM-Showed-Decrease-in-incidence-19102009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-withdraws-regulatory-submissions-for-Zactima-28102009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-PLC-Third-Quarter-2009-29102009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/Discovery-Research-Leader-Leaves-AstraZeneca-13112009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/BRILINTA-Demonstrated-Greater-Efficacy-Over-Clopidogrel-16112009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/Results-from-Two-Phase-II-Trials-Add-to-Understanding-18112009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-Submits-US-New-Drug-Application-for-Brilinta-19112009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-and-Targacept-Form-Global-Collaboration-and-Licence-Agreement-03122009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/US-FDA-Approves-Seroquel-XR-For-AddOn-Treatment-Of-Major-Depressive-Disorder-04122009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/US-FDA-Approves-Seroquel-For-The-Paediatric-Treatment-04122009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/Advisory-Committee-Briefing-Materials-For-Crestor-sND-11122009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/Favourable-Vote-From-FDA-Advisory-Committee-On-Benefit-15122009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-To-Acquire-Infection-Research-Company-Novexel-23122009.html
- https://www.astrazeneca.com/media-centre/press-releases/2009/MedImmune-Replies-to-FDA-Complete-Response-Letter-on-Motavizumab-24122009.html
- https://www.astrazeneca.com/media-centre/articles.html
- https://www.astrazeneca.com/media-centre/articles/2025/advancing-sustainable-respiratory-care-with-the-transition-to-pMDIs-with-near-zero-GWP-propellant.html
- https://www.astrazeneca.com/media-centre/articles/2025/upskillingAI.html
- https://www.astrazeneca.com/media-centre/articles/2025/caresa-a-pioneering-tool-to-model-the-environmental-impact-of-patient-care-pathways.html
- https://www.astrazeneca.com/media-centre/articles/2025/our-commitment-to-improving-lung-health-equity.html
- https://www.astrazeneca.com/media-centre/articles/2025/transforming-cardiovascular-care-burden-heart-failure.html
- https://www.astrazeneca.com/media-centre/articles/2024.html
- https://www.astrazeneca.com/media-centre/articles/2024/early-intervention-key-to-driving-sustainability-in-cardiorenal-care.html
- https://www.astrazeneca.com/media-centre/articles/2024/coaching-feedforward.html
- https://www.astrazeneca.com/media-centre/articles/2024/wef-annual-meeting.html
- https://www.astrazeneca.com/media-centre/articles/2024/reducing-burden-viral-respiratory-infections-aging-adults.html
- https://www.astrazeneca.com/media-centre/articles/2024/accelerating-transition-renewables-decarbonise-medicines-manufacturing-china.html
- https://www.astrazeneca.com/media-centre/articles/2024/oncology-trailblazers-digital-pathology.html
- https://www.astrazeneca.com/media-centre/articles/2024/oncology-r-and-d-strategy-driving-innovation.html
- https://www.astrazeneca.com/media-centre/articles/2024/upskilling-AI.html
- https://www.astrazeneca.com/media-centre/articles/2024/making-heart-failure-global-health-priority.html
- https://www.astrazeneca.com/media-centre/articles/2024/oncology-trailblazers-building-path-progress.html
- https://www.astrazeneca.com/media-centre/articles/2024/world-environment-day-restoring-protecting-land-future.html
- https://www.astrazeneca.com/media-centre/articles/2024/mitigating-risk-pharmaceuticals-environment.html
- https://www.astrazeneca.com/media-centre/articles/2024/embedding-sustainability-across-r-d-centres.html
- https://www.astrazeneca.com/media-centre/articles/2024/AI-solutions-healthcare-emerging-markets.html
- https://www.astrazeneca.com/media-centre/articles/2024/earlier-amyloidosis-diagnosis.html
- https://www.astrazeneca.com/media-centre/articles/2024/oncology-trailblazers-risk-and-hope-driving-improvements-in-cancer-care.html
- https://www.astrazeneca.com/media-centre/articles/2024/global-operations-digital-ai-wef-lighthouse.html
- https://www.astrazeneca.com/media-centre/articles/2024/transforming-patient-care-partnerships.html
- https://www.astrazeneca.com/media-centre/articles/2024/protecting-restoring-nature-for-a-healthier-future.html
- https://www.astrazeneca.com/media-centre/articles/2024/astrazeneca-in-top-five-in-access-to-medicine-index.html
- https://www.astrazeneca.com/media-centre/articles/2024/electronic-product-information-epi-digitalising-medicine-information-for-patients.html
- https://www.astrazeneca.com/media-centre/articles/2024/strengthening-health-systems-through-the-partnership-for-health-system-sustainability-and-resilience.html
- https://www.astrazeneca.com/media-centre/articles/2023.html
- https://www.astrazeneca.com/media-centre/articles/2023/oncology-trailblazers-treating-cancer-personal.html
- https://www.astrazeneca.com/media-centre/articles/2023/ncd-toll-deeply-inequitable.html
- https://www.astrazeneca.com/media-centre/articles/2023/detecting-amyloidosis-understanding-the-different-types-of-attr.html
- https://www.astrazeneca.com/media-centre/articles/2023/advancing-the-science-in-immune-mediated-diseases.html
- https://www.astrazeneca.com/media-centre/articles/2023/putting-health-at-the-heart-of-cop28.html
- https://www.astrazeneca.com/media-centre/articles/2023/astrazeneca-launches-a-healthtech-business-evinova.html
- https://www.astrazeneca.com/media-centre/articles/2023/global-healthcare-leaders-advance-sector-decarbonisation-cop28.html
- https://www.astrazeneca.com/media-centre/articles/2023/oncology-trailblazers-adcs.html
- https://www.astrazeneca.com/media-centre/articles/2023/fostering-culture-lifelong-learning.html
- https://www.astrazeneca.com/media-centre/articles/2023/common-cold-price-rsv-families-healthcare-systems.html
- https://www.astrazeneca.com/media-centre/articles/2023/az-forest-expanding-investment-in-climate-action-and-nature.html
- https://www.astrazeneca.com/media-centre/articles/2023/oncology-trailblazers-working-with-time.html
- https://www.astrazeneca.com/media-centre/articles/2023/equitable-sustainable-approach-cancer.html
- https://www.astrazeneca.com/media-centre/articles/2023/oncology-trailblazers-moving-mountains-patients.html
- https://www.astrazeneca.com/media-centre/articles/2023/transforming-kidney-health-burden-ckd.html
- https://www.astrazeneca.com/media-centre/articles/2023/current-state-hyperkalaemia.html
- https://www.astrazeneca.com/media-centre/articles/2023/transforming-cardiovascular-care-burden-heart-failure.html
- https://www.astrazeneca.com/media-centre/articles/2023/decarbonising-respiratory-care.html
- https://www.astrazeneca.com/media-centre/articles/2023/powering-emissions-reductions-clean-heat-renewable-energy.html
- https://www.astrazeneca.com/media-centre/articles/2023/climate-week-un-general-assembly.html
- https://www.astrazeneca.com/media-centre/articles/2022.html
- https://www.astrazeneca.com/media-centre/articles/2022/UK-partnerships-drive-emission-reductions.html
- https://www.astrazeneca.com/media-centre/articles/2022/progressing-ambition-zero-carbon-through-collaboration.html
- https://www.astrazeneca.com/media-centre/articles/2022/celebrating-the-life-and-legacy-of-jose-baselga.html
- https://www.astrazeneca.com/media-centre/articles/2022/sustainable-markets-initiative-health-systems-task-force.html
- https://www.astrazeneca.com/media-centre/articles/2022/neurodiversity-in-workplace.html
- https://www.astrazeneca.com/media-centre/articles/2022/AZ-Forest-New-Partnership-Commitments.html
- https://www.astrazeneca.com/media-centre/articles/2022/accelerating-sustainable-healthcare-for-a-healthier-tomorrow.html
- https://www.astrazeneca.com/media-centre/articles/2022/Connecting-innovating-transforming-to-deliver-a-common-future.html
- https://www.astrazeneca.com/media-centre/articles/2022/supporting-early-talent-inclusive-diverse-future-workforce.html
- https://www.astrazeneca.com/media-centre/articles/2022/raising-awareness-attr.html
- https://www.astrazeneca.com/media-centre/articles/2022/science-led-commitments-to-action-at-cop27.html
- https://www.astrazeneca.com/media-centre/articles/2022/seven-pharma-ceos-announce-new-joint-action-to-accelerate-net-zero-healthcare.html
- https://www.astrazeneca.com/media-centre/articles/2022/building-resilient-sustainable-health-systems.html
- https://www.astrazeneca.com/media-centre/articles/2022/oncology-trailblazers-breast-cancer.html
- https://www.astrazeneca.com/media-centre/articles/2022/accessibility-workplace.html
- https://www.astrazeneca.com/media-centre/articles/2022/cancer-therapy-value-assessment.html
- https://www.astrazeneca.com/media-centre/articles/cancer-care-africa.html
- https://www.astrazeneca.com/media-centre/articles/sustainable-science-lab-to-patient.html
- https://www.astrazeneca.com/media-centre/articles/rare-disease-day.html
- https://www.astrazeneca.com/media-centre/articles/accelerating-transition-electric-vehicles.html
- https://www.astrazeneca.com/media-centre/articles/optimising-asthma-care-patients-planet.html
- https://www.astrazeneca.com/media-centre/articles/data-driven-approaches-to-accelerate-clinical-trial-diversity.html
- https://www.astrazeneca.com/media-centre/articles/transforming-respiratory-care.html
- https://www.astrazeneca.com/media-centre/articles/breast-cancer-grant-programme.html
- https://www.astrazeneca.com/media-centre/articles/astrazeneca-at-esc.html
- https://www.astrazeneca.com/media-centre/medical-releases.html
- https://www.astrazeneca.com/media-centre/medical-releases/Arthritis-and-Rheumatology-publishes-positive-Phase-II-data-on-anifrolumab-in-lupus-14112016.html
- https://www.astrazeneca.com/media-centre/medical-releases/durvalumab-monotherapy-demonstrates-efficacy-in-urothelial-bladder-cancer.html
- https://www.astrazeneca.com/media-centre/medical-releases/astrazenecas-combination-of-durvalumab-with-tremelimumab-shows-clinical-activity-in-non-small-cell-lung-cancer-irrespective-of-pd-l1-status-cancer-0120160.html
- https://www.astrazeneca.com/media-centre/medical-releases/durvalumab-shows-promising-preliminary-early-data-in-lung-and-head-and-neck-cancers-10102016.html
- https://www.astrazeneca.com/media-centre/medical-releases/euclid-trial-results-for-brilinta-brilique-presented-at-the-american.html
- https://www.astrazeneca.com/media-centre/medical-releases/Early-data-demonstrate-clinical-activity-of-acalabrutinib-in-difficult-to-treat-chronic-lymphocytic-leukaemia-05122016.html
- https://www.astrazeneca.com/media-centre/medical-releases/astrazeneca-supports-the-publication-of-the-2017-gold-strategy-for-improving-copd-diagnosis-management-and-prevention-09122016.html
- https://www.astrazeneca.com/media-centre/medical-releases/US-FDA-approves-Symbicort-budesonide-formoterol-for-the-treatment-of-asthma-in-paediatric-patients-300120170.html
- https://www.astrazeneca.com/media-centre/medical-releases/lynparza--olaparib--maintenance-treatment-offers-sustained-quality-of-life-alongside-improved-progression-free-survival-in-women-with-brca-mutated-ovarian-cancer-02072017.html
- https://www.astrazeneca.com/media-centre/medical-releases/astrazeneca-presents-tagrisso-osimertinib-data-in-patients-with-egfr-t790m-mutation-positive-lung-cancer-and-central-nervous-system-metastases-06062017.html
- https://www.astrazeneca.com/media-centre/medical-releases/new-data-supports-long-term-efficacy-of-ticagrelor-in-patients-up-to-five-years-following-a-heart-attack-06092017.html
- https://www.astrazeneca.com/media-centre/medical-releases/astrazeneca-presents-new-evidence-on-symbicort-budesonide-formoterol-in-copd-patients-at-risk-of-exacerbation.html
- https://www.astrazeneca.com/media-centre/medical-releases/forxiga-depict-1-trial-demonstrates-improved-glycaemic-control-without-increasing-hypoglycaemia-14092017.html
- https://www.astrazeneca.com/media-centre/medical-releases/astrazeneca-and-chi-meds-savolitinib-shows-encouraging-clinical-activity-in-2nd-line-egfr-mutation-positive-lung-cancer-with-met-amplification-171017.html
- https://www.astrazeneca.com/media-centre/medical-releases/zs-9-sodium-zirconium-cyclosilicate-phase-iii-long-term-safety-and-efficacy-data-presented-at-asn-kidney-week-201702112017.html
- https://www.astrazeneca.com/media-centre/medical-releases/faslodex-fulvestrant-receives-eu-approval-for-the-treatment-of-hormone-receptor-positive-advanced-breast-cancer-in-combination-with-palbociclib-14112017.html
- https://www.astrazeneca.com/media-centre/medical-releases/new-data-show-benefit-of-tagrisso-in-patients-with-egfr-mutated-non-small-cell-lung-cancer-and-central-nervous-system-metastases-20112017.html
- https://www.astrazeneca.com/media-centre/medical-releases/new-england-journal-of-medicine-publishes-results-of-phase-iii-flaura-trial-in-the-1st-line-treatment-of-egfr-mutated-non-small-cell-lung-cancer-20112017.html
- https://www.astrazeneca.com/media-centre/medical-releases/risk-of-repeat-heart-attack-twice-as-likely-from-occlusions-in-arteries-that-did-not-cause-initial-event.html
- https://www.astrazeneca.com/media-centre/medical-releases/astrazeneca-enrols-first-patient-in-new-brilinta-ticagrelor-stroke-trial-23012018.html
- https://www.astrazeneca.com/media-centre/medical-releases/brilinta-meets-primary-endpoint-in-phase-iii-thrombolysis-trial.html
- https://www.astrazeneca.com/media-centre/medical-releases/brilinta-ticagrelor-associated-with-a-reduction-in-risk-for-cardiovascular-events-versus-clopidogrel-in-heart-attack-survivors-with-moderate-kidney-disease-090418.html
- https://www.astrazeneca.com/media-centre/medical-releases/astrazeneca-presents-imfinzi-durvalumab-plus-tremelimumab-combination-data-at-aacr-annual-meeting-170418.html
- https://www.astrazeneca.com/media-centre/medical-releases/astrazeneca-and-medimmune-present-phase-ii-data-for-medi0382-at-ada-2018-demonstrating-significant-improvements-in-glycaemic-control-and-weight-loss-in-patients-with-type-2-diabetes.html
- https://www.astrazeneca.com/media-centre/medical-releases/farxiga-in-combination-with-onglyza-demonstrates-similar-glycaemic-control-with-additional-benefits-vs-insulin-glargine-in-patients-with-type-2-diabetes25062018.html
- https://www.astrazeneca.com/media-centre/medical-releases/astrazeneca-expands-heart-failure-research-with-new-phase-iii-deliver-trial-of-forxiga-in-patients-with-and-without-type-2-diabetes23082018.html
- https://www.astrazeneca.com/media-centre/medical-releases/new-data-from-real-world-evidence-indicates-need-for-better-secondary-prevention-to-reduce-long-term-ischaemic-risk-in-heart-attack-survivors-29082018.html
- https://www.astrazeneca.com/media-centre/medical-releases/european-respiratory-journal-publishes-phase-iii-telos-trial-for-pt009-dual-combination-therapy-in-moderate-to-very-severe-chronic-obstructive-pulmonary-disease-16092018.html
- https://www.astrazeneca.com/media-centre/medical-releases/first-patients-enrolled-in-phase-iiib-ponente-trial-evaluating-the-elimination-of-oral-corticosteroids-with-fasenra-in-severe-eosinophilic-asthma-18092018.html
- https://www.astrazeneca.com/media-centre/medical-releases/new-pegasus-timi-54-sub-analyses-provide-direction-on-selecting-patients-most-likely-to-benefit-from-long-term-treatment-with-brilinta-ticagrelor.html
- https://www.astrazeneca.com/media-centre/medical-releases/imfinzi-demonstrates-clinical-activity-in-stage-iv-1st-line-non-small-cell-lung-cancer-in-phase-iii-mystic-trial-13122018.html
- https://www.astrazeneca.com/media-centre/medical-releases/phase-iii-treat-trial-provides-evidence-on-the-use-of-brilinta-in-high-risk-patients-treated-with-pharmacological-thrombolysis18032019.html
- https://www.astrazeneca.com/media-centre/medical-releases/astrazeneca-supports-new-global-recommendations-on-asthma-care12042019.html
- https://www.astrazeneca.com/media-centre/medical-releases/phase-iii-combination-trial-of-bydureon-and-forxiga-shows-signif.html
- https://www.astrazeneca.com/media-centre/medical-releases/socrates-trial-results-for-brilinta-brilique-presented-at-europe.html
- https://www.astrazeneca.com/media-centre/medical-releases/astrazeneca-announces-two-new-phase-iiib-trials-for-forxiga-in-c.html
- https://www.astrazeneca.com/media-centre/medical-releases/astrazeneca-receives-approval-in-the-eu-for-qtern--saxagliptin-a.html
- https://www.astrazeneca.com/media-centre/medical-releases/positive-chmp-opinion-in-eu-for-saxa-dapa--saxagliptin-and-dapag.html
- https://www.astrazeneca.com/media-centre/medical-releases/acalabrutinib-recommended-for-orphan-drug-designation-in-Europe-for-three-indications.html
- https://www.astrazeneca.com/media-centre/medical-releases/Tagrisso-osimertinib-shows-clinical-activity-in-patients-with-leptomeningeal-disease-from-lung-cancer.html
- https://www.astrazeneca.com/media-centre/medical-releases/AstraZeneca-presents-further-evidence-for-the-potential-of-AZD9291-in-first-line-and-pre-treated-non-small-cell-lung-cancer.html
- https://www.astrazeneca.com/media-centre/medical-releases/AstraZeneca-presents-advances-in-oncology-research-at-ECC-2015-with-data-on-AZD9291-durvalumab-and-LYNPARZA-olaparib.html
- https://www.astrazeneca.com/media-centre/medical-releases/AstraZeneca-presents-positive-Tagrisso-osimertinib-follow-up-data-in-lung-cancer-at-ELCC-2016.html
- https://www.astrazeneca.com/media-centre/medical-releases/Lynparza-olaparib-latest-data-suggest-potential-overall-survival-advantage-in-patients-with-platinum-sensitive-ovarian-cancer.html
- https://www.astrazeneca.com/media-centre/medical-releases/AstraZeneca-to-present-anifrolumab-lupus-data-at-Annual-European-Congress-of-Rheumatology-EULAR-2016.html
- https://www.astrazeneca.com/media-centre/medical-releases/farxiga-heart-failure-research-broadened-with-new-phase-iii-determine-trials.html
- https://www.astrazeneca.com/media-centre/medical-releases/astrazeneca-announces-two-lancet-oncology-publications-of-phase-i-dose-expansion-results-of-trastuzumab-deruxtecan-in-her2-positive-metastatic-breast-and-gastric-cancer.html
- https://www.astrazeneca.com/media-centre/medical-releases/astrazeneca-enters-strategic-collaboration-with-transgene-to-develop-innovative-oncolytic-virus-immunotherapies30042019.html
- https://www.astrazeneca.com/media-centre/medical-releases/fasenra-reduces-oral-corticosteroid-use-and-maintains-long-term-efficacy-and-safety-profile-in-severe-eosinophilic-asthma.html
- https://www.astrazeneca.com/media-centre/medical-releases/farxiga-study-showed-reduced-progression-of-kidney-disease-or-renal-death-in-patients-with-type-2-diabetes10062019.html
- https://www.astrazeneca.com/media-centre/medical-releases/archive.html
- https://www.astrazeneca.com/media-centre/medical-releases/positive-results-from-two-roxadustat-phase-iii-trials-in-china-for-the-treatment-of-anaemia-published-in-the-new-england-journal-of-medicine-24072019.html
- https://www.astrazeneca.com/media-centre/medical-releases/new-data-show-symbicort-used-as-an-anti-inflammatory-reliever-in-mild-to-moderate-asthma-is-more-effective-at-preventing-severe-asthma-attacks--27082019.html
- https://www.astrazeneca.com/media-centre/medical-releases/forxiga-reduced-the-risk-of-a-composite-of-cardiovascular-death-or-hospitalisation-for-heart-failure-in-patients-with-type-2-diabetes-both-with-and-without-kidney-disease-31082019.html
- https://www.astrazeneca.com/media-centre/medical-releases/new-analysis-of-fasenra-phase-iii-galathea-and-terranova-copd-trials-identifies-factors-associated-with-exacerbation-rate-reductions.html
- https://www.astrazeneca.com/media-centre/medical-releases/brilinta-monotherapy-in-high-bleeding-risk-patients-who-underwent-pci-had-reduced-risk-of-clinically-relevant-bleeding-than-with-dual-antiplatelet-therapy-in-the-twilight-trial.html
- https://www.astrazeneca.com/media-centre/medical-releases/new-data-from-the-phase-iii-dapa-hf-trial-showed-farxiga-dapagliflozin-reduced-the-worsening-of-heart-failure-or-cv-death-in-hfref-patients-with-and-without-ckd.html
- https://www.astrazeneca.com/media-centre/medical-releases/subgroup-analysis-of-twilight-trial-patients-with-nste-acs.html
- https://www.astrazeneca.com/media-centre/medical-releases/consistent-effects-of-farxiga-in-heart-failure-patients-with-reduced-ejection-fraction-shown-in-new-analyses-from-landmark-phase-iii-dapa-hf-trial.html
- https://www.astrazeneca.com/media-centre/medical-releases/three-clinical-trials-announced-for-fasenra-in-eosinophil-driven-skin-diseases.html
- https://www.astrazeneca.com/media-centre/medical-releases/lokelma-us-label-updated-to-include-dosing-guidance-for-the-treatment-of-hyperkalaemia-in-patients-with-end-stage-renal-disease-on-haemodialysis.html
- https://www.astrazeneca.com/media-centre/medical-releases/lokelma-label-update-approved-in-eu-for-patients-with-hyperkalaemia-on-stable-haemodialysis.html
- https://www.astrazeneca.com/media-centre/medical-releases/anifrolumab-showed-early-and-sustained-treatment-benefit-for-patients-with-systemic-lupus-erythematosus-in-the-tulip-clinical-trial-programme.html
- https://www.astrazeneca.com/media-centre/medical-releases/astrazeneca-licenses-preclinical-porcupine-inhibitor-rxc006-for-idiopathic-pulmonary-fibrosis.html
- https://www.astrazeneca.com/media-centre/medical-releases/fasenra-significantly-reduced-exacerbation-rate-for-severe-eosinophilic-asthma-patients-in-phase-iiib-andhi-trial.html
- https://www.astrazeneca.com/media-centre/medical-releases/Anifrolumab-reduces-disease-flares-in-patients-with-systemic-lupus-erythematosus-while-allowing-oral-corticosteroid-tapering.html
- https://www.astrazeneca.com/media-centre/medical-releases/brilinta-reduced-subsequent-disabling-stroke-or-death-in-patients-who-had-an-acute-ischaemic-stroke-or-transient-ischaemic-attack-in-phase-iii-thales-trial-sub-analysis.html
- https://www.astrazeneca.com/media-centre/medical-releases/farxiga-showed-cardiovascular-and-renal-benefit-in-patients-with-chronic-kidney-disease-irrespective-of-cardiovascular-disease-status.html
- https://www.astrazeneca.com/media-centre/medical-releases/brilinta-reduced-the-composite-of-stroke-and-death-in-patients-with-head-and-neck-artery-atherosclerosis.html
- https://www.astrazeneca.com/media-centre/medical-releases/lokelma-label-update-approved-in-china-for-patients-with-hyperka.html
- https://www.astrazeneca.com/media-centre/medical-releases/first-patients-dosed-in-phase-iii-trials-evaluating-fasenra.html
- https://www.astrazeneca.com/media-centre/medical-releases/new-data-show-overuse-of-reliever-medication-in-asthma-is-responsible-for-250k-tonnes-of-greenhouse-gas-emissions-every-year-in-the-uk.html
- https://www.astrazeneca.com/media-centre/medical-releases/first-patients-dosed-in-three-dermatology-trials-evaluating-fasenra-in-bullous-pemphigoid-atopic-dermatitis-and-chronic-spontaneous-urticaria.html
- https://www.astrazeneca.com/media-centre/medical-releases/new-tezepelumab-data-continue-to-strengthen-profile-for-a-broad-population-of-severe-asthma-patients.html
- https://www.astrazeneca.com/media-centre/medical-releases/new-fasenra-data-from-the-meltemi-extension-trial-confirm-long-term-safety-and-efficacy-in-severe-eosinophilic-asthma-for-up-to-5-years.html
- https://www.astrazeneca.com/media-centre/medical-releases/new-data-at-heart-failure-2021-showcases-astrazenecas-leading-and-diverse-heart-failure-portfolio.html
- https://www.astrazeneca.com/media-centre/medical-releases/astrazenecas-investigational-mpo-inhibitor-azd4831-shows-promise-in-patients-with-heart-failure-and-a-preserved-ejection-fraction.html
- https://www.astrazeneca.com/media-centre/medical-releases/bydureon-bcise-exenatide-extended-release-approved-in-the-us-for-the-treatment-of-type-2-diabetes-in-paediatric-patients-ages-10-years-and-older.html
- https://www.astrazeneca.com/media-centre/medical-releases/new-data-at-esc-congress-2021-showcase-astrazenecas-leading-cardiovascular-renal-and-metabolic-portfolio.html
- https://www.astrazeneca.com/media-centre/medical-releases/new-tezepelumab-data-show-86-reduction-in-exacerbations-in-patients-with-severe-asthma-and-comorbid-nasal-polyps.html
- https://www.astrazeneca.com/media-centre/medical-releases/new-fasenra-data-from-the-ponente-trial-show-sustained-robust-oral-corticosteroid-reductions.html
- https://www.astrazeneca.com/media-centre/medical-releases/carbon-studies-showed-uncontrolled-asthma-is-associated-with-an-increased-carbon-footprint-of-asthma-care.html
- https://www.astrazeneca.com/media-centre/medical-releases/saphnelo-consistently-reduces-systemic-lupus-erythematosus-disease-activity-regardless-of-disease-duration-and-prior-treatment.html
- https://www.astrazeneca.com/media-centre/medical-releases/new-sub-analyses-further-support-consistency-of-farxigas-cardiorenal-and-mortality-benefits-in-treating-chronic-kidney-disease.html
- https://www.astrazeneca.com/media-centre/medical-releases/fasenra-granted-orphan-drug-and-fast-track-designations-in-the-us-for-eosinophilic-gastritis-and-eosinophilic-gastroenteritis.html
- https://www.astrazeneca.com/media-centre/medical-releases/lokelma-granted-fast-track-designation-in-the-us-to-reduce-cardiovascular-outcomes-in-patients-on-chronic-haemodialysis-with-hyperkalaemia.html
- https://www.astrazeneca.com/media-centre/medical-releases/eplontersen-granted-orphan-drug-designation-in-the-us-for-transthyretin-amyloidosis.html
- https://www.astrazeneca.com/media-centre/medical-releases/new-data-further-reinforce-efficacy-of-tezspire-in-a-broad-population-of-severe-asthma-patients.html
- https://www.astrazeneca.com/media-centre/medical-releases/evusheld-long-acting-antibody-combination-retains-neutralising-activity-against-omicron-variants-including-ba2-in-new-independent-studies.html
- https://www.astrazeneca.com/media-centre/medical-releases/sabina-programme-demonstrates-saba-reliever-overuse-is-a-global-issue-in-asthma-management.html
- https://www.astrazeneca.com/media-centre/medical-releases/new-nirsevimab-data-analyses-reinforce-efficacy-rsv.html
- https://www.astrazeneca.com/media-centre/medical-releases/evusheld-long-acting-antibody-combination-retains-neutralising-activity-omicron-variants-ba4-ba5-according-new-study-university-oxford.html
- https://www.astrazeneca.com/media-centre/medical-releases/first-patients-dosed-in-iris-phase-iii-trial-evaluating-saphnelo-in-lupus-nephritis.html
- https://www.astrazeneca.com/media-centre/medical-releases/bydureon-bcise-exenatide-prolonged-release-approved-in-the-eu-for-paediatric-patients-with-type-2-diabetes.html
- https://www.astrazeneca.com/media-centre/medical-releases/propel-phase-iii-trial-positive-results-of-lynparza-plus-abiraterone.html
- https://www.astrazeneca.com/media-centre/medical-releases/astrazeneca-shares-data-at-easl-and-esmo-world-gi-for-imfinzi-combinations-in-patients-with-liver-and-biliary-tract-cancers.html
- https://www.astrazeneca.com/media-centre/medical-releases/vaxzevria-shown-in-expert-review-to-provide-equally-effective-protection-against-covid-19.html
- https://www.astrazeneca.com/media-centre/medical-releases/vaxzevria-73-effective-at-preventing-omicron-related-infections-after-fourth-dose-according-to-real-world-evidence-study-in-thailand.html
- https://www.astrazeneca.com/media-centre/medical-releases/poseidon-phase-iii-post-hoc-exploratory-analyses-presented-at-wclc-2022.html
- https://www.astrazeneca.com/media-centre/medical-releases/new-analyses-in-real-world-setting-support-the-effectiveness-of-fasenra-in-severe-eosinophilic-asthma.html
- https://www.astrazeneca.com/media-centre/medical-releases/new-tezspire-data-at-ers-international-congress-2022-continue-to-strengthen-profile-for-a-broad-population-of-severe-asthma-patients.html
- https://www.astrazeneca.com/media-centre/medical-releases/astrazeneca-advancing-clinical-practice-in-heart-failure-with-unprecedented-data-and-number-of-simultaneous-publications-of-deliver-phase-iii-results.html
- https://www.astrazeneca.com/media-centre/medical-releases/vaxzevria-highly-effective-at-preventing-covid-19-severe-outcomes-and-death.html
- https://www.astrazeneca.com/media-centre/medical-releases/new-beyfortus-data-reinforce-efficacy-against-infant-rsv-hospitalisations.html
- https://www.astrazeneca.com/media-centre/medical-releases/farxiga-demonstrated-consistent-benefit-regardless-of-heart-failure-duration-and-across-the-full-spectrum-of-cardiorenal-disease.html
- https://www.astrazeneca.com/media-centre/medical-releases/new-astrazeneca-data-presented-at-ats-2023-strengthen-the-body-of-evidence-supporting-early-intervention-with-breztri-in-copd.html
- https://www.astrazeneca.com/media-centre/medical-releases/real-world-evidence-highlights-the-urgent-need-to-act-on-the-growing-global-burden-of-chronic-kidney-disease.html
- https://www.astrazeneca.com/media-centre/medical-releases/real-world-evidence-study-shows-the-significant-impact-of-hyperkalaemia-on-cardiorenal-patient-outcomes.html
- https://www.astrazeneca.com/media-centre/medical-releases/eplontersen-phase-iii-results-published-in-jama.html
- https://www.astrazeneca.com/media-centre/medical-releases/large-real-world-evidence-studies-reveal-disproportionate-burden-of-covid-19-on-the-immunocompromised.html
- https://www.astrazeneca.com/media-centre/medical-releases/astrazeneca-celebrates-science-in-pictures.html
- https://www.astrazeneca.com/media-centre/medical-releases/astrazeneca-establishes-new-world-class-functional-genomics-laboratory-with-medical-research-council-and-the-milner-therapeutics-institute-at-the-university-of-cambridge.html
- https://www.astrazeneca.com/media-centre/medical-releases/mandara-phase-iii-data-published-new-england-journal-medicine-show-remission-achievable-goal-eosinophilic-granulomatosis-polyangiitis-egpa-fasenra.html
- https://www.astrazeneca.com/media-centre/medical-releases/astrazeneca-announces-initiation-tharros-phase-iii-clinical-trial-investigating-potential-breztri-improve-cardiopulmonary-outcomes-people-with-copd.html
- https://www.astrazeneca.com/media-centre/medical-releases/saphnelo-demonstrates-higher-rates-of-remission-in-patients-with-systemic-lupus-erythematosus-compared-to-standard-therapy-alone-over-4-year-period.html
- https://www.astrazeneca.com/media-centre/medical-releases/results-miracle-phase-iii-trial-show-treatment-fasenra-statistically-reduction-74-annual-exacerbation-rate-patients-asia-severe-eosinophilic-asthma.html
- https://www.astrazeneca.com/media-centre/medical-releases/real-world-evidence-eccmid-2024-further-substantiate-continued-significant-disproportionate-risk-severe-covid-19-facing-immunocompromised-individuals.html
- https://www.astrazeneca.com/media-centre/medical-releases/new-data-presented-at-ats-2024-show-the-potential-of-tezepelumab-to-play-a-role-in-the-future-treatment-of-chronic-obstructive-pulmonary-disease.html
- https://www.astrazeneca.com/media-centre/medical-releases/azd0780-an-oral-pcsk9-inhibitor-demonstrated-significant-ldl-c-reduction-on-top-of-statin-in-phase-i-trial.html
- https://www.astrazeneca.com/media-centre/medical-releases/astrazeneca-unveils-latest-research-at-esc-congress-2024-showcasing-strength-of-its-cardiovascular-renal-and-metabolism-portfolio-and-pipeline.html
- https://www.astrazeneca.com/media-centre/medical-releases/astrazeneca-new-ai-technology-milton-predicts-more-than-1000-diseases-before-diagnosis.html
- https://www.astrazeneca.com/media-centre/medical-releases/astrazeneca-announces-start-of-recruitment-in-2-new-phase-iii-trials-evaluating-saphnelo-in-cle-and-in-iim.html
- https://www.astrazeneca.com/media-centre/medical-releases/new-long-term-alpha-phase-iii-trial-data-published-in-blood-show-voydeya-as-add-on-to-ultomiris-or-soliris-maintained-clinical-improvements-for-the-subset-of-people-with-pnh-experiencing-clinically-significant-extravascular-haemolysis.html
- https://www.astrazeneca.com/media-centre/medical-releases/ultomiris-ravulizumab-meaningful-survival-87-at-26-weeks-children-thrombotic-mp-after-haematopoietic-stem-cell-transplant-phase-iii-open-label-trial.html
- https://www.astrazeneca.com/media-centre/image-and-broadcast-library.html
- https://www.astrazeneca.com/media-centre/archive.html
- https://www.astrazeneca.com/media-centre/social-media-community-guidelines.html
- https://www.astrazeneca.com/media-centre/contacts.html
- https://www.astrazeneca.com/media-centre/astrazeneca-investor-day-media-hub.html
- https://www.astrazeneca.com/media-centre/pdf.html
- https://www.astrazeneca.com/sustainability.html
- https://www.astrazeneca.com/sustainability/climate-change.html
- https://www.astrazeneca.com/sustainability/climate-change/renewable-energy.html
- https://www.astrazeneca.com/sustainability/climate-change/product-sustainability.html
- https://www.astrazeneca.com/sustainability/climate-change/az-forest.html
- https://www.astrazeneca.com/sustainability/access-to-healthcare.html
- https://www.astrazeneca.com/sustainability/access-to-healthcare/affordability-and-pricing.html
- https://www.astrazeneca.com/sustainability/access-to-healthcare/health-system-resilience.html
- https://www.astrazeneca.com/sustainability/access-to-healthcare/equitable-access.html
- https://www.astrazeneca.com/sustainability/environmental-protection.html
- https://www.astrazeneca.com/sustainability/environmental-protection/natural-resources.html
- https://www.astrazeneca.com/sustainability/environmental-protection/ambition-zero-carbon.html
- https://www.astrazeneca.com/sustainability/ethics-and-transparency.html
- https://www.astrazeneca.com/sustainability/ethics-and-transparency/ethical-business-culture.html
- https://www.astrazeneca.com/sustainability/partnerships-and-alliances.html
- https://www.astrazeneca.com/sustainability/resources.html
- https://www.astrazeneca.com/sustainability/resources/policies-and-standards.html
- https://www.astrazeneca.com/sustainability/resources/double-materiality-assessment.html
- https://www.astrazeneca.com/sustainability/resources/archive.html
- https://www.astrazeneca.com/sustainability/resources/our-impact.html
- https://www.astrazeneca.com/sustainability/resources/sustainability-governance.html
- https://www.astrazeneca.com/sustainability/health-systems-resilience.html
- https://www.astrazeneca.com/sustainability/health-systems-resilience/PHSSR.html
- https://www.astrazeneca.com/sustainability/nature.html
- https://www.astrazeneca.com/sustainability/nature/waste-circularity.html
- https://www.astrazeneca.com/sustainability/nature/pharmaceuticals-in-the-environment.html
- https://www.astrazeneca.com/sustainability/nature/pharmaceuticals-in-the-environment/dashboard-archive.html
- https://www.astrazeneca.com/sustainability/nature/pharmaceuticals-in-the-environment/EcoPharmacoVigilance-Dashboard.html
- https://www.astrazeneca.com/sustainability/nature/water-stewardship.html
- https://www.astrazeneca.com/sustainability/ethics-compliance.html
- https://www.astrazeneca.com/sustainability/ethics-compliance/data-and-ai-ethics.html
- https://www.astrazeneca.com/sustainability/ethics-compliance/our-commitment-to-clinical-trial-transparency.html
- https://www.astrazeneca.com/sustainability/ethics-compliance/astrazeneca-and-global-transparency.html
- https://www.astrazeneca.com/sustainability/ethics-compliance/animals-in-research.html
- https://www.astrazeneca.com/sustainability/health-equity.html
- https://www.astrazeneca.com/sustainability/health-equity/healthcare-delivery.html
- https://www.astrazeneca.com/sustainability/health-equity/science.html
- https://www.astrazeneca.com/sustainability/health-equity/healthy-heart-africa.html
- https://www.astrazeneca.com/sustainability/health-equity/community-investment.html
- https://www.astrazeneca.com/sustainability/workforce-safety-and-health.html
- https://www.astrazeneca.com/investor-relations.html
- https://www.astrazeneca.com/investor-relations/meet-the-management-at-esmo-2025.html
- https://www.astrazeneca.com/investor-relations/astrazeneca-investor-day.html
- https://www.astrazeneca.com/investor-relations/resources.html
- https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements.html
- https://www.astrazeneca.com/investor-relations/results-and-presentations.html
- https://www.astrazeneca.com/investor-relations/results-and-presentations/archive.html
- https://www.astrazeneca.com/investor-relations/annual-reports.html
- https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2015.html
- https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2015/cautionary-statement.html
- https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2015/reader-information.html
- https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2016.html
- https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2016/contact-information.html
- https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2016/annual-report-and-cautionary-statement.html
- https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2017.html
- https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2018.html
- https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2019.html
- https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2020.html
- https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2021.html
- https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2022.html
- https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2023.html
- https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2024.html
- https://www.astrazeneca.com/investor-relations/corporate-governance.html
- https://www.astrazeneca.com/investor-relations/shareholder-information.html
- https://www.astrazeneca.com/investor-relations/dividend-policy.html
- https://www.astrazeneca.com/investor-relations/key-facts.html
- https://www.astrazeneca.com/investor-relations/faqs.html
- https://www.astrazeneca.com/investor-relations/debt-investors.html
- https://www.astrazeneca.com/investor-relations/debt-investors/emtn-programme.html
- https://www.astrazeneca.com/investor-relations/events.html
- https://www.astrazeneca.com/investor-relations/astrazeneca-adr-programme.html
- https://www.astrazeneca.com/investor-relations/9m-and-q3-2023-results.html
- https://www.astrazeneca.com/investor-relations/jp-morgan-42nd-annual-healthcare-conference.html
- https://www.astrazeneca.com/investor-relations/full-year-and-q4-2023-results-event.html
- https://www.astrazeneca.com/investor-relations/q1-2024-results-event.html
- https://www.astrazeneca.com/investor-relations/sustainability-2023-highlights-summary-call.html
- https://www.astrazeneca.com/investor-relations/meet-the-management-event-at-asco-2024.html
- https://www.astrazeneca.com/investor-relations/h1-and-q2-2024-results-event.html
- https://www.astrazeneca.com/investor-relations/tools.html
- https://www.astrazeneca.com/investor-relations/meet-the-management-event-at-esmo-2024.html
- https://www.astrazeneca.com/investor-relations/meet-the-management-lung-cancer-and-qcs.html
- https://www.astrazeneca.com/investor-relations/astrazeneca-health-equity-investor-event.html
- https://www.astrazeneca.com/investor-relations/9m-and-q3-2024-results-event.html
- https://www.astrazeneca.com/investor-relations/meet-the-management-weight-management-virtual-event.html
- https://www.astrazeneca.com/investor-relations/full-year-and-q4-2024-results-event.html
- https://www.astrazeneca.com/investor-relations/q1-2025-results-event.html
- https://www.astrazeneca.com/investor-relations/sustainability-2024-highlights-summary-call.html
- https://www.astrazeneca.com/investor-relations/meet-the-management-event-at-asco-2025.html
- https://www.astrazeneca.com/investor-relations/h1-and-q2-2025-results-event.html
- https://www.astrazeneca.com/investor-relations/contacts-information.html
- https://www.astrazeneca.com/investor-relations/meet-the-management-at-esc-2025.html
- https://www.astrazeneca.com/partnering.html
- https://www.astrazeneca.com/partnering/externally-sponsored-scientific-research-partner-portal.html
- https://www.astrazeneca.com/partnering/externally-sponsored-scientific-research-partner-portal/training-centre.html
- https://www.astrazeneca.com/partnering/our-partnering-teams.html
- https://www.astrazeneca.com/partnering/our-areas-of-partnering-interest.html
- https://www.astrazeneca.com/partnering/why-partner-with-astrazeneca.html
- https://www.astrazeneca.com/partnering/externally-sponsored-scientific-research.html
- https://www.astrazeneca.com/partnering/Externally-sponsored-scientific-research-training-centre.html
- https://www.astrazeneca.com/partnering/external-funding.html
- https://www.astrazeneca.com/partnering/a-catalyst-network.html
- https://www.astrazeneca.com/partnering/az-suppliers.html
- https://www.astrazeneca.com/partnering/az-suppliers/supplier-contact-form.html
- https://www.astrazeneca.com/partnering/supplier-sustainability-hub.html
- https://www.astrazeneca.com/partnering/sustainable-procurement.html
- https://www.astrazeneca.com/terms-and-conditions.html
- https://www.astrazeneca.com/what-science-can-do.html
- https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/high-proteinuria-chronic-kidney-disease.html
- https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/understanding-links-between-genetics-and-biology-to-advance-drug-discovery.html
- https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/new-era-multi-omic-data-analysis-oncology.html
- https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/endothelin-1.html
- https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/strategic-treatment-combinations-cancer.html
- https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/the-unmet-need-in-dyslipidaemia.html
- https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/unpacking-raas-pathway-role-aldosterone.html
- https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/transforming-astrazenecas-rd-productivity.html
- https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/pioneers-in-asthma-where-is-the-science-leading-us.html
- https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/Hitting-the-bullseye-finding-better-targets-for-drug-development.html
- https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/nash-a-new-approach-brings-new-hope.html
- https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/modelling-chronic-kidney-disease-in-3d.html
- https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/novel-genetic-targets-for-fatty-liver-disease.html
- https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/exploring-the-genome-to-find-novel-targets-for-chronic-diseases.html
- https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/inflammation-remodelling-chronic-diseases.html
- https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/understanding-impacts-cardiomyopathy.html
- https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/research-idiopathic-pulmonary-fibrosis.html
- https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/precision-medicine-approach-immunology-targeted-biology.html
- https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/navigating-genetics-diabetes-resistance.html
- https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/cosolve-forging-partnerships-solve-research-challenges.html
- https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/tumour-microenvironment.html
- https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/premalignantdisease.html
- https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/impacts-severe-infection-respiratory-viruses.html
- https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/bronchiectasis-research.html
- https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/creating-better-health-outcomes-holistic-approach-weight-management.html
- https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/rethinking-prevention-of-recurrent-c-diff-infections.html
- https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/multifaceted-mechanisms-and-approaches-in-weight-management.html
- https://www.astrazeneca.com/what-science-can-do/topics/next-generation-therapeutics/targeting-progression-of-liver-damage-in-nash.html
- https://www.astrazeneca.com/what-science-can-do/topics/next-generation-therapeutics/transforming-treatment-for-billions-of-people-living-with-chronic-diseases.html
- https://www.astrazeneca.com/what-science-can-do/topics/next-generation-therapeutics/MRC-collaboration-cell-oligonucleotide-therapies.html
- https://www.astrazeneca.com/what-science-can-do/topics/next-generation-therapeutics/advances-epigenetics-oncology.html
- https://www.astrazeneca.com/what-science-can-do/topics/next-generation-therapeutics/novel-gene-editing-efficient-route-gene-therapies.html
- https://www.astrazeneca.com/what-science-can-do/topics/next-generation-therapeutics/Accelerating-innovation-to-transform-cancer-care.html
- https://www.astrazeneca.com/what-science-can-do/topics/next-generation-therapeutics/exploring-new-frontiers-in-immuno-oncology.html
- https://www.astrazeneca.com/what-science-can-do/topics/next-generation-therapeutics/breast-cancer-research.html
- https://www.astrazeneca.com/what-science-can-do/topics/next-generation-therapeutics/liquid-biopsy-ctdna.html
- https://www.astrazeneca.com/what-science-can-do/topics/next-generation-therapeutics/developing-cell-based-therapies-to-put-cancer-cures-within-reach.html
- https://www.astrazeneca.com/what-science-can-do/topics/next-generation-therapeutics/r-d-postdoctoral-challenge-final.html
- https://www.astrazeneca.com/what-science-can-do/topics/next-generation-therapeutics/unique-complexities-cell-therapy-manufacturing.html
- https://www.astrazeneca.com/what-science-can-do/topics/next-generation-therapeutics/precision-medicine-NASH.html
- https://www.astrazeneca.com/what-science-can-do/topics/next-generation-therapeutics/developing-the-next-generation-of-drug-delivery-technologies.html
- https://www.astrazeneca.com/what-science-can-do/topics/next-generation-therapeutics/cell-lineage-targeted-regeneration-research.html
- https://www.astrazeneca.com/what-science-can-do/topics/next-generation-therapeutics/t-cell-receptor-therapies.html
- https://www.astrazeneca.com/what-science-can-do/topics/next-generation-therapeutics/immunotherapy-cancer-treatment-bispecific-antibodies-and-immune-cell-engagers.html
- https://www.astrazeneca.com/what-science-can-do/topics/next-generation-therapeutics/engineering-novel-cancer-treatments.html
- https://www.astrazeneca.com/what-science-can-do/topics/next-generation-therapeutics/regulatory-success-cell-therapy.html
- https://www.astrazeneca.com/what-science-can-do/topics/next-generation-therapeutics/multispecific-antibodies-redefining-medicine.html
- https://www.astrazeneca.com/what-science-can-do/topics/next-generation-therapeutics/advancing-beyond-the-genome.html
- https://www.astrazeneca.com/what-science-can-do/topics/next-generation-therapeutics/transforming-care-for-serious-bacterial-infections.html
- https://www.astrazeneca.com/what-science-can-do/topics/clinical-innovation/innovative-analytics-bridging-the-gap-between-science-and-patient.html
- https://www.astrazeneca.com/what-science-can-do/topics/clinical-innovation/Streamlining-clinical-trials-through-digital-solutions.html
- https://www.astrazeneca.com/what-science-can-do/topics/clinical-innovation/haematology-research-blood-cancer-care.html
- https://www.astrazeneca.com/what-science-can-do/topics/clinical-innovation/nash-clinical-development.html
- https://www.astrazeneca.com/what-science-can-do/topics/clinical-innovation/clinical-innovation-digital-health-solutions-transforming-trials.html
- https://www.astrazeneca.com/what-science-can-do/topics/clinical-innovation/clinical-innovation-driving-sustainable-clinical-trials.html
- https://www.astrazeneca.com/what-science-can-do/topics/clinical-innovation/diagnosis-monitoring-respiratory-diseases.html
- https://www.astrazeneca.com/what-science-can-do/topics/clinical-innovation/oncology-partnerships.html
- https://www.astrazeneca.com/what-science-can-do/topics/clinical-innovation/rare-disease-research.html
- https://www.astrazeneca.com/what-science-can-do/topics/clinical-innovation/new-era-rare-neurological-disease.html
- https://www.astrazeneca.com/what-science-can-do/topics/clinical-innovation/advancing-gene-editing-with-epscas9-technology.html
- https://www.astrazeneca.com/what-science-can-do/topics/clinical-innovation/leading-cardiovascular-renal-metabolism-innovation.html
- https://www.astrazeneca.com/what-science-can-do/topics/clinical-innovation/investing-in-clinical-trials.html
- https://www.astrazeneca.com/what-science-can-do/topics/clinical-innovation/data-visualisation-turning-science-into-stories.html
- https://www.astrazeneca.com/what-science-can-do/topics/technologies/smart-factories-delivering-more-for-patients-worldwide.html
- https://www.astrazeneca.com/what-science-can-do/topics/technologies/synthetic-data-biopharma-research.html
- https://www.astrazeneca.com/what-science-can-do/topics/technologies/discover-me-south-africa-enabling-diversity-discovery-science.html
- https://www.astrazeneca.com/what-science-can-do/topics/technologies/precision-medicine-history.html
- https://www.astrazeneca.com/what-science-can-do/topics/technologies/matching-drug-disease-omic-signatures-drug-repurposing.html
- https://www.astrazeneca.com/what-science-can-do/topics/technologies/Kidney-disease-research-organoids.html
- https://www.astrazeneca.com/what-science-can-do/topics/technologies/mapping-immunological-landscape-cancer.html
- https://www.astrazeneca.com/what-science-can-do/topics/technologies/developing-global-supply-network-fit-future.html
- https://www.astrazeneca.com/what-science-can-do/topics/technologies/virus-like-particles-next-generation-vaccines.html
- https://www.astrazeneca.com/what-science-can-do/topics/technologies/translational-science.html
- https://www.astrazeneca.com/what-science-can-do/topics/technologies/science-and-innovation-for-cancer-chronic-and-rare-disease.html
- https://www.astrazeneca.com/what-science-can-do/topics/technologies/every-breath-counts-local-efforts-impact-global-asthma-care.html
- https://www.astrazeneca.com/what-science-can-do/topics/technologies/aiming-to-revolutionise-gi-cancer-care.html
- https://www.astrazeneca.com/what-science-can-do/topics/technologies/multiple-myeloma-lymphoma-leukemia-treatment-advances.html
- https://www.astrazeneca.com/what-science-can-do/topics/data-science-ai/how-data-and-ai-are-helping-unlock-the-secrets-of-disease.html
- https://www.astrazeneca.com/what-science-can-do/topics/data-science-ai/democratising-data-from-no-to-know.html
- https://www.astrazeneca.com/what-science-can-do/topics/data-science-ai/uniting-human-and-machine-intelligence-for-drug-discovery.html
- https://www.astrazeneca.com/what-science-can-do/topics/data-science-ai/targeting-the-drivers-of-immune-mediated-diseases.html
- https://www.astrazeneca.com/what-science-can-do/topics/data-science-ai/computational-pathology-potential-transform-cancer-diagnostics.html
- https://www.astrazeneca.com/what-science-can-do/topics/data-science-ai/neural-networks-strengthen-drug-discovery-approaches.html
- https://www.astrazeneca.com/what-science-can-do/topics/data-science-ai/unlocking-potential-data-ai-driven-drug-discovery-development.html
- https://www.astrazeneca.com/what-science-can-do/topics/data-science-ai/connected-medicines-innovations-data-science-ai.html
- https://www.astrazeneca.com/what-science-can-do/topics/data-science-ai/generative-ai-drug-discovery-development.html
- https://www.astrazeneca.com/what-science-can-do/topics/data-science-ai/biologics-discovery.html
- https://www.astrazeneca.com/what-science-can-do/topics/data-science-ai/unlocking-future-drug-discovery-through-AI-advances.html
- https://www.astrazeneca.com/what-science-can-do/topics/sustainability/driving-sustainability-in-healthcare.html
- https://www.astrazeneca.com/what-science-can-do/topics/sustainability/sustainable-drug-discovery-using-green-chemistry.html
- https://www.astrazeneca.com/what-science-can-do/topics/sustainability/biocatalysis-perform-sustainable-chemical-reactions.html
- https://www.astrazeneca.com/what-science-can-do/topics/sustainability/creating-culture-sustainability-across-labs.html
- https://www.astrazeneca.com/what-science-can-do/topics/sustainability/medicine-and-a-lower-carbon-future.html
- https://www.astrazeneca.com/what-science-can-do/topics/sustainability/personal-growth-can-transform-societies.html
- https://www.astrazeneca.com/what-science-can-do/topics/sustainability/improving-global-health-through-climate-action-and-equity.html
- https://www.astrazeneca.com/what-science-can-do/topics/sustainability/building-more-resilient-more-sustainable-health-systems.html
- https://www.astrazeneca.com/what-science-can-do/topics/sustainability/collaboration-for-sustainable-healthcare-transformation.html
- https://www.astrazeneca.com/what-science-can-do/topics/sustainability/cardiovascular-and-renal-disease-climate-change-and-a-more-resilient-future.html
- https://www.astrazeneca.com/what-science-can-do/topics/covid-19/viral-variants-and-immunocompromised.html
- https://www.astrazeneca.com/what-science-can-do/topics/covid-19/immunobridging-trials.html
- https://www.astrazeneca.com/what-science-can-do/topics/covid-19/burden-of-disease.html
- https://www.astrazeneca.com/what-science-can-do/stories-of-impact.html
- https://www.astrazeneca.com/what-science-can-do/stories-of-impact/early-diagnosis-and-treatment-to-transform-care.html
- https://www.astrazeneca.com/our-company.html
- https://www.astrazeneca.com/our-company/our-locations/cambridge.html
- https://www.astrazeneca.com/our-company/our-locations/cambridge/Community-in-Cambridge.html
- https://www.astrazeneca.com/our-company/our-locations/gothenburg.html
- https://www.astrazeneca.com/our-company/our-locations/gaithersburg.html
- https://www.astrazeneca.com/our-company/our-people.html
- https://www.astrazeneca.com/our-company/our-people/cristina-duran.html
- https://www.astrazeneca.com/our-company/our-people/mark-cobbold.html
- https://www.astrazeneca.com/our-company/our-people/magnus-johansson.html
- https://www.astrazeneca.com/our-company/our-people/pablo-panella.html
- https://www.astrazeneca.com/our-company/our-people/teresa-klinowska.html
- https://www.astrazeneca.com/our-company/our-people/malin-lemurell.html
- https://www.astrazeneca.com/our-company/our-people/serban-ghiorghiu.html
- https://www.astrazeneca.com/our-company/our-people/ezogelin-oflazoglu-gruyters.html
- https://www.astrazeneca.com/our-company/our-people/carlos-doti.html
- https://www.astrazeneca.com/our-company/our-people/christopher-j-rhodes.html
- https://www.astrazeneca.com/our-company/our-people/nicolas-jose-guzman.html
- https://www.astrazeneca.com/our-company/our-people/ruth-march.html
- https://www.astrazeneca.com/our-company/our-people/mark-o-connor.html
- https://www.astrazeneca.com/our-company/our-people/regina-fritsche-danielson.html
- https://www.astrazeneca.com/our-company/our-people/mark-fielding.html
- https://www.astrazeneca.com/our-company/our-people/paul-harper.html
- https://www.astrazeneca.com/our-company/our-people/ella-ekholm.html
- https://www.astrazeneca.com/our-company/our-people/per-lindblom.html
- https://www.astrazeneca.com/our-company/our-people/elisa-lazaro-ibanez.html
- https://www.astrazeneca.com/our-company/our-people/tom-keith-roach.html
- https://www.astrazeneca.com/our-company/our-people/clive-green.html
- https://www.astrazeneca.com/our-company/our-people/ola-engkvist.html
- https://www.astrazeneca.com/our-company/our-people/qing-dong-wang.html
- https://www.astrazeneca.com/our-company/our-people/anna-sundgren.html
- https://www.astrazeneca.com/our-company/our-people/Lutz-Jermutus.html
- https://www.astrazeneca.com/our-company/our-people/Elisabeth-Bjork.html
- https://www.astrazeneca.com/our-company/our-people/fredrik-rook.html
- https://www.astrazeneca.com/our-company/our-people/andrea-burgos-prieto.html
- https://www.astrazeneca.com/our-company/our-people/joris-silon.html
- https://www.astrazeneca.com/our-company/our-people/asa-sjoholm-timen.html
- https://www.astrazeneca.com/our-company/our-people/jim-weatherall.html
- https://www.astrazeneca.com/our-company/our-people/simon-bradford.html
- https://www.astrazeneca.com/our-company/our-people/annette-bak.html
- https://www.astrazeneca.com/our-company/our-people/marianne-ashford.html
- https://www.astrazeneca.com/our-company/our-people/alan-sabirsh.html
- https://www.astrazeneca.com/our-company/our-people/Lennart-lindfors.html
- https://www.astrazeneca.com/our-company/our-people/renee-bailey-iacona.html
- https://www.astrazeneca.com/our-company/our-people/puja-sapra.html
- https://www.astrazeneca.com/our-company/our-people/sunil-verma.html
- https://www.astrazeneca.com/our-company/our-people/andrew-foxley.html
- https://www.astrazeneca.com/our-company/our-people/anas-younes.html
- https://www.astrazeneca.com/our-company/our-people/per-alfredsson.html
- https://www.astrazeneca.com/our-company/our-people/ti-hwei-how.html
- https://www.astrazeneca.com/our-company/our-people/shin-morita.html
- https://www.astrazeneca.com/our-company/our-people/leora-horn.html
- https://www.astrazeneca.com/our-company/our-people/tonya-villafana.html
- https://www.astrazeneca.com/our-company/our-people/slave-petrovski.html
- https://www.astrazeneca.com/our-company/our-people/Steve-rees.html
- https://www.astrazeneca.com/our-company/our-people/stewart-owen.html
- https://www.astrazeneca.com/our-company/our-people/mark-T-esser.html
- https://www.astrazeneca.com/our-company/our-people/dafni-bika.html
- https://www.astrazeneca.com/our-company/our-people/matt-bonam.html
- https://www.astrazeneca.com/our-company/our-people/ryan-hicks.html
- https://www.astrazeneca.com/our-company/our-people/mohit-manrao.html
- https://www.astrazeneca.com/our-company/our-people/ingrid-a-mayer.html
- https://www.astrazeneca.com/our-company/our-people/lisa-hickey.html
- https://www.astrazeneca.com/our-company/our-people/judy-campagnari.html
- https://www.astrazeneca.com/our-company/our-people/Mina-Makar.html
- https://www.astrazeneca.com/our-company/our-people/maurizio-scaltriti.html
- https://www.astrazeneca.com/our-company/our-people/research-and-development.html
- https://www.astrazeneca.com/our-company/our-people/sofia-tapani.html
- https://www.astrazeneca.com/our-company/our-people/chris-miller.html
- https://www.astrazeneca.com/our-company/our-people/elaine-jones.html
- https://www.astrazeneca.com/our-company/our-people/gayathri-mohankumar.html
- https://www.astrazeneca.com/our-company/our-people/tatiana-scetinina.html
- https://www.astrazeneca.com/our-company/our-people/gurinder-kaur.html
- https://www.astrazeneca.com/our-company/our-people/gemma-satterthwaite.html
- https://www.astrazeneca.com/our-company/our-people/ben-challis.html
- https://www.astrazeneca.com/our-company/our-people/ken-grime.html
- https://www.astrazeneca.com/our-company/our-people/suzanne-cohen.html
- https://www.astrazeneca.com/our-company/our-people/rare-disease.html
- https://www.astrazeneca.com/our-company/our-people/oncology.html
- https://www.astrazeneca.com/our-company/our-people/enabling-functions.html
- https://www.astrazeneca.com/our-company/our-people/operations.html
- https://www.astrazeneca.com/our-company/our-people/international.html
- https://www.astrazeneca.com/our-company/our-people/biopharmaceuticals.html
- https://www.astrazeneca.com/our-company/our-people/caterina-brindicci.html
- https://www.astrazeneca.com/our-company/our-people/elsa-abranches.html
- https://www.astrazeneca.com/our-company/our-people/adam-platt.html
- https://www.astrazeneca.com/our-company/our-people/david-baker.html
- https://www.astrazeneca.com/our-company/our-people/francesco-dazzi.html
- https://www.astrazeneca.com/our-company/our-people/shalini-andersson.html
- https://www.astrazeneca.com/our-company/our-people/kenny-hansson.html
- https://www.astrazeneca.com/our-company/our-people/natalie-fishburn.html
- https://www.astrazeneca.com/our-company/our-people/eniola-ashafa.html
- https://www.astrazeneca.com/our-company/our-people/sonny-shergill.html
- https://www.astrazeneca.com/our-company/our-people/victoria-parker.html
- https://www.astrazeneca.com/our-company/our-people/rasmus-jansson-lofmark.html
- https://www.astrazeneca.com/our-company/our-people/nayyar-iqbal.html
- https://www.astrazeneca.com/our-company/our-people/martin-cowie.html
- https://www.astrazeneca.com/our-company/our-people/tina-ryden-bergsten.html
- https://www.astrazeneca.com/our-company/our-people/michele-sample.html
- https://www.astrazeneca.com/our-company/our-people/femi-d-etti.html
- https://www.astrazeneca.com/our-company/our-people/matt-hellmann.html
- https://www.astrazeneca.com/our-company/our-people/gerardo-teja-rivera.html
- https://www.astrazeneca.com/our-company/our-people/jorge-reis-filho.html
- https://www.astrazeneca.com/our-company/our-people/bob-li.html
- https://www.astrazeneca.com/our-company/our-people/david-brocklehurst.html
- https://www.astrazeneca.com/our-company/our-people/mikhail-kosiborod.html
- https://www.astrazeneca.com/our-company/our-people/shaun-grady.html
- https://www.astrazeneca.com/our-company/our-people/anish-konkar.html
- https://www.astrazeneca.com/our-company/leadership.html
- https://www.astrazeneca.com/our-company/leadership/susan-galbraith.html
- https://www.astrazeneca.com/our-company/Contact-us.html
- https://www.astrazeneca.com/our-company/uk-hr-policies.html
- https://www.astrazeneca.com/our-company/history.html
- https://www.astrazeneca.com/country-sites.html
- https://www.astrazeneca.com/country-sites/serbia.html
- https://www.astrazeneca.com/country-sites/vietnam.html
- https://www.astrazeneca.com/country-sites/vietnam/legal-notice-and-terms-of-use.html
- https://www.astrazeneca.com/country-sites/african-cluster.html
- https://www.astrazeneca.com/country-sites/slovenia.html
- https://www.astrazeneca.com/country-sites/uruguay.html
- https://www.astrazeneca.com/country-sites/israel.html
- https://www.astrazeneca.com/country-sites/indonesia.html
- https://www.astrazeneca.com/country-sites/thailand.html
- https://www.astrazeneca.com/country-sites/thailand/press-release.html
- https://www.astrazeneca.com/country-sites/thailand/press-release/thai20210428.html
- https://www.astrazeneca.com/country-sites/thailand/press-release/astrazenecas-covid-19-vaccines-made-by-siam-bioscience-pass-quality-testing-in-europe-and-us-first-batch-delivery-is-near.html
- https://www.astrazeneca.com/country-sites/thailand/press-release/astrazeneca-commences-new-covid-19-vaccine-supply-chain-in-thailand.html
- https://www.astrazeneca.com/country-sites/thailand/press-release/astrazeneca-to-deliver-six-million-covid-19-vaccine-doses-in-thailand.html
- https://www.astrazeneca.com/country-sites/thailand/press-release/an-open-letter-to-the-people-of-thailand-en.html
- https://www.astrazeneca.com/country-sites/thailand/press-release/an-open-letter-to-the-people-of-thailand-th.html
- https://www.astrazeneca.com/country-sites/thailand/press-release/astrazeneca-delivers-53-million-doses-of-covid-19-vaccine-to-thailand-during-july.html
- https://www.astrazeneca.com/country-sites/thailand/press-release/travelling-with-covid-19-vaccine-astrazeneca-made-in-thailand.html
- https://www.astrazeneca.com/country-sites/thailand/press-release/astrazeneca-ceo-met-with-prime-minister-prayut-chan-o-cha-about-the-delivery-of-the-vaccine-against-covid-19-to-thailand-th.html
- https://www.astrazeneca.com/country-sites/thailand/press-release/astrazeneca-delivers-5-3-million-doses-of-covid-19-vaccine-to--t.html
- https://www.astrazeneca.com/country-sites/thailand/press-release/astrazeneca-to-supply-thailand-with-an-additional-60-million-cov.html
- https://www.astrazeneca.com/country-sites/thailand/an-open-letter-to-the-people-of-thailand-nov.html
- https://www.astrazeneca.com/country-sites/thailand/an-open-letter-to-the-people-of-thailand-nov-th.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/thai20210428.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazenecas-covid-19-vaccines-made-by-siam-bioscience-pass-quality-testing-in-europe-and-us-first-batch-delivery-is-near.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-commences-new-covid-19-vaccine-supply-chain-in-thailand.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-to-deliver-six-million-covid-19-vaccine-doses-in-thailand.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-delivers-53-million-doses-of-covid-19-vaccine-to-thailand-during-july.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/travelling-with-covid-19-vaccine-astrazeneca-made-in-thailand.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-ceo-met-with-prime-minister-prayut-chan-o-cha-about-the-delivery-of-the-vaccine-against-covid-19-to-thailand-th.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-delivers-5-3-million-doses-of-covid-19-vaccine-to--t.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-to-supply-thailand-with-an-additional-60-million-cov.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazenecas-covid-19-vaccine-manufactured-in-thailand-authorised-for-world-health-organization-emergency-use.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazenecas-covid-19-vaccine-manufactured-in-thailand-authorised-for-world-health-organization-emergency-use-thai.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-a-leading-science-led-biopharmaceutical-company.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-a-leading-science-led-biopharmaceutical-company-thai.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/girls-take-over.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/girls-take-over-thai.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/new-analyses-of-two-azd7442-covid-19-phase-iii-trials-in-high-risk-populations-confirm-robust-efficacy-and-long-term-prevention.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/new-analyses-of-two-azd7442-covid-19-phase-iii-trials-in-high-risk-populations-confirm-robust-efficacy-and-long-term-prevention1.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/thailand-becoming-better-protected-from-non-communicable-diseases-as-over-14-million-young-people.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/thailand-becoming-better-protected-from-non-communicable-diseases-as-over-14-million-young-people1.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/evusheld-formerly-azd7442-long-acting-antibody-combination-authorised-for-emergency.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/evusheld-formerly-azd7442-long-acting-antibody-combination-authorised-for-emergency-thailand.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/vaxzevria-significantly-boosted-antibody-levels-against-omicron.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/th-vaxzevria-significantly-boosted-antibody-levels-against-omicron.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-completes-delivery-of-61-million-covid-19-vaccine-doses-to-thailand.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/th-astrazeneca-completes-delivery-of-61-million-covid-19-vaccine-doses-to-thailand.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/new-vaxzevria-data-further-support-its-use-as-third-dose-booster-english.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/new-vaxzevria-data-further-support-its-use-as-third-dose-booster-thai.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/the-thoracic-society-of-thailand-under-royal-patronage--in-partn.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/the-thoracic-society-of-thailand-under-royal-patronage--in-partn-thai.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-thailand-certified-as-top-employer-2022-in-thailand.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-thailand-certified-as-top-employer-2022-in-thailand-thai.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazenecas-antibody-combination-evusheld-tixagevimab-co-packaged-with-cilgavimab-authorised-for-use-in-great-britain-for-pre-exposure-prophylaxis-prevention-of-covid-19.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-thailand-certified-as-top-employer-2022-in-thailand-thai1.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/evusheld-long-acting-antibody-combination-retains-neutralising-activity-against-omicron-eng.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/evusheld-long-acting-antibody-combination-retains-neutralising-activity-against-omicron-thai.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-announces-evusheld-long-acting-antibody-combination-approved-in-the-eu-for-the-pre-exposure-prophylaxis-prevention-of-covid-19-in-a-broad-population.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-announces-evusheld-long-acting-antibody-combination-approved-in-the-eu-for-the-pre-exposure-prophylaxis-prevention-of-covid-19-in-a-broad-population1.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/evusheld-significantly-protected-against-symptomatic-covid-19-for-at-least-six-months-in-provent-phase-iii-trial-in-high-risk-populations.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazenecas-covid-19-vaccine-shelf-life-extended-in-thailand.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazenecas-and-mrna-vaccines-provide-equivalent-protection-against-covid-19-hospitalisation-and-deaths.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazenecas-and-mrna-vaccines-provide-equivalent-protection-against-covid-19-hospitalisation-and-deaths1.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/evusheld-significantly-protected-against-symptomatic-covid-19-for-at-least-six-months-in-provent-phase-iii-trial-in-high-risk-populations1.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/vaxzevria-approved-in-the-eu-as-third-dose-booster-against-covid-19.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/vaxzevria-approved-in-the-eu-as-third-dose-booster-against-covid-191.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazenecas-covid-19-vaccine-shelf-life-extended-in-thailand1.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/banphaeo-general-hospital-collaborates-with-depa-astrazeneca-thailand-in-launching-dont-wait-get-checked-campaign-embraces-ai-to-detect-lung-cancer-in-early-stage1.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/banphaeo-general-hospital-collaborates-with-depa-astrazeneca-thailand-in-launching-dont-wait-get-checked-campaign-embraces-ai-to-detect-lung-cancer-in-early-stage.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/evusheld-significantly-prevented-COVID-19.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/evusheld-significantly-prevented-COVID-19-TH.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/YHP-World-No-Tobacco-Day-2022_Press-release-EN_Final_website.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/YHP-World-No-Tobacco-Day-2022_Press-release-TH_Final_website.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-to-supply-thailand-with-257500-doses-of-its-covid-19-long-acting-antibody-combination-azd7442.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-to-supply-thailand-with-257500-doses-of-its-covid-19-long-acting-antibody-combination-azd7442-TH.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/covid-19-vaccine-provides-equally-effective-protection-against-hospitalisation-and-deaths-compared-with-mrna-vaccines.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/covid-19-vaccine-provides-equally-effective-protection-against-hospitalisation-and-deaths-compared-with-mrna-vaccines-th.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/vaxzevria-73-effective-at-preventing-omicron-related-infections-after-fourth-dose-according-to-real-world-evidence-study-in-thailand.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/vaxzevria-73-effective-at-preventing-omicron-related-infections-after-fourth-dose-according-to-real-world-evidence-study-in-thailand-th.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazenecas-long-acting-antibody-laab-combination-administered-to-first-group-of-patients-in-thailand-to-protect-against-covid-19-th.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/azd7442-long-acting-antibody-combination-approved-for-prevention-and-treatment-of-covid-19-in-japan-EN.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/azd7442-long-acting-antibody-combination-approved-for-prevention-and-treatment-of-covid-19-in-japan-TH.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/boosting-with-astrazenecas-vaccine-provides-high-protection-against-omicron-equivalent-to-mrna-covid-19-vaccines.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/boosting-with-astrazenecas-vaccine-provides-high-protection-against-omicron-equivalent-to-mrna-covid-19-vaccines-th.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-announces-azd7442-long-acting-antibody-combination-approved-in-the-eu-for-the-treatment-of-covid-19.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-announces-azd7442-long-acting-antibody-combination-approved-in-the-eu-for-the-treatment-of-covid-19-th.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-delivers-additional-41575-units-of-COVID-19-long-acting-antibody-LAAB-to-thailand.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-delivers-additional-41575-units-of-COVID-19-long-acting-antibody-LAAB-to-thailand-TH.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-and-plan-international-celebrate-international-day-of-the-girl-supporting-gender-equality-and-girls-rights-advocacy-through-the-girls-belong-here-campaign.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-and-plan-international-celebrate-international-day-of-the-girl-supporting-gender-equality-and-girls-rights-advocacy-through-the-girls-belong-here-campaign-TH.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-launches-its-making-health-happen-campaign-in-thailand-to-build-a-healthy-future-for-people-society-and-the-planet.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-launches-its-making-health-happen-campaign-in-thailand-to-build-a-healthy-future-for-people-society-and-the-planet-TH.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/department-of-medicine-national-cancer-institute-in-collaboration-with-astrazeneca-create-video-clips-to-educate-and-enhance-understanding-about-cancer-under-the-new-normal-same-cancer-campaign.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazenecas-long-acting-antibody-laab-combination-granted-conditional-marketing-approval-for-the-treatment-of-covid-19-in-thailand.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazenecas-long-acting-antibody-laab-combination-granted-conditional-marketing-approval-for-the-treatment-of-covid-19-in-thailand-th.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-thailand-wins-two-aces-2022-awards.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-thailand-wins-two-aces-2022-awards-th.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-thailand-sends-campaign-prepare-immunity-for-every-special.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/covid-19-vaccine-astrazeneca-highly-effective-at-preventing-covid-19-severe-outcomes-and-death-according-to-new-real-world-evidence-study-in-thailand.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/covid-19-vaccine-astrazeneca-highly-effective-at-preventing-covid-19-severe-outcomes-and-death-according-to-new-real-world-evidence-study-in-thailand-TH.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/healthy-lung-in-health-region-11-th.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-thailand-wins-top-employer-award-2023-for-the-third-year-in-a-row-reaffirming-its-position-as-a-great-place-to-work.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-thailand-wins-top-employer-award-2023-for-the-third-year-in-a-row-reaffirming-its-position-as-a-great-place-to-work-th.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-launch-campaign-parker-panda-and-dr-bunny-th.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/the-effects-of-chronic-pm25-crisis-result-in-gene-mutations-causing-lung-cancer-near-body-menace-that-should-not-be-overlooked-th.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/international-womens-day-article-2023-th.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/LAAB-enhancing-immunity-for-the-elderly-th.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-thailand-announces-partnership-with-phyathai-2-hospital-introduces-ai-to-enhance-the-diagnosis-of-early-stage-lung-cancer.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-thailand-announces-partnership-with-phyathai-2-hospital-introduces-ai-to-enhance-the-diagnosis-of-early-stage-lung-cancer-th.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/asthma-close-matter-that-should-not-be-overlooked.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-suggest-factors-that-women-should-not-overlook-on-international-ovarian-cancer-day.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-thailand-appoints-roman-ramos-as-country-president.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-thailand-appoints-roman-ramos-as-country-president-th.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/az-x-phyathai2the-art-of-x-ray-TH.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-trains-young-peer-educators-for-the-fourth-consecutive-year-as-support-for-the-young-health-programme-in-thailand.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-trains-young-peer-educators-for-the-fourth-consecutive-year-as-support-for-the-young-health-programme-in-thailand-TH.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/common-seasonal-diseases-in-children-TH.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/leading-organizations-in-thailand-join-the-discussion-inclusion-and-inclusion-in-the-workplace-on-the-occasion-of-lgbt-pride-mont-th.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-revealing-the-results-of-a-survey-of-at-risk-populations-in-thailand-more-than-60-still-affected-in-life-from-covid-19.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-thailand-commitment-dealing-health-crises-non-communicable-diseases-ncds-killer-people-worldwide.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-thailand-collaboration-songkhla-nakarin-hospital-developed-innovative-asthma-smart-kiosk-project-enhance-efficiency-asthma-care.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/why-does-rsv-have-to-be-vigilant-respiratory-infections-caused-by-viruses-childrens-villains-that-parents-must-be-prepared-to-deal-with.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/asthma-smart-kiosk-healthy-lung-smart-care-healthy-lung-smart-care.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-and-plan-international-thailand-organized-the-event-2023-young-health-program-ncd-seminar-promote-thai-youth-to-stay-away-from-chronic-non-communicable-diseases.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/matters-of-the-heart-not-far-away-astrazeneca-together-with-samitivej-hospital-organized-the-event-healthy-heart-can-start-it-now-on-world-heart-day-2023.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-thailand-cooperates-with-bangkok-metropolitan-administration-on-the-dont-wait-get-checked-enhances-the-diagnosis-of-early-stage-lung-cancer-through-ai-innovations.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-thailand-cooperates-with-bangkok-metropolitan-administration-on-the-dont-wait-get-checked-enhances-the-diagnosis-of-early-stage-lung-cancer-through-ai-innovations-TH.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/depa-partners-with-astrazeneca-thailand-to-boost-digital-healthcare-innovation-for-thai-public-health-system-and-improved-quality-of-life.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/depa-partners-with-astrazeneca-thailand-to-boost-digital-healthcare-innovation-for-thai-public-health-system-and-improved-quality-of-life-TH.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/rethink-pink-we-care-event-TH.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/extra-protection-for-ics-and-high-risk-TH.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-collaborates-with-plan-international-and-4-other-world-class-organisations-in-continuing-girls-take-over-activity-to-mark-the-international-day-of-the-girl-child.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-collaborates-with-plan-international-and-4-other-world-class-organisations-in-continuing-girls-take-over-activity-to-mark-the-international-day-of-the-girl-child-TH.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/az-laa-policy-maker-interview.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/az-siriraj-genomics-mou.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astraZeneca-thailand-collaboration-bangkok-cancer-hospital-wattanosoth-launches-pilot-collaboration-alleviate-gap-reduce-cancer-mortality-rate.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astraZeneca-thailand-collaboration-bangkok-cancer-hospital-wattanosoth-launches-pilot-collaboration-alleviate-gap-reduce-cancer-mortality-rate-EN.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-thailand-wins-top-employer-2024-fourth-consecutive-year-demonstrating-achievement-organisational-leadership-personnel-excellence.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-thailand-wins-top-employer-2024-fourth-consecutive-year-demonstrating-achievement-organisational-leadership-personnel-excellence-TH.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astraZeneca-joins-hands-with-buddhachinaraj-phitsanulok-hospital-advance-proactive-healthcaintroducing-asthma-smart-kiosk-innovation-pioneer-enhanced-lung-disease-management.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astraZeneca-joins-hands-with-buddhachinaraj-phitsanulok-hospital-advance-proactive-healthcaintroducing-asthma-smart-kiosk-innovation-pioneer-enhanced-lung-disease-management-TH.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-joins-forces-with-bnh-hospital-to-enhance-respiratory-health-among-the-thai-population-pioneering-innovations-in-precise-severe-asthma-care-and-immunisation-against-respiratory-syncytial-virus-rsv.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-joins-forces-with-bnh-hospital-to-enhance-respiratory-health-among-the-thai-population-pioneering-innovations-in-precise-severe-asthma-care-and-immunisation-against-respiratory-syncytial-virus-rsv-TH.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-strengthened-its-commitment-with-the-thai-government-to-collaborate-on-tackling-ncds-in-thailand.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-strengthened-its-commitment-with-the-thai-government-to-collaborate-on-tackling-ncds-in-thailand-TH.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/mdkku-astrazeneca-and-depa-thailand-join-forces-to-utilise-ai-for-early-detection-of-heart-failure-and-lung-cancer.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/mdkku-astrazeneca-and-depa-thailand-join-forces-to-utilise-ai-for-early-detection-of-heart-failure-and-lung-cancer-TH.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-thailand-empowers-young-female-leaders-at-annual-girlstakeover-event.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-thailand-empowers-young-female-leaders-at-annual-girlstakeover-event-TH.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-thailand-launches-ncd-certification-programme-to-enhance-chronic-disease-care.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-thailand-launches-ncd-certification-programme-to-enhance-chronic-disease-care-TH.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-and-siriraj-genomics-join-forces-for-the-third-annual-rethink-pink-we-care-event-empowering-thai-women-against-breast-cancer.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-and-siriraj-genomics-join-forces-for-the-third-annual-rethink-pink-we-care-event-empowering-thai-women-against-breast-cancer-TH.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-awarded-most-innovative-company-by-british-chamber-of-commerce-thailand-TH.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-awarded-most-innovative-company-by-british-chamber-of-commerce-thailand.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-honored-with-thai-swedish-chambers-company-of-the-year-advancing-healthcare-for-thai-people-through-transformative-contributions-and-medical-innovations.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-honored-with-thai-swedish-chambers-company-of-the-year-advancing-healthcare-for-thai-people-through-transformative-contributions-and-medical-innovations-TH.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-expands-pioneering-ai-screening-project-enhance-early-disease-detection.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-expands-pioneering-ai-screening-project-enhance-early-disease-detection-th.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-prapokklao-hospital-chanthaburi-sign-mou-elevate-centre-excellence-cancer.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-prapokklao-hospital-chanthaburi-sign-mou-elevate-centre-excellence-cancer-th.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-signs-memorandum-understanding.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-signs-memorandum-understanding-th.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/the-born-a-fighter-campaign-supports-and-educates-neurofibromatosis-nf-warriors-celebrating-the-7th-event-on-nf1-awareness-day-in-thailand.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/the-born-a-fighter-campaign-supports-and-educates-neurofibromatosis-nf-warriors-celebrating-the-7th-event-on-nf1-awareness-day-in-thailand-th.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-thailand-recognised-top-employer-celebrating-five-consecutive-years-excellence.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-thailand-recognised-top-employer-celebrating-five-consecutive-years-excellence-TH.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-reveals-success-in-using-ai-to-screen-lung-cancer-from-x-ray-images-enhancing-sustainable-health-security.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-reveals-success-in-using-ai-to-screen-lung-cancer-from-x-ray-images-enhancing-sustainable-health-security-TH.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-faculty-pharmaceutical-sciences-chulalongkorn-university-signed-mou-announce-collaboration-enhancing-potential-pharmaceutical-personnel-TH.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-faculty-pharmaceutical-sciences-chulalongkorn-university-signed-mou-announce-collaboration-enhancing-potential-pharmaceutical-personnel.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/hat-joins-forces-ministry-public-health-astrazeneca-thailand-unveiling-collaborative-excellence-heart-failure-management-initiative-th.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/hat-joins-forces-ministry-public-health-astrazeneca-thailand-unveiling-collaborative-excellence-heart-failure-management-initiative.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/lampang-cancer-hospital-and-astrazeneca-sign-mou-to-advance-cancer-treatment-and-improve-survival-outcomes-th.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/lampang-cancer-hospital-and-astrazeneca-sign-mou-to-advance-cancer-treatment-and-improve-survival-outcomes.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/department-of-disease-control-the-kidney-foundation-astrazeneca-partners-launch-first-national-collaborative-excellence-for-chronic-kidney-disease-screening-th.html
- https://www.astrazeneca.com/country-sites/thailand/press-releases/department-of-disease-control-the-kidney-foundation-astrazeneca-partners-launch-first-national-collaborative-excellence-for-chronic-kidney-disease-screening.html
- https://www.astrazeneca.com/country-sites/thailand/an-open-letter-to-the-people-of-thailand-en.html
- https://www.astrazeneca.com/country-sites/thailand/an-open-letter-to-the-people-of-thailand-th.html
- https://www.astrazeneca.com/country-sites/georgia.html
- https://www.astrazeneca.com/country-sites/croatia.html
- https://www.astrazeneca.com/country-sites/near-east.html
- https://www.astrazeneca.com/country-sites/austria.html
- https://www.astrazeneca.com/country-sites/egypt.html
- https://www.astrazeneca.com/country-sites/egypt/az-egypt-statement-30052018.html
- https://www.astrazeneca.com/country-sites/greece.html
- https://www.astrazeneca.com/country-sites/gulf.html
- https://www.astrazeneca.com/country-sites/ireland.html
- https://www.astrazeneca.com/country-sites/taiwan.html
- https://www.astrazeneca.com/country-sites/taiwan/23032020.html
- https://www.astrazeneca.com/country-sites/the-philippines.html
- https://www.astrazeneca.com/country-sites/saudi-arabia.html
- https://www.astrazeneca.com/country-sites/singapore.html
- https://www.astrazeneca.com/country-sites/singapore/press-releases.html
- https://www.astrazeneca.com/country-sites/singapore/press-releases/astrazeneca-and-oncoshot-establish-strategic-partnership-to-bett0.html
- https://www.astrazeneca.com/country-sites/singapore/press-releases/diabetics--guide-to-fasting-during-ramadan-launched-by-diabetes-.html
- https://www.astrazeneca.com/country-sites/singapore/press-releases/leaders-from-mcdonald-s--astrazeneca--nomura--and-dell-advocate-.html
- https://www.astrazeneca.com/country-sites/singapore/press-releases/sgh-and-astrazeneca-unveil-promising-intervention-to-improve-ast.html
- https://www.astrazeneca.com/country-sites/singapore/press-releases/unlikely-partners-join-hands-as-part-of-sweden--s-pore-initiativ.html
- https://www.astrazeneca.com/country-sites/singapore/press-releases/the-big-read--enough-is-enough--just-what-does-it-take-to-break-.html
- https://www.astrazeneca.com/country-sites/singapore/press-releases/astrazeneca-and-lucence-collaborate-in-south-east-asia.html
- https://www.astrazeneca.com/country-sites/singapore/press-releases/astrazeneca-singapore-signs-mou-with-tech-partners-on-innovation-projects.html
- https://www.astrazeneca.com/country-sites/singapore/press-releases/astrazenecas-antibody-drug-for-covid-19-treatment-to-arrive-in-spore-by-end-of-the-year.html
- https://www.astrazeneca.com/country-sites/singapore/press-releases/astrazeneca-signs-mou-to-empower-the-breast-cancer-community-in-singapore.html
- https://www.astrazeneca.com/country-sites/singapore/press-releases/singhealth-polyclinics-launches-primary-care-research-institute.html
- https://www.astrazeneca.com/country-sites/singapore/press-releases/astrazeneca-to-manufacture-adcs-in-singapore.html
- https://www.astrazeneca.com/country-sites/singapore/press-releases/astrazeneca-to-hire-over-800-employees-to-produce-cancer-medicines-at-adc-manufacturing-facility-in-singapore.html
- https://www.astrazeneca.com/country-sites/singapore/press-releases/national-university-health-system-sahlgrenska-university-hospital-and-industry-partners-astrazeneca-and-ericsson-establish-global-health-innovation-network.html
- https://www.astrazeneca.com/country-sites/estonia.html
- https://www.astrazeneca.com/country-sites/latvia.html
- https://www.astrazeneca.com/country-sites/lithuania.html
- https://www.astrazeneca.com/legal-notice-and-terms-of-use.html
- https://www.astrazeneca.com/legal-notice-and-terms-of-use/id.html
- https://www.astrazeneca.com/legal-notice-and-terms-of-use/ro.html
- https://www.astrazeneca.com/global.html
- https://www.astrazeneca.com/global/en.html
- https://www.astrazeneca.com/global/en/AstraZeneca-Websites.html
- https://www.astrazeneca.com/global/en/annualreport.html
- https://www.astrazeneca.com/global/en/Resources.html
- https://www.astrazeneca.com/global/en/sitemap.html
- https://www.astrazeneca.com/search_results.html